



Published in final edited form as:

*Am J Cardiovasc Drugs*. 2008 ; 8(6): 373–418.

## Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism

Beatrice A. Golomb, M.D., Ph.D.<sup>a,b</sup> and Marcella A. Evans, B.S.<sup>a,c</sup>

<sup>a</sup> Department of Medicine, University of California, San Diego, USA

<sup>b</sup> Department of Family & Preventive Medicine, University of California, San Diego, USA

<sup>c</sup> School of Medicine, University of California, Irvine, California, USA

### Abstract

HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like all medications have potential for adverse effects (AEs). Here we review the statin AE literature, first focusing on muscle AEs as the most reported problem both in the literature and by patients. Evidence regarding the statin muscle AE mechanism, dose effect, drug interactions, and genetic predisposition is examined. We hypothesize, and provide evidence, that the demonstrated mitochondrial mechanisms for muscle AEs have implications to other nonmuscle AEs in patients treated with statins. In meta-analyses of randomized controlled trials (RCTs), muscle AEs are more frequent with statins than with placebo. A number of manifestations of muscle AEs have been reported, with rhabdomyolysis the most feared. AEs are dose dependent, and risk is amplified by drug interactions that functionally increase statin potency, often through inhibition of the cytochrome P450 (CYP)3A4 system. An array of additional risk factors for statin AEs are those that amplify (or reflect) mitochondrial or metabolic vulnerability, such as metabolic syndrome factors, thyroid disease, and genetic mutations linked to mitochondrial dysfunction. Converging evidence supports a mitochondrial foundation for muscle AEs associated with statins, and both theoretical and empirical considerations suggest that mitochondrial dysfunction may also underlie many non-muscle statin AEs. Evidence from RCTs and studies of other designs indicates existence of additional statin-associated AEs, such as cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction. Physician awareness of statin AEs is reportedly low even for the AEs most widely reported by patients. Awareness and vigilance for AEs should be maintained to enable informed treatment decisions, treatment modification if appropriate, improved quality of patient care, and reduced patient morbidity.

### Introduction

HMG-CoA reductase inhibitors (statins) have been the best selling prescription drug class in the US and include atorvastatin, the best-selling prescription drug in the world – indeed in history.<sup>1-3</sup> These drugs are perceived to have a favorable safety profile<sup>4-6</sup> and have well documented benefits to cardiovascular disease in many groups, including persons who are younger and older, male and female, at moderate and high cardiovascular risk. In addition, benefits have been objectively shown to exceed risks on average for both total mortality and total morbidity (indexed by serious adverse events), specifically in clinical-trial equivalent middle-aged men who are at high cardiovascular risk.<sup>7-9</sup> Although many people treated with statins do well, no drug is without potential for adverse effects (AEs). There is need for

awareness of risks as well as benefits of all drugs, particularly those that, like statins, are used on a wide scale where even uncommon effects can translate to significant public health impact.

Statins inhibit the enzyme HMG-CoA reductase, at a stage early in the mevalonate pathway.<sup>10</sup> This pathway generates a range of other products in addition to cholesterol, such as coenzyme Q10, heme-A, and isoprenylated proteins,<sup>10</sup> which have pivotal roles in cell biology and human physiology and potential relevance to benefits as well as risks of statins.<sup>11-13</sup> Additionally, cholesterol itself is not merely a final product (with its own range of vital roles) but also an intermediate to a suite of additional products of fundamental relevance to health and well-being, such as sex steroids, corticosteroids, bile acids and vitamin D, several of which have been shown to be affected with statin administration.<sup>14, 15</sup> The biochemical influences of statins extend well beyond the lipid profile and its constituents (low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides), and even beyond the direct products of the mevalonate pathway, to include a wide swath of products and functions modified through these as well as nonmevalonate effects of statins, ranging from nitric oxide and inflammatory markers<sup>16</sup> to polyunsaturated fatty acids,<sup>17</sup> among many others.

This report reviews evidence related to statin induction of AEs and evidence for a dose-response relationship, and describes reported drug interactions. Muscle AEs are emphasized as they are the best recognized AEs of statins (liver AEs are perhaps second most recognized), and the AEs on which much of the information on mechanism, drug interactions, and dose-response has been obtained – information that, as we show, has relevance to other statin AEs.<sup>18, 19</sup> Statins lead to dose-dependent reductions in coenzyme Q10,<sup>20-22</sup> a key mitochondrial antioxidant and electron transport carrier that serves to help bypass existing mitochondrial respiratory chain defects.<sup>23-25</sup> We review convergent evidence supporting a role for mitochondrial predispositions and mechanisms for statin muscle AEs. We seek to place other statin AEs in the context this evidence provides, proposing that mitochondrial dysfunction may underlie additional AEs reported on statins.

## Muscle Adverse Effects (AEs)

### Myositis and Myalgia

The best recognized and most commonly reported AEs of statins are muscle AEs,<sup>26, 27</sup> and include muscle pain, fatigue and weakness as well as rhabdomyolysis. While individual randomized controlled trials (RCTs) often fail to show an excess of muscle problems or symptoms, meta-analysis of randomized double-blind, placebo-controlled trials have shown increased myositis in patients receiving statins relative to placebo (odds ratio [OR] 2.56, 95% CI 1.12-5.85), with myositis there defined as creatinine kinase (CK) > 10 times the upper limit of normal with myalgia.<sup>28</sup>

In contrast to myositis, myalgia was not increased on average based on meta-analysis of RCTs that compared statins to placebo (relative risk [RR] 1.09, 95% CI 0.97-1.23).<sup>28</sup> However, this does not necessarily mean that statins do not cause myalgia, and this point seems not to be uniformly appreciated. Rather, evidence has shown that statins reduce pain and improve walking distance in many individuals (for instance, but not confined to, persons with peripheral arterial disease),<sup>29</sup> an effect that may arise through improved blood flow deriving from endothelial function benefits in persons with endothelial dysfunction.<sup>30</sup> An overall null effect of statins on muscle pain in clinical trials may therefore indicate that, in the samples selected for these trials, statins caused muscle pain in approximately as many people as they relieved it.

In support of this view, triangulating evidence suggest that statins have a causal role in myalgia as well as muscle weakness in some people. For instance: A double-blind, placebo-controlled,

crossover biopsy study showed partially reversible mitochondrial myopathy in persons reporting non-CK-elevating or minimally CK-elevating muscle symptoms on statins.<sup>31</sup> In a family in which multiple members experienced statin-associated non-CK elevating muscle pain, objective investigation affirmed myopathic findings.<sup>32</sup> Prior muscle symptoms on statins or other cholesterol drugs represent a predictor for future symptoms with statin rechallenge and may signal elevated risk for rhabdomyolysis on statins.<sup>33-36</sup> Patients who experienced muscle symptoms on statins (typically with normal or slightly elevated levels of CK), that reverse with discontinuation, most often re-experienced muscle symptoms if rechallenged with an equivalent or higher expected potency statin based on calculated potency equivalencies; in contrast, those rechallenged with a lower potency statin re-experience problems significantly less frequently,  $p < 0.01$ .<sup>37</sup> These data support the view that muscle symptoms arising on statins and reversing with discontinuation are in many individual cases causally statin-associated, whether or not on average an increase in muscle symptoms occurs with statins.

This observation underscores a critically important point relevant to drug AEs in general, which merits emphasis and has relevance to other reported statin AEs. A significant increase in rates of a problem on drug vs placebo in RCTs supports a causal link between that drug and that AE, in some persons. However, absence of an average significant increase in a problem, or even presence of a significant average reduction in a problem, does not preclude causal occurrence of that problem in some individuals. Illustrating this point are the recognized occurrence of ‘paradoxical’ increases in blood pressure (BP) in some people with use of medicines designed to lower BP in most people, and ‘paradoxical’ increases in anxiety or aggression in some people who are given drugs designed to produce the opposite effect.<sup>38-45</sup>

In the case of statins, a potential basis for opposing effects occurring in muscle and in other organs can be identified. Evidence supports the proposition that antioxidant effects of statins underlie (or contribute to) many fundamental statin benefits – including benefits to flow and oxygen delivery<sup>46-48</sup> and inflammation.<sup>49, 50</sup> These effects may participate in improved walking distance in patients on statins, including benefits to muscle/walking in persons with and without peripheral artery disease.<sup>29</sup> Yet a subset of people reproducibly exhibit increases in markers of oxidation on statins,<sup>51</sup> and the occurrence of this increase has been tied to muscle pain on statins.<sup>52, 53</sup>

RCTs are important for evaluating average effects that may have relevance to use of a drug for treatment in a group overall. However, AEs are important to an individual even if they do not occur on average, and non-RCT data, including case-based data, have recognized importance in AE assessments.<sup>54-57</sup> Bearing this in mind, Table I shows a range of additional muscle problems that have been reported on statins beyond the classical ‘myalgia’ and ‘myositis.’<sup>17, 29, 51, 58-78</sup>

### Persistent Muscle Effects

Muscle effects arising on statins do not uniformly resolve fully with statin discontinuation.<sup>155</sup> Crossover biopsy studies show a partially reversible mitochondrial myopathy in persons presenting with recurrent muscle pain on statins.<sup>31</sup> Statins elevate the respiratory exchange ratio and do so even in asymptomatic persons, while persons who have been symptomatic on statins show an elevated off-statin respiratory exchange ratio.<sup>156-158</sup> This altered cell respiratory function in persons with AEs may represent a cause (predisposing to statin myopathy) and/or a consequence of statin myopathy; the relative contributions of each awaits prospective study.

A range of cases have now been reported in which statin use has “uncovered” previously clinically silent or clinically tolerated conditions, ranging from McArdle disease<sup>159, 160</sup> to myotonic dystrophy<sup>159</sup> to acid maltase deficiency<sup>161</sup> to possible Kennedy disease.<sup>159</sup> Statins

have also exacerbated known muscle conditions, such as myasthenia gravis.<sup>78</sup> In the case of mitochondrial myopathies, the relative degree to which statins have unmasked vs induced disease may not always be clear.<sup>159, 162</sup>

## Rhabdomyolysis

Rhabdomyolysis is among the best-recognized and most feared complications of statins; it occurs when muscle damage is severe, leading to a marked elevation of CK (e.g. in excess of 10 times the upper limit of normal) often accompanied by evidence of renal dysfunction and occasionally renal failure and death.<sup>81, 94, 163-166</sup> Over 900 unique PubMed citations (as of January 2009) pair the keywords 'rhabdomyolysis' with terms referring to statins, i.e. 'statins', 'HMG', or each generic statin name individually. However, the recognition of rhabdomyolysis as a statin complication does not rest on randomized trial data, which even on meta-analysis do not support a significant increase (e.g. OR 1.59, 95% CI 0.54-4.70).<sup>28</sup>

A case report has suggested that misinterpretation of evidence-based medicine from RCTs on statin rhabdomyolysis may have fatal consequences – and perhaps has had.<sup>81</sup> Underscoring the limitations of clinical trials for AE identification, cerivastatin was withdrawn from the market due to excess risk of rhabdomyolysis, although no cases of rhabdomyolysis occurred on cerivastatin in a meta-analysis of randomized trials.<sup>28</sup> In contrast, observational studies of real-world use reported that rhabdomyolysis occurred with substantially higher frequency on cerivastatin than other statins,<sup>167, 168</sup> particularly for cerivastatin in combination with fibrates (and specifically gemfibrozil).<sup>168</sup> This was true for postmarketing surveillance data<sup>169</sup> and for claims data.<sup>168</sup> Illustrative of this, in one study, claims data rates per 10,000 person-years of treatment were 0.44 for simvastatin, atorvastatin or pravastatin alone (95% CI 0.20-0.84); 5.34 for cerivastatin (95% CI 1.46-13.68); 2.82 for fibrates (95% CI 0.58-8.24); and 0 for no lipid therapy (95% CI 0-0.48). With a modest number of total rhabdomyolysis cases, the difference approached but did not quite reach significance ( $p=0.056$ ). Rates rose to 5.98 for statin (non-cerivastatin) combined with a fibrate (95% CI 0.72-216.0), and 1035 for cerivastatin-fibrate combinations (95% CI 389-2117).<sup>168</sup>

Emphasizing that figures for a larger group need not apply to subgroups within that group, per year of therapy the number needed to treat, to see one case of rhabdomyolysis was 22,727 for statin (monotherapy) overall, but 484 for older patients with diabetes mellitus treated with combined statin and fibrate, and 9.7 to 12.7 for patients who received cerivastatin plus fibrate.<sup>168</sup> (As reviewed below, much of the excess in cases is attributable to high potency resulting specifically from gemfibrozil-cerivastatin interaction effects.<sup>170, 171</sup>)

In the setting of statin rhabdomyolysis, other organs may also be severely affected. Renal failure is well recognized and is a consequence of the rhabdomyolysis, but concurrent heart,<sup>96, 109, 110</sup> pancreas,<sup>96, 105</sup> liver,<sup>96, 106-108, 172</sup> bone marrow,<sup>96, 173, 174</sup> respiratory,<sup>96, 98</sup> and CNS toxicity<sup>96, 112</sup> – or all of the above<sup>96</sup> – are also reported.

## Dose Response

A range of sources support a dose relation for statin AEs (Table II<sup>37, 167, 170, 171, 175-184</sup>), although there may exist AEs that are not dose dependent. Meta-analyses of RCTs comparing lower vs higher potency statins are of greatest relevance among the clinical trial data because these examine *similar* patients (within the same study) placed on drugs of different potencies.<sup>176, 178</sup> Results of these meta-analyses have supported more total AEs with statin vs placebo<sup>175</sup> (although this may not be equally true in all settings), more total AEs with intensive vs nonintensive statin use,<sup>176</sup> and more AEs leading to dropouts with intensive vs nonintensive statin use.<sup>176</sup> (Dropout rates are not, however, necessarily greater for lower intensity statin use

vs placebo in clinical trial samples.<sup>28</sup>) In addition, CK elevations and liver function test (LFT elevations) occur more frequently with higher dose vs lower dose statins.<sup>176, 178</sup>

Rechallenge data also support dose-related effects. This study design examines muscle symptom recurrence in persons with prior statin AEs. Patients rechallenged with same-or-higher potency statins (relative to the potency of the statin on which problems originally arose) usually re-experienced the problem, and did so significantly more frequently than those rechallenged with lower potency statins.<sup>37</sup> Examination of rechallenge data provides a highly efficient study design because at-risk patients are selected for, and by comparing subjects to themselves, erosion of power arising from cross-subject variability is reduced.

Although some investigators promote very low LDL-C targets, proposing that lower is better and no LDL-C is too low,<sup>191-193</sup> the US FDA has stated that “all statins... should be prescribed at the lowest dose that achieves the goals of therapy (e.g. target LDL-C level).”<sup>180</sup> Intensive statin treatment in RCTs does not improve mortality, even in patients with heart disease, relative to less intensive treatment (although it may do so in the setting of acute coronary syndrome).<sup>194</sup> Moreover, intensive treatment comes at the cost of an increased risk of adverse outcomes.<sup>176, 194</sup>

## Drug Interactions

Fibrates, particularly gemfibrozil, amplify the risk of rhabdomyolysis on statins (most powerfully for cerivastatin<sup>170, 171</sup>), and are present in many statin rhabdomyolysis reports,<sup>82, 99, 105, 109, 195-221</sup> likely due to their effect of impeding statin metabolism and perhaps their additional lipid-modifying effects. (Other cholesterol-lowering drugs have also been implicated in muscle toxicity<sup>222</sup> and in statin rhabdomyolysis cases, although less frequently.<sup>223-225</sup>) However, lipid-lowering drugs are not the sole drug class that may increase risk of statin rhabdomyolysis and other statin AEs (see Table III,<sup>105 155, 169-171, 179, 195-199, 202, 210, 223-233</sup>).

Drug interactions arise when drugs inhibit metabolic pathways of statins, compete for metabolism with statins, or cause similar or interacting toxicity. Additionally, apparent interactions may arise when drugs serve as markers for existing problems that signal vulnerability to statin AEs.

Several widely used statins – atorvastatin, simvastatin, and lovastatin (and previously cerivastatin, now off the market) – are metabolized by the cytochrome P450 (CYP)3A4 pathway.<sup>318</sup> (Simvastatin acid is also metabolized by CYP2C8; fluvastatin is primarily metabolized by the CYP2C9 pathway, while pravastatin and rosuvastatin are not metabolized by these systems.<sup>318</sup>) Concurrent administration of statins with CYP3A4 inhibitors may raise statin concentrations and risk of toxicity, including rhabdomyolysis.<sup>185</sup> The CYP3A4 pathway is inhibited by a variety of agents including cyclosporin, erythromycin, azole antifungals, and antiretrovirals such as ritonavir.<sup>318, 319</sup> (Antiretrovirals may also cause lipids to rise, thus creating both the need for lipid therapy and the setting in which it is more toxic.<sup>302</sup>) Some agents, such as calcium channel blockers, are considered weaker CYP3A4 inhibitors and appear to increase statin rhabdomyolysis risk, perhaps to a lower degree.<sup>186, 318, 320</sup> However, interaction effects vary dramatically among statins as well as among subjects for a single statin. Regarding the former, increases in simvastatin concentrations may be several times greater than in atorvastatin concentrations with concurrent CYP3A4 inhibitors.<sup>321</sup> Regarding the latter, one study of 12 subjects showed more than tenfold interindividual variation in the extent of interaction between simvastatin and both erythromycin and verapamil as indexed by these drugs' effect on simvastatin concentration.<sup>322</sup> Of note, in a large study using administrative



claims data, statin-associated muscle disorders including rhabdomyolysis were six-fold elevated in persons on concurrent CYP3A4 inhibitors.<sup>167</sup>

Grapefruit juice and perhaps pomegranate juice inhibit CYP3A4 and have been presumptively linked to statin rhabdomyolysis.<sup>230, 323</sup> (Combined rosuvastatin-ezetimibe therapy was involved in the report involving pomegranate juice.<sup>230</sup>) Although some urge caution only with consumption of greater than a quart of grapefruit juice a day,<sup>94, 324, 325</sup> far smaller quantities of grapefruit juice can pose a potential risk in vulnerable subjects: less than a cup daily of grapefruit juice for three days, consumed prior to subjects' simvastatin dose, reportedly increased simvastatin concentrations by four-fold on average (range: ~two-fold to nine-fold,  $p < 0.01$ ).<sup>326</sup>

The CYP3A pathway has a prominent role in drug metabolism in liver and intestine<sup>327</sup> and approximately half of prescription drugs are metabolized by CYP3A4.<sup>328</sup> For this reason polypharmacy may lead to competition for a common metabolic pathway. This competition may increase statin concentrations and the risk of dose-related statin AEs.

Individuals may differ in their response to individual statins, in terms of both efficacy and tolerability, due to pharmacogenomic differences, including those that affect statin hepatic uptake, clearance, and CYP pathways.<sup>329-332</sup> Differences in these pathways may also lead to differential vulnerability to drug interactions.

Fibrates have special relevance to statin AEs, and as noted above, gemfibrozil, in particular, interferes with statin metabolism (an effect that was found to be singularly powerful in combination with cerivastatin<sup>170, 171</sup>). Additionally, fibrates themselves may be linked to rhabdomyolysis.<sup>168</sup> Finally, fibrates may serve as markers for a population at risk for statin AEs – persons with high triglycerides and impaired fatty acid oxidation (those most likely to receive fibrates) may also be at amplified risk of statin AEs.<sup>94, 155, 333</sup>

## Risk Factors for Adverse Effects

In addition to dose and drug interactions, a multitude of other factors have been associated with an increased risk of statin AEs. Reported risk factors and corresponding citations are delineated in Table IV.<sup>36, 37, 51, 52, 94, 163, 176, 178, 180, 186, 191, 192, 283-288, 300, 325, 334-340</sup>

Most risk factors depicted can be viewed as sharing one or both of two primary mediating pathways: increased statin exposure (e.g. dose, drug interactions, genetic variants or other factors that affect clearance or hepatic uptake) or mitochondrial derangement or vulnerability (with factors producing mitochondrial problems or serving as a marker for existing ones). Reduced concentrations of coenzyme Q10 are particularly a problem in the setting of existing mitochondrial dysfunction because ample coenzyme Q10 can bypass a range of respiratory chain defects,<sup>23-25</sup> fostering adequate ATP production and improving the redox state. Additionally, toxicity of certain interacting drugs may be mediated through mitochondrial mechanisms (as Table III shows), and mitochondrial-relevant genetic defects have been disproportionately found in patients who experience statin myopathy (reviewed below), strongly supporting mitochondrial vulnerability. Metabolic syndrome factors, particularly hypertension, are linked to increased risk of statin AEs; and these factors, including obesity, hypertriglyceridemia, hyperglycemia and particularly hypertension, have been linked to mitochondrial dysfunction and mitochondrial DNA defects.<sup>377</sup>

## Mitochondrial Effects

While a medley of potential mechanisms may cause or contribute to statin AEs (and these merit more full review in another venue), mitochondrial mechanisms have been repeatedly

implicated in muscle AEs. Mitochondrial defects predispose to problems on statins (as shown in the second to last entry of Table IV, ‘Genetic mutations associated with mitochondrial dysfunction’). Additionally, statins predispose to mitochondrial defects (Table V,<sup>2231, 32, 112, 155, 158, 162, 397, 406-414</sup>) – in all users and, to a greater degree, in vulnerable individuals. Dose-dependent reductions in coenzyme Q10<sup>20-22</sup> can reduce cell energy, promote oxidation,<sup>362, 415</sup> promote apoptosis, and unmask silent mitochondrial defects.<sup>23-25, 362, 415-418</sup> The mevalonate pathway, which statins inhibit, also produces heme-A, which has its own central involvement in mitochondrial electron transport.<sup>419</sup>

Statins reduce<sup>20-22</sup> and coenzyme Q10 supplementation increases<sup>420-422</sup> serum coenzyme Q10 levels. The ability to demonstrate tissue changes in coenzyme Q10 with administration of either agent is more variable; however, irrespective of changes in tissue coenzyme Q10 levels, changes in tissue mitochondrial and respiratory function clearly occur (improved with coenzyme Q10, impaired with statins).<sup>25, 156-158, 407, 423</sup> Indeed, a range of study types have shown mitochondrial and metabolic predispositions to statin AE vulnerability, and mitochondrial and metabolic effects of statins in animals<sup>317, 347, 424-428</sup> as well as humans, with mitochondrial effects in humans arising in all users or selectively in those who express AEs (Tables V and VI).

## Non-muscle Statin Adverse Effects

Muscle is highly aerobically dependent and selectively vulnerable to mitochondrial pathology.<sup>430</sup> But given the evidence for mitochondrial vulnerability and pathology related to statin AEs, it merits note that other organs – including brain, liver, heart and kidney – can be affected by mitochondrial pathology as well,<sup>430</sup> and we suggest mitochondrial mechanisms may also be involved in a range of nonmuscle statin AEs. The occurrence of failure of other organs in concert with rhabdomyolysis is noteworthy in this regard, and multiple organ injury or failure has been reported in the context of statin rhabdomyolysis.<sup>81, 91, 96, 98, 100, 105, 107-109, 112, 431</sup>

Cognitive problems are second only to muscle problems among patient reports of statin AEs.<sup>432</sup> Brain tissue shares with muscle tissue a high mitochondrial vulnerability as both are postmitotic tissue with high metabolic demand.<sup>433-437</sup> Muscle has a very high dynamic range of demand; and the brain, while reflecting only about 2-4% of (nonobese) body mass, accounts for approximately 20% of oxygen<sup>438</sup> and 50% of glucose utilization.<sup>439</sup> Muscle and brain are the organs most classically affected in mitochondrial disease (mitochondrial myopathy and encephalomyopathy are classical manifestations of respiratory chain diseases). For instance, mitochondrial encephalomyopathy resulting from heritable coenzyme Q10 deficiency classically produces fatigue, muscle symptoms, and cognitive problems,<sup>440</sup> although the cases referred for analysis are often relatively severe.<sup>429, 441</sup> Gastrointestinal<sup>26</sup> and neurological symptoms,<sup>432, 442</sup> psychiatric symptoms,<sup>443-446</sup> sleep problems,<sup>444, 447</sup> glucose elevations,<sup>182</sup> and a range of other symptoms reported on statins also arise in mitochondrial dysfunction.<sup>379, 448-457</sup>

Table VII,<sup>2831, 108, 172, 178, 181, 458-481</sup> shows those AEs for which there is RCT support in some subject groups (and provides, in some cases, additional non-RCT evidence). Randomized trials have recognized limitations for AE detection, due in part to selection considerations.<sup>482</sup> Even among RCTs, studies that differ in selection criteria are expected to differ in expression of, and power for, AE occurrence due to effect modification. (This issue is not specific to statins, but is germane to assessment of risks and benefits for all drugs.)

When the average effect (of drug on outcome) is harmful in RCTs, then it can be concluded that adverse consequences to that outcome occur in at least some individuals. However, when

average effects are *not* harmful, AEs to that outcome are *not* on that basis excluded. Recall that randomized trials seek to determine the overall or average impact of a drug on an outcome (in the selected sample), in order to assess whether the drug may be used to benefit that outcome *on average*. It is worth re-emphasizing that harms in an individual are important even if benefits occur on average.

Case reports coupled with triangulating evidence can represent an important source of evidence regarding occurrence of specific AEs, and case reports and case series are reportedly the primary grounds upon which label changes with drugs occur.<sup>54-57</sup> For identification of AEs *in an individual*, the experience of the individual is the most relevant since average effects need not apply to an individual, whether average effects are determined by RCT or observational designs. Table VIII,<sup>15369, 444, 538-560</sup> characterizes reported AEs that do not have identified RCT support.

Effect modification – leading to statins producing different effects on the same outcome in different individuals – is recognized in the context of statin (and other lipid-lowering drug) effects on lipids,<sup>881, 882</sup> and has previously been discussed in relation to statin muscle effects (benefits to walking occur in some,<sup>29</sup> while detriments occur in others<sup>113</sup>). As Table VII shows, a similar theme pervades other statin effects, with statins reported to benefit and worsen proteinuria and to benefit and worsen arrhythmia, cardiac function, and an array of other outcomes. We speculate that a common source of effect modification underlies many of these reported benefits and harms – with statin-induced antioxidant effects and improved flow benefiting many organs in some individuals; and statin-induced pro-oxidant effects and mitochondrial dysfunction adversely affecting a range of organs and outcomes in other individuals. Indeed, even RCT evidence has differed for the same outcome in different subject groups, generally along the lines this proposition predicts.

## Prevention, Treatment, and Recovery of Statin Adverse Effects

Observational and limited randomized trial data variably suggest partial (though incomplete) benefit of coenzyme Q10 supplementation to muscle symptoms; and to other AEs of statins (observational data).<sup>883-886</sup> Additional studies are required to better understand the role of coenzyme Q10 supplementation in prevention and mitigation of statin AEs. It merits note that preparations of coenzyme Q10 vary widely in their bioavailability.<sup>887</sup>

Randomized trial evidence has little to offer in understanding recovery profiles for statin AEs, although some evidence is beginning to emerge. While one study reported uniform recovery of statin muscle AEs,<sup>888</sup> a larger statin myopathy clinic including more objective data noted that recovery is often incomplete when objective measures are used.<sup>889</sup> Other evidence supports this, noting for muscle AEs that “variable persistent symptoms occurred in 68% of patients despite cessation of therapy.”<sup>155</sup> Incomplete resolution in some subjects has been reported for other AEs. Thus, in an analysis of data, presented in the *Australian Adverse Drug Reaction Bulletin*, it was noted that “Statin-associated peripheral neuropathy may persist for months or years after withdrawal of the statin... In two ADRAC (Adverse Drug Reactions Advisory Committee) cases of persistent peripheral neuropathy, motor and sensory conduction tests showed minimal recovery 4 and 12 months, respectively, after discontinuation of simvastatin, despite clinical improvement.”<sup>561</sup>

## Underrecognition of Statin Adverse Effects

As others have observed, “finding potential drug-safety problems requires skillful observation by clinicians who are attuned to the possibility of drug-related adverse events.”<sup>890</sup> and (according to FDA officials) “physicians need to think ‘adverse drug reactions’ when encountering unexpected symptoms in their patients.”<sup>891</sup>



Even for the most commonly reported AEs involving statins, patients state that physicians often dismiss the *possibility* that their AE may be statin related.<sup>432</sup> Failure to recognize drug AEs can prevent needed reassessment of the risk-benefit profile for statin treatment – and where appropriate, modification of the treatment regimen, in the face of possible or probable statin AEs. This may reduce quality of patient care, reduce medication compliance relative to a modified regimen, and place patient safety in peril both for morbidity and mortality from not only the AEs, but also perhaps from the conditions the medication is designed to treat.

The converse is also true: awareness of statin AEs is vitally important as it may improve recognition of these effects when they arise, enable more informed treatment decisions by patient and provider, improve the quality of patient care – and reduce patient suffering and morbidity.

It has been observed that “as more information is learned through the results of clinical trials, LDL-C goals become more stringent and difficult to attain. Large doses of high-potency statins, sometimes given in combination with other lipid-lowering agents, are frequently necessary to achieve these goals. As a result, the frequency of AEs from statin therapy may be expected to increase, and less common AEs may occur more often.”<sup>734</sup> This increases the importance of recognition of statin AEs.

As reviewed here, AEs on statins may signal a mitochondrial vulnerability, which may alter or perhaps even reverse an otherwise favorable impact of statins on cell energetics. And AEs may signal occurrence of a net prooxidant rather than antioxidant effect of statins<sup>53</sup> with possible unfavorable implications for a range of statins' proposed pleiotropic effects.<sup>892</sup>

## Conclusion

When possible side effects arise in a patient on any drug, the risk-benefit balance of treatment should be reassessed. Statins are a linchpin of current approaches to cardiovascular protection: however, AEs of statins are neither vanishingly rare nor of trivial impact. For statins, as for all medications, vigilance for potential AEs is imperative. Recognition of potential statin AEs is needed and may be fostered by an improved awareness both of relevant literature and of its limitations.

## Acknowledgments

The authors have no conflicts of interest to report. Work that contributed to this paper was funded by a Robert Wood Johnson Generalist Physician Faculty Scholar award to Dr Golomb. The study sponsor did not participate in study design; in the collection, analysis, or interpretation of data; in the writing of this report; or in the decision to submit this paper for publication. The authors would like to thank Hanh Nguyen and Jersey Neilson for kind assistance securing articles; and Sabrina Koperski for excellent editorial and administrative assistance.

## References

1. IMS Health. US Top Ten Products by Prescriptions. 2002. <http://www.imshealth.com/public/structure/discontent/1,2779,1343-1343-144004,00.html>Downloaded 4-19-02:Source: IMS HEALTH, National Prescription Audit Plus™, 2002
2. IMS Health. Lipitor leads the way in 2003. Mar 18. 2004 [http://www.ims-global.com/insight/news\\_story/0403/news\\_story\\_040316.htm](http://www.ims-global.com/insight/news_story/0403/news_story_040316.htm)
3. IMS Health. IMS Global Insights - IMS Retail Drug Monitor December 2007. 2007. [http://www.imshealth.com/web/content/0,3148,64576068\\_63872702\\_70260998\\_83746585,00.html](http://www.imshealth.com/web/content/0,3148,64576068_63872702_70260998_83746585,00.html)
4. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. *Drugs* 2001;61:197–206. [PubMed: 11270938]
5. Smith SCJ. Bridging the treatment gap. *American Journal of Cardiology* 2000;85:3E–7E.

6. Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. *Cardiovasc Drugs Ther* 2001;15:211–8. [PubMed: 11713888]
7. Criqui MH, Golomb BA. Low and lowered cholesterol and total mortality. *J Am Coll Cardiol* 2004;44:1009–10. [PubMed: 15337211]
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994;344:1383–9. [PubMed: 7968073]
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [see comments]. *New England Journal of Medicine* 1998;339:1349–57. [PubMed: 9841303]
10. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. *Clin Biochem* 2007;40:575–84. [PubMed: 17467679]
11. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. *Nature* 1990;343:425–30. [PubMed: 1967820]
12. Mach F. Statins as immunomodulatory agents. *Circulation* 2004;109:III5–7. [PubMed: 15173058]
13. Keyhani J, Keyhani E. Mevalonic acid as a precursor of the alkyl sidechain of heme a of cytochrome c oxidase in yeast *Saccharomyces cerevisiae*. *FEBS Lett* 1978;93:271–4. [PubMed: 213310]
14. Mol MJ, Stalenhoef AF, Stuyt PM, Hermus AR, Demacker PN, Van TLA. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. *Clin Endocrinol (Oxf)* 1989;31:679–89. [PubMed: 2560686]
15. Hyypya MT, Kronholm E, Virtanen A, Leino A, Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. *Psychoneuroendocrinology* 2003;28:181–94. [PubMed: 12510011]
16. Cimino M, Gelosa P, Gianella A, Nobili E, Tremoli E, Sironi L. Statins: multiple mechanisms of action in the ischemic brain. *Neuroscientist* 2007;13:208–13. [PubMed: 17519364]
17. Harris JJ, Hibbeln JR, Mackey RH, Muldoon MF. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. *Prostaglandins Leukot Essent Fatty Acids* 2004;71:263–9. [PubMed: 15310527]
18. Maritz FJ. Efficacy and dangers of statin therapy. *Cardiovasc J S Afr* 2002;13:200–3. [PubMed: 12389064]
19. Talbert RL. Safety issues with statin therapy. *J Am Pharm Assoc (Wash DC)* 2006;46:479–88. quiz 488-90.
20. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. *Mol Aspects Med* 1997;18(Suppl):S137–44. [PubMed: 9266515]
21. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol* 2004;61:889–92. [PubMed: 15210526]
22. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. *British Journal of Clinical Pharmacology* 1996;42:333–7. [PubMed: 8877024]
23. Mahoney DJ, Parise G, Tarnopolsky MA. Nutritional and exercise-based therapies in the treatment of mitochondrial disease. *Curr Opin Clin Nutr Metab Care* 2002;5:619–29. [PubMed: 12394637]
24. Rosenfeldt FL, Pepe S, Linnane A, et al. Coenzyme Q10 protects the aging heart against stress: studies in rats, human tissues, and patients. *Ann N Y Acad Sci* 2002;959:355–9. discussion 463-5. [PubMed: 11976209]
25. Barbiroli B, Frassinetti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. *Cell Mol Biol (Noisy-le-grand)* 1997;43:741–9. [PubMed: 9298596]
26. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. *New Zealand Medical Journal* 1991;104:493–5. [PubMed: 1745460]

27. Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. *Qjm* 1999;92:387–94. [PubMed: 10627888]
28. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. *Pharmacoepidemiol Drug Saf* 2007;16:132–43. [PubMed: 17072896]
29. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. *Circulation* 2003;107:757–61. [PubMed: 12578881]
30. Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. *Arch Mal Coeur Vaiss* 2005;98:661–6. [PubMed: 16007821]
31. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. *Ann Intern Med* 2002;137:581–5. [PubMed: 12353945]
32. Troseid M, Henriksen OA, Lindal S. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. *Apmis* 2005;113:635–7. [PubMed: 16218940]
33. Sinzinger H. Statin-induced myositis migrans. *Wien Klin Wochenschr* 2002;114:943–4. [PubMed: 12528328]
34. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. *Cardiovasc Drugs Ther* 2005;19:403–14. [PubMed: 16453090]
35. Franc S, Bruckert E, Giral P, Turpin G. Rhabdomyolysis in patients with preexisting myopathy, treated with antilipemic agents. *Presse Med* 1997;26:1855–8. [PubMed: 9569908]
36. Hosein, S. Warnings issued in Canada and the European Union about lipid drug. *CATIE News*. Jun 28. 2004 2004; <http://www.aegis.com/news/catie/2004/CATE-N20040602.html>
37. Golomb B, Yang E, Denenberg J, Criqui M. Statin-associated muscle adverse effects. *Circulation* 2003;107:e7028–9.
38. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. *Pharmacotherapy* 2004;24:1177–85. [PubMed: 15460178]
39. Gutierrez MA, Roper JM, Hahn P. Paradoxical reactions to benzodiazepines. *Am J Nurs* 2001;101:34–9. quiz 39–40. [PubMed: 11469127]
40. Tanquary J, Masand P. Paradoxical reaction to buspirone augmentation of fluoxetine. *J Clin Psychopharmacol* 1990;10:377. [PubMed: 2258456]
41. Stewart JT. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. *J Clin Psychiatry* 1987;48:385–6. [PubMed: 2957363]
42. Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines--a genetically determined phenomenon? *Anaesth Intensive Care* 1987;15:330–1. [PubMed: 3661967]
43. Warren SE, Ebert E, Swerdlin AH, Steinberg SM, Stone R. Clonidine and propranolol paradoxical hypertension. *Arch Intern Med* 1979;139:253. [PubMed: 434988]
44. Lion JR, Azcarate CL, Koepke HH. "Paradoxical rage reactions" during psychotropic medication. *Dis Nerv Syst* 1975;36:557–8. [PubMed: 1164858]
45. Blum I, Atsmon A, Steiner M, Wysenbeek H. Paradoxical rise in blood pressure during propranolol treatment. *Br Med J* 1975;4:623. [PubMed: 1203703]
46. Mitani H, Egashira K, Ohashi N, et al. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. *Pharmacology* 2003;68:121–30. [PubMed: 12784083]
47. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C, et al. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. *J Hypertens* 2002;20:429–37. [PubMed: 11875310]
48. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. *Stroke* 1999;30:1969–73. [PubMed: 10471452]
49. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. *Heart Vessels* 2005;20:133–6. [PubMed: 16025360]

50. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? *Semin Dial* 2004;17:449–54. [PubMed: 15660575]
51. Sinzinger H, Chehne F, Lupattelli G. Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without Enzyme Elevation or Myopathy. *Drug Saf* 2002;25:877–83. [PubMed: 12241128]
52. Sinzinger H, Lupattelli G, Chehne F. Increased lipid peroxidation in a patient with CK-elevation and muscle pain during statin therapy. *Atherosclerosis* 2000;153:255–6. [PubMed: 11058722]
53. Sinzinger H, Lupattelli G, Chehne F, Oguogho A, Furberg CD. Isoprostane 8-epi-PGF<sub>2</sub>alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. *J Clin Pharm Ther* 2001;26:303–10. [PubMed: 11493374]
54. Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. *Eur J Clin Pharmacol* 2001;57:89–91. [PubMed: 11372600]
55. Goldman SA, Kennedy DL. MedWatch: FDA's Medical Products Reporting Program. *Postgrad Med* 1998;103:13–6. [PubMed: 9519028]
56. Rossi AC, Knapp DE. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. *Jama* 1984;252:1030–3. [PubMed: 6748207]
57. McNeil JJ, Grabsch EA, McDonald MM. Postmarketing surveillance: strengths and limitations. The flucloxacillin-dicloxacillin story. *Medical Journal of Australia* 1999;170:270–3. [PubMed: 10212650]
58. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. *Br J Clin Pharmacol* 2004;57:525–8. [PubMed: 15025753]
59. Eagles CJ, Kendall MJ. The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects. *Br J Clin Pharmacol* 1997;43:291–300. [PubMed: 9088584]
60. Seachrist JL, Loi CM, Evans MG, Criswell KA, Rothwell CE. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. *Toxicol Sci* 2005;88:551–61. [PubMed: 16141437]
61. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. *Metabolism* 1997;46:1206–10. [PubMed: 9322808]
62. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. *Arterioscler Thromb Vasc Biol* 2005;25:2560–6. [PubMed: 16224050]
63. Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. *Rev Med Interne* 2004;25:294–8. [PubMed: 15050796]
64. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin [letter]. *Lancet* 1997;349:1600–1. [PubMed: 9174565]
65. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. *Aust NZ J Med* 1995;25:745–6.
66. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis [letter; comment]. *British Journal of Rheumatology* 1994;33:199. [PubMed: 8162495]
67. Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. *Am J Med* 2001;110:670–1. [PubMed: 11388341]
68. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, Toribio E. Severe polymyositis with simvastatin use. *Rev Neurol* 2003;37:934–6. [PubMed: 14634922]
69. Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dermatomyositis [letter]. *Postgraduate Medical Journal* 1996;72:694. [PubMed: 8944218]
70. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. *N Engl J Med* 1992;327:649–50. [PubMed: 1640970]
71. Takagi A, Shiio Y. Pravastatin-associated polymyositis, a case report. *Rinsho Shinkeigaku* 2004;44:25–7. [PubMed: 15199734]

72. Thual N, Penven K, Chevallier JM, Domp Martin A, Leroy D. Fluvastatin-induced dermatomyositis. *Ann Dermatol Venereol* 2005;132:996–9. [PubMed: 16446645]
73. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. *Muscle Nerve* 2004;30:803–7. [PubMed: 15389654]
74. Zuech P, Pauwels C, Duthoit C, et al. Pravastatin-induced dermatomyositis. *Rev Med Interne* 2005;26:897–902. [PubMed: 16154665]
75. Scalvini T, Marocolo D, Cerudelli B, Sleiman I, Balestrieri GP, Giustina G. Pravastatin-associated myopathy. Report of a case. *Recenti Progressi in Medicina* 1995;86:198–200. [PubMed: 7604176]
76. Witko-Sarsat V, Nguyen Khoa T, Jungers P, Druke T, Descamps-Latscha B. Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. *Adv Nephrol Necker Hosp* 1998;28:321–41. [PubMed: 9889997]
77. Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. *J Leukoc Biol* 2004;75:995–1000. [PubMed: 14982943]
78. Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. *Neurology* 2004;63:2188. [PubMed: 15596782]
79. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. *Cardiovasc Drugs Ther* 2003;17:459–65. [PubMed: 15107601]
80. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivisto KT. Muscle symptoms associated with statins: a series of twenty patients. *Basic Clin Pharmacol Toxicol* 2006;98:51–4. [PubMed: 16433891]
81. Eriksson M, Angelin B, Sjoberg S. Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of ‘evidence-based medicine’. *J Intern Med* 2005;257:313–4. [PubMed: 15715689]
82. Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. *Angiology* 2000;51:695–7. [PubMed: 10959522]
83. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. *New Engl J Med* 2002;346:539–40. [PubMed: 11844864]
84. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. *Am J Med* 2000;108:351–2. [PubMed: 11014734]
85. Scheen AJ. Fatal rhabdomyolysis caused by cerivastatin. *Rev Med Liege* 2001;56:592–4. [PubMed: 11584446]
86. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. *Clin Infect Dis* 2002;35:e111–2. [PubMed: 12410494]
87. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. *South Med J* 2001;94:1023–6. [PubMed: 11702815]
88. Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. *Ann Intern Med* 2004;140:W31. [PubMed: 15096363]
89. Kahri J, Valkonen M, Backlund T, Vuoristo M, Kivisto KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. *Eur J Clin Pharmacol* 2005;60:905–7. [PubMed: 15625612]
90. Jamil S, Iqbal P. Rhabdomyolysis induced by a single dose of a statin. *Heart* 2004;90:e3. [PubMed: 14676266]
91. Al Shohaib S. Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. *American Journal of Nephrology* 2000;20:212–3. [PubMed: 10878403]
92. Jose J, Saravu K, Shastry BA. Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome. *Am J Health Syst Pharm* 2007;64:726–9. [PubMed: 17384358]
93. Archambeaud-Mouveroux F, Lopez S, Combes C, et al. Rhabdomyolysis induced by fenofibrate monotherapy. *Rev Med Interne* 2006;27:573–4. [PubMed: 16716459]
94. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. *Am J Med* 2006;119:400–9. [PubMed: 16651050]
95. Schindler C, Thorns M, Matschke K, Tugtekin SM, Kirch W. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin. *Clin Ther* 2007;29:172–6. [PubMed: 17379057]



96. Sreenarasimhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. *Am J Med* 2002;113:348–9. [PubMed: 12361829]
97. Akoglu H, Yilmaz R, Kirkpantur A, Arici M, Altun B, Turgan C. Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. *Ann Pharmacother* 2007;41:143–7. [PubMed: 17148651]
98. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. *Postgraduate Medical Journal* 1990;66:294–6. [PubMed: 2385552]
99. Sirvent AE, Cabezuelo JB, Enriquez R, Amoros F, Gonzalez C, Reyes A. Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination. *Nefrologia* 2001;21:497–500. [PubMed: 11795020]
100. Chu PH, Chen WJ, Chiang CW, Lee YS. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy. *Japanese Heart Journal* 1997;38:541–5. [PubMed: 9350151]
101. Bravo JJ, Novoa D, Romero R, Sanchez-Guisande D. Cerivastatin and acute kidney failure caused by rhabdomyolysis. *Nefrologia* 2001;21:509. [PubMed: 11795023]
102. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. *Jama* 1988;260:239–41. [PubMed: 3290520]
103. Fernandez Zatarain G, Navarro V, Garcia H, Villatoro J, Calvo C. Rhabdomyolysis and acute renal failure associated with lovastatin. *Nephron* 1994;66:483–4. [PubMed: 8015659]
104. Knoll RW, Ciafone R, Galen M. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibrozil. *Conn Med* 1993;57:593–4. [PubMed: 8252847]
105. Abdul-Ghaffar NU, el-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. *Journal of Clinical Gastroenterology* 1995;21:340–1. [PubMed: 8583121]
106. Stein CA, Goel S, Ghavamian R. Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy. *Invest New Drugs* 2007;25:277–8. [PubMed: 17216557]
107. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. *Ann Pharmacother* 2006;40:753–7. [PubMed: 16537817]
108. Bielecki JW, Schraner C, Briner V, Kuhn M. Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and chlorzoxazone. *Schweiz Med Wochenschr* 1999;129:514–8. [PubMed: 10322565]
109. Su M, Hoffman RS, Flomenbaum M. Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis. *Am J Forensic Med Pathol* 2002;23:305–6. [PubMed: 12198364]
110. Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. *Ann Intern Med* 2005;142:949–50. [PubMed: 15941707]
111. Dromer C, Vedrenne C, Billey T, Pages M, Fournie B, Fournie A. Rhabdomyolysis due to simvastatin. Apropos of a case with review of the literature. *Rev Rhum Mal Osteoartic* 1992;59:281–3. [PubMed: 1496277]
112. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. *Am J Med* 1993;94:109–10. [PubMed: 8420287]
113. Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. *Neurorehabil Neural Repair* 2005;19:259–63. [PubMed: 16093417]
114. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. *Atherosclerosis* 1999;143:459–60. [PubMed: 10217378]
115. Pearce PZ. Statin-induced myopathy in a competitive amateur cyclist. *Curr Sports Med Rep* 2008;7:149–51. [PubMed: 18477872]
116. Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. *Jama* 1990;264:2992. [PubMed: 2243421]
117. Andreu AL, Tanji K, Bruno C, et al. Exercise intolerance due to a nonsense mutation in the mtDNA ND4 gene. *Ann Neurol* 1999;45:820–3. [PubMed: 10360780]

118. DiMauro S. Exercise intolerance and the mitochondrial respiratory chain. *Ital J Neurol Sci* 1999;20:387–93. [PubMed: 10937858]
119. DiMauro S, Andreu AL. Mutations in mitochondrial DNA as a cause of exercise intolerance. *Ann Med* 2001;33:472–6. [PubMed: 11680795]
120. Haller RG, Lewis SF, Estabrook RW, DiMauro S, Servidei S, Foster DW. Exercise intolerance, lactic acidosis, and abnormal cardiopulmonary regulation in exercise associated with adult skeletal muscle cytochrome c oxidase deficiency. *J Clin Invest* 1989;84:155–61. [PubMed: 2544623]
121. Nishigaki Y, Bonilla E, Shanske S, Gaskin DA, DiMauro S, Hirano M. Exercise-induced muscle “burning,” fatigue, and hyper-CKemia: mtDNA T10010C mutation in tRNA(Gly). *Neurology* 2002;58:1282–5. [PubMed: 11971101]
122. Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. *Brain* 2003;126:413–23. [PubMed: 12538407]
123. Hooper RG, Thomas AR, Kearn RA. Mitochondrial enzyme deficiency causing exercise limitation in normal-appearing adults. *Chest* 1995;107:317–22. [PubMed: 7842754]
124. Engel WK. Reversible ocular myasthenia gravis or mitochondrial myopathy from statins? *Lancet* 2003;361:85–6. [PubMed: 12517506]
125. Windler E. Should lipid-lowering agents be prescribed in myasthenia? *Dtsch Med Wochenschr* 1996;121:80. [PubMed: 8565815]
126. Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors. *Toxicol Appl Pharmacol* 2001;177:17–25. [PubMed: 11708896]
127. Milatovic D, Gupta RC, Aschner M. Anticholinesterase toxicity and oxidative stress. *ScientificWorldJournal* 2006;6:295–310. [PubMed: 16518518]
128. Marchiori PE, Levy JA, Carvalho-Alegro MS, et al. Mitochondrial dysfunction in myasthenia gravis. Report of a case. *Arq Neuropsiquiatr* 1989;47:355–8. [PubMed: 2619615]
129. Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. *Muscle Nerve* 2006;34:478–81. [PubMed: 16688722]
130. Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillain-Barre syndrome on initiation of statin therapy. *Muscle Nerve* 2004;30:663–6. [PubMed: 15389662]
131. Daghfous R, El Aidli S, Ghenni R, Belkahia C. Drug tendon disorders. *Tunis Med* 2005;83:253–7. [PubMed: 16044896]
132. Chazerain P, Hayem G, Hamza S, Best C, Ziza JM. Four cases of tendinopathy in patients on statin therapy. *Joint Bone Spine* 2001;68:430–3. [PubMed: 11707010]
133. Pullatt RC, Gadarla MR, Karas RH, Alsheikh-Ali AA, Thompson PD. Tendon rupture associated with simvastatin/ezetimibe therapy. *Am J Cardiol* 2007;100:152–3. [PubMed: 17599460]
134. Movahed MR, Samsamshariaat SA. Reproducible tendinitis-like symptoms related to statin therapy. *J Clin Rheumatol* 2006;12:320–1. [PubMed: 17149069]
135. Medicines Adverse Reactions Committee of the New Zealand Medicines and Medical Services Safety Authority. Adverse Reaction Reporting and IMMMP; Minutes of the 114th Medicines Adverse Reactions Committee Meeting. 3.2.2 Statins and tendonopathy; 2003.
136. Marie I, Delafenetre H, Massy N, Thuillez C, Noblet C. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. *Arthritis Rheum* 2008;59:367–72. [PubMed: 18311771]
137. Ouedraogo G, Morliere P, Santus R, Miranda, Castell JV. Damage to mitochondria of cultured human skin fibroblasts photosensitized by fluoroquinolones. *J Photochem Photobiol B* 2000;58:20–5. [PubMed: 11195848]
138. Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. *Mol Pharmacol* 1996;50:1178–88. [PubMed: 8913349]
139. Pouzaud F, Dutot M, Martin C, Debray M, Warnet JM, Rat P. Age-dependent effects on redox status, oxidative stress, mitochondrial activity and toxicity induced by fluoroquinolones on primary cultures of rabbit tendon cells. *Comp Biochem Physiol C Toxicol Pharmacol* 2006;143:232–41. [PubMed: 16574493]

140. Guis S, Jouglard J, Kozak-Ribbens G, et al. Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment. *J Rheumatol* 2001;28:1405–6. [PubMed: 11409139]
141. Guis S, Bendahan D, Kozak-Ribbens G, et al. Investigation of fluoroquinolone-induced myalgia using (31)P magnetic resonance spectroscopy and in vitro contracture tests. *Arthritis Rheum* 2002;46:774–8. [PubMed: 11920414]
142. Petitjeans F, Nadaud J, Perez JP, et al. A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin. *Eur J Clin Pharmacol* 2003;59:779–80. [PubMed: 14576967]
143. Harada K, Tsuruoka S, Fujimura A. Shoulder stiffness: a common adverse effect of HMG-CoA reductase inhibitors in women? *Intern Med* 2001;40:817–8. [PubMed: 11518133]
144. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. *Drug Saf* 2007;30:515–25. [PubMed: 17536877]
145. Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions arising in association with cholesterol-lowering drugs: Hypothesized role for oxidative stress and mitochondrial injury. *Drug Safety* 2009;32:649–661. [PubMed: 19591530]
146. Boltan DD, Lachar W, Khetan A, Bouffard JP, Roberts WC. Fatal and widespread skeletal myopathy confirmed morphologically years after initiation of simvastatin therapy. *Am J Cardiol* 2007;99:1171–6. [PubMed: 17437752]
147. Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in western New York. *Arch Intern Med* 2000;160:1199–203. [PubMed: 10789615]
148. Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Loeffler JP. Mitochondrial dysfunction in amyotrophic lateral sclerosis also affects skeletal muscle. *Muscle Nerve* 2006;34:253–4. [PubMed: 16642501]
149. Krasnianski A, Deschauer M, Neudecker S, et al. Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. *Brain* 2005;128:1870–6. [PubMed: 15901649]
150. Soraru G, Vergani L, Fedrizzi L, et al. Activities of mitochondrial complexes correlate with nNOS amount in muscle from ALS patients. *Neuropathol Appl Neurobiol* 2007;33:204–11. [PubMed: 17359361]
151. Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. *Brain* 2000;123(Pt 7):1339–48. [PubMed: 10869047]
152. Wiedemann FR, Winkler K, Kuznetsov AV, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. *J Neurol Sci* 1998;156:65–72. [PubMed: 9559989]
153. Walker JL, Smith GH, Gaston MS, Robinson CM. Spontaneous compartment syndrome in association with simvastatin-induced myositis. *Emerg Med J* 2008;25:305–6. [PubMed: 18434476]
154. Ramdass MJ, Singh G, Andrews B. Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism. *Postgrad Med J* 2007;83:152–3. [PubMed: 17344566]
155. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. *Muscle Nerve* 2006;34:153–62. [PubMed: 16671104]
156. Phillips CT, Gray NL, Puhek LM, McDonald FG, Sullivan MJ, Phillips PS. Cardiopulmonary Function Is Abnormal After Statin-Induced Rhabdomyolysis and Myositis [abstract]. *J Am Coll Cardiol* 2004;43(suppl A):16a.
157. Phillips CT, Gray NL, Puhek LM, McDonald FG, Sullivan MJ, Phillips PS. Basal Respiratory Exchange Ratio Is Altered With Statin Use in Normals [abstract]. *J Am Coll Cardiol* 2004;43(suppl A):233a.
158. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. *Atherosclerosis* 2004;177:183–8. [PubMed: 15488882]
159. Tsvigoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. *Arch Intern Med* 2006;166:1519–24. [PubMed: 16864763]

160. Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. *Ann Clin Biochem* 2004;41:338–40. [PubMed: 15298748]
161. Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. *J Intern Med* 2005;258:196–7. [PubMed: 16018797]
162. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin [letter]. *Australian and New Zealand Journal of Medicine* 1995;25:374–5. [PubMed: 8540887]
163. Ronaldson KJ, O'Shea JM, Boyd IW. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. *Drug Saf* 2006;29:1061–7. [PubMed: 17061911]
164. Tenenbaum A, Fisman EZ, Motro M. Rhabdomyolysis and lipid-lowering drugs. *Jama* 2005;293:1448. author reply 1448-9. [PubMed: 15784863]
165. Phillips PS. How common is rhabdomyolysis in patients receiving lipid-lowering therapy? *Nat Clin Pract Cardiovasc Med* 2005;2:130–1. [PubMed: 16265453]
166. Ardati A, Stolley P, Knapp DE, Wolfe SM, Lurie P. Statin-associated rhabdomyolysis. *Pharmacoepidemiol Drug Saf* 2005;14:287. [PubMed: 15782398]
167. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. *Am J Cardiol* 2006;97:61C–68C. [PubMed: 16377285]
168. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *Jama* 2004;292:2585–90. [PubMed: 15572716]
169. Andrejak M, Gras V, Caron J. Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin. *Therapie* 2005;60:299–304. [PubMed: 16128274]
170. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. *Drug Metab Dispos* 2002;30:1280–7. [PubMed: 12386136]
171. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. *J Pharmacol Exp Ther* 2002;301:1042–51. [PubMed: 12023536]
172. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. *Tenn Med* 2001;94:339–41. [PubMed: 11550401]
173. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. *Prev Cardiol* 2005;8:95–7. [PubMed: 15860984]
174. Sun D, Fernandes G. Lovastatin inhibits bone marrow-derived dendritic cell maturation and upregulates proinflammatory cytokine production. *Cell Immunol* 2003;223:52–62. [PubMed: 12914758]
175. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. *Clin Ther* 2006;28:26–35. [PubMed: 16490577]
176. Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. *Clin Ther* 2007;29:253–60. [PubMed: 17472818]
177. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. *Circulation* 2006;114:2788–97. [PubMed: 17159064]
178. Dale, KM.; Coleman, CI.; Henyan, NN.; Kluger, J.; White, CM. Does More Aggressive Statin Therapy Increase Muscle and Liver Risk?; 55th Annual Scientific Sessions of the American College of Cardiology; Atlanta, GA. Mar 11-14, 2006;
179. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. *Drug Metab Dispos* 2002;30:505–12. [PubMed: 11950779]
180. Food and Drug Administration. FDA Public Health Advisory on Crestor (rosuvastatin). Mar 2. 2005 [http://www.fda.gov/cder/drug/advisory/crestor\\_3\\_2005.htm](http://www.fda.gov/cder/drug/advisory/crestor_3_2005.htm)2005
181. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. *J Am Coll Cardiol* 2007;50:409–18. [PubMed: 17662392]
182. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. *J Atheroscler Thromb* 2006;13:123–9. [PubMed: 16835466]

183. Raskin P, Ganda OP, Willard D, et al. Efficacy and safety of pravastatin in the treatment of Type I or Type II diabetes mellitus and hypercholesterolemia. *Am J Med* 1995;99:362–369. [PubMed: 7573090]
184. Sabatine MS, Cannon CP. High-dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 substudy. *Circulation* 2004;100(Suppl III):834. III.
185. Scranton RE, Cantillon C, Gagnon D, Fiore L, Gaziano JM. Occurrences of rhabdomyolysis or myositis among statin users in a Veteran Affairs population (abstract from presentation at the AHA Council on Epidemiology and Prevention meeting in March 2004, San Francisco). *Circulation* 2004;109:P154.
186. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. *N Engl J Med* 2008;359:789–99. [PubMed: 18650507]
187. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195–207. [PubMed: 18997196]
188. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. *Clin Pharmacokinet* 1997;32:403–25. [PubMed: 9160173]
189. Omkumar RV, Gaikwad AS, Ramasarma T. Feedback-type inhibition of activity of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ubiquinone. *Biochem Biophys Res Commun* 1992;184:1280–7. [PubMed: 1590790]
190. Kumar, A.; Kaur, H.; Kumar, S.; Mohan, V. Atorvastatin alone/ in combination with coenzyme Q10 in 103 cases of heart failure (HF) due to ischemic cardiomyopathy (ICM); Fourth Conference of the International Coenzyme Q10 Association; Los Angeles. Apr 14-17, 2005;
191. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. *J Lipid Res* 2004;45:1583–93. [PubMed: 15102877]
192. Stein E. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. *Atheroscler Suppl* 2002;2:19–23. discussion 23-5. [PubMed: 11976073]
193. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. *J Am Coll Cardiol* 2004;43:2142–6. [PubMed: 15172426]
194. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. *Heart* 2007;93:914–21. [PubMed: 17277349]
195. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. *Am J Cardiol* 2005;95:120–2. [PubMed: 15619408]
196. Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil. *Jama* 1990;264:2991–2. [PubMed: 2243420]
197. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. *Jama* 1990;264:71–5. [PubMed: 2355431]
198. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. *American Journal of Cardiology* 1998;81:368–9. [PubMed: 9468088]
199. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. *Southern Medical Journal* 1997;90:546–7. [PubMed: 9160078]
200. Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil [letter]. *American Journal of Medicine* 2000;109:261–2. [PubMed: 11023440]
201. Birmingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. *American Journal of Health-System Pharmacy* 2000;57:461–4. [PubMed: 10711527]
202. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. *Ann Intern Med* 1990;112:228–30. [PubMed: 2297197]
203. Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. *Ann Pharmacother* 2002;36:820–3. [PubMed: 11978159]



204. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. *J Intern Med* 1996;240:403–4. [PubMed: 9010388]
205. Hyman DJ, Henry A, Taylor A. Severe rhabdomyolysis related to cerivastatin without gemfibrozil. *Ann Intern Med* 2002;137:74. [PubMed: 12093260]
206. Carretero MM, Manrique CA, Callol JA. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. *Br J Gen Pract* 2002;52:235–6.
207. Roca B, Calvo B, Monferrer R. Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy. *Ann Pharmacother* 2002;36:730–1. [PubMed: 11936088]
208. Bosch, Rovira T.; Llupart Pou, JA.; Forteza-Rey, J. Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil. *Rev Clin Esp* 2001;201:731–2.
209. Hendriks F, Kooman JP, van der Sande FM. Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil. *Nephrol Dial Transplant* 2001;16:2418–9. [PubMed: 11733637]
210. Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhabdomyolysis. *Ann Pharmacother* 2001;35:1016–9. [PubMed: 11573847]
211. de Arriba Mendez JJ, Gomez Merino E, Saez Barcelona JA, Saez Mendez L. Severe rhabdomyolysis associated with cerivastatin and gemfibrozil. *Med Clin (Barc)* 2001;117:278–9. [PubMed: 11562335]
212. Vasconez Espinosa F, Gomez Rodriguez N, Martin Joven A, Posada Garcia FJ. Rhabdomyolysis complicated with acute renal insufficiency in a patient treated with gemfibrozil and cerivastatin. *Rev Clin Esp* 2001;201:228–9. [PubMed: 11447919]
213. Tomlinson B, Lan IW. Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable? *Am J Med* 2001;110:669–70. [PubMed: 11388340]
214. Mastroianni CM, d'Ettorre G, Forcina G, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. *Aids* 2001;15:820–1. [PubMed: 11371708]
215. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. *Am J Cardiol* 1999;83:1146. [PubMed: 10190540]
216. Kind AH, Zakowski LJ, McBride PE. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction. *Wmj* 2002;101:53–6. [PubMed: 12426921]
217. Marsa Carretero M, Alos Manrique C, Valles Callol JA. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen. *Br J Gen Pract* 2002;52:235–6. [PubMed: 12030671]
218. SantaCruz PL, Gonzalez A, Leon ME, Fernandez MY. Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence. *Nefrologia* 2002;22:301–2. [PubMed: 12123135]
219. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. *Pharmacoepidemiol Drug Saf* 2004;13:417–26. [PubMed: 15269925]
220. Lau TK, Leachman DR, Lufschanowski R. Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy: report of a case. *Tex Heart Inst J* 2001;28:142–5. [PubMed: 11453128]
221. Farswan M, Rathod SP, Upaganlawar AB, Semwal A. Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. *Indian J Exp Biol* 2005;43:845–8. [PubMed: 16235714]
222. Gouton M. Hypothyroidism, hypocholesteremic agents and rhabdomyolysis. *Arch Mal Coeur Vaiss* 1993;86:1761–4. [PubMed: 8024378]
223. Chrysanthopoulos C, Kounis N. Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine. *Bmj (Clinical Research Ed.)* 1992;304:1225.
224. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. *Ann Intern Med* 1988;109:597–8. [PubMed: 3421570]

225. Piedra Leon M, Garcia Unzueta MT, Otero Martinez M, Amado Senaris JA. Rhabdomyolysis associated to combined ezetimibe-statin treatment. *Rev Clin Esp* 2007;207:425–6. [PubMed: 17688879]
226. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. *Ann Pharmacother* 2002;36:288–95. [PubMed: 11847951]
227. Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias [see comments]. *American Journal of Cardiology* 1992;70:1–9. [PubMed: 1615846]
228. Plotkin E, Bernheim J, Ben-Chetrit S, Mor A, Korzets Z. Influenza vaccine--a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. *Nephrol Dial Transplant* 2000;15:740–1. [PubMed: 10809833]
229. Jacob SS, Jacob S, Williams C, Deeg MA. Simvastatin, fenofibrate, and rhabdomyolysis. *Diabetes Care* 2005;28:1258. [PubMed: 15855605]
230. Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. *Am J Cardiol* 2006;98:705–6. [PubMed: 16923466]
231. Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. *Pharmacotherapy* 2007;27:309–11. [PubMed: 17253923]
232. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. *Ann Pharmacother* 2001;35:1096–107. [PubMed: 11573861]
233. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. *Pharmacotherapy* 2007;27:603–7. [PubMed: 17381388]
234. Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil [letter; comment]. *Jama* 1990;264:2991–2. [PubMed: 2243420]
235. Molden E, Andersson KS, Jacobsen D. Interactions between statins and macrolide antibiotics. *Tidsskr Nor Laegeforen* 2007;127:1660–1. [PubMed: 17571108]
236. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. *West J Med* 1991;154:213–5. [PubMed: 2006579]
237. Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. *Annals of Pharmacotherapy* 1997;31:859–63. [PubMed: 9220046]
238. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. *Annals of Pharmacotherapy* 2001;35:26–31. [PubMed: 11197581]
239. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. *Ann Pharmacother* 2003;37:808–11. [PubMed: 12773066]
240. Trieu J, Emmett L, Perera C, Thanakrishnan K, Van Der Wall H. Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. *Clin Nucl Med* 2004;29:803–4. [PubMed: 15545884]
241. Kahri AJ, Valkonen MM, Vuoristo MK, Pentikainen PJ. Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin. *Ann Pharmacother* 2004;38:719. [PubMed: 14966253]
242. Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. *Intern Med J* 2002;32:486–90. [PubMed: 12380704]
243. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. *Clinical Neuropharmacology* 1999;22:295–7. [PubMed: 10516882]
244. Itakura H, Vaughn D, Haller DG, O'Dwyer PJ. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. *J Urol* 2003;169:613. [PubMed: 12544321]
245. Akram K, Rao S, Parker M. A lesson for everyone in drug-drug interactions. *Int J Cardiol* 2007;118:e19–20. [PubMed: 17368833]
246. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. *N Engl J Med* 1995;333:664–5. [PubMed: 7637734]

247. Vlahakos DV, Manginas A, Chilidou D, Zamanika C, Alivizatos PA. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. *Transplantation* 2002;73:1962–4. [PubMed: 12131698]
248. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. *Arch Dermatol* 1996;132:1254. [PubMed: 8859048]
249. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. *Ann Pharmacother* 2003;37:1032–5. [PubMed: 12841814]
250. Moro H, Tsukada H, Tanuma A, et al. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. *AIDS Patient Care STDS* 2004;18:687–90. [PubMed: 15659879]
251. Rodriguez JA, Crespo-Leiro MG, Paniagua MJ, et al. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. *Transplant Proc* 1999;31:2522–3. [PubMed: 10500698]
252. Hermida Lazcano I, Revillo Pinilla P, Nerin Sanchez C, Lechuga Duran I, Fernandez Lopez J. Rhabdomyolysis in a patient treated with lovastatin and cyclosporine. *An Med Interna* 1997;14:488. [PubMed: 9453765]
253. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuhl S. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity. *Schweiz Med Wochenschr* 1995;125:1342–6. [PubMed: 7624744]
254. Mora C, Rodriguez ML, Navarro JF. Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin. *Transplantation* 2001;72:551. [PubMed: 11502997]
255. Gumprecht J, Zychma MJ, Grzeszczak W, et al. Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient. *Med Sci Monit* 2003;9:CS89–91. [PubMed: 12960932]
256. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. *Nephron* 2001;89:117–8. [PubMed: 11528245]
257. Chiffolleau A, Trochu JN, Veyrac G, et al. Rhabdomyolysis in cardiac transplant recipient due to verapamil interaction with simvastatin and cyclosporin treatment. *Therapie* 2003;58:168–70. [PubMed: 12942860]
258. Wombolt DG, Jackson A, Punn R, Smith S, McCune TR, Williams PB. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin. *J Clin Pharmacol* 1999;39:310–2. [PubMed: 10073331]
259. Schmassmann-Suhjar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. *Lancet* 1998;351:1929–30. [PubMed: 9654265]
260. Giner V, Munoz R, Redon J. Risperidone and severe cerivastatin-induced rhabdomyolysis. *J Intern Med* 2002;251:177–8. [PubMed: 11905593]
261. Webber MA, Mahmud W, Lightfoot JD, Shekhar A. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. *J Psychopharmacol* 2004;18:432–4. [PubMed: 15358990]
262. Patier JL, Ferrere F, Moreno-Cobo MA, Echaniz A. Rhabdomyolysis caused by the association of simvastatin and risperidone. *Med Clin (Barc)* 2007;129:439. [PubMed: 17927942]
263. Shelton PS, Barnett FL, Krick SE. Hyperventilation associated with quetiapine. *Ann Pharmacother* 2000;34:335–7. [PubMed: 10917381]
264. Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. *Eur Neuropsychopharmacol* 1999;9:301–9. [PubMed: 10422890]
265. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD Jr. Neuroleptic medications inhibit complex I of the electron transport chain. *Ann Neurol* 1993;33:512–7. [PubMed: 8098932]
266. Aguilar, Garcia MD.; Garmendia, Leiza JR.; Cuende, Melero JI.; Del Campo Del Campo, F. Rhabdomyolysis in neuroleptics: are we talking of neuroleptic malignant syndrome? *Aten Primaria* 2003;32:66–7. [PubMed: 12812699]
267. Baumgart U, Schmid R, Spiessl H. Olanzapine-induced acute rhabdomyolysis—a case report. *Pharmacopsychiatry* 2005;38:36–7. [PubMed: 15706465]
268. Himmerich H, Ehrlinger M, Hackenberg M, Lohr B, Nickel T. Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine. *J Clin Psychopharmacol* 2006;26:676–7. [PubMed: 17110835]

269. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. *Medicine (Baltimore)* 2005;84:377–85. [PubMed: 16267412]
270. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. *Neuropsychopharmacology* 1996;15:395–405. [PubMed: 8887994]
271. Pezza M, Busiello L, Palmese S, Cascella M, Di Domenico MG, De Robertis E. Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment. *Minerva Anestesiol* 2003;69:591–6. [PubMed: 14564256]
272. Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Olanzapine-induced rhabdomyolysis. *Ann Pharmacother* 2001;35:1020–3. [PubMed: 11573848]
273. Shuster J. Olanzapine and rhabdomyolysis. *Nursing* 2000;30:87. [PubMed: 11022553]
274. Smith RP, Puckett BN, Crawford J, Elliott RL. Quetiapine overdose and severe rhabdomyolysis. *J Clin Psychopharmacol* 2004;24:343. [PubMed: 15118490]
275. Waring WS, Wrate J, Bateman DN. Olanzapine overdose is associated with acute muscle toxicity. *Hum Exp Toxicol* 2006;25:735–40. [PubMed: 17286152]
276. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. *Am J Psychiatry* 2002;159:1435. [PubMed: 12153844]
277. Zink M, Knopf U, Argiriou S, Kuwilsky A. A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone. *J Clin Psychiatry* 2006;67:835. [PubMed: 16841636]
278. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. *J Neurochem* 2002;83:1241–51. [PubMed: 12472879]
279. Roten L, Schoenenberger RA, Krahenbuhl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. *Ann Pharmacother* 2004;38:978–81. [PubMed: 15069169]
280. de Denus S, Spinler SA. Amiodarone's role in simvastatin-associated rhabdomyolysis. *Am J Health Syst Pharm* 2003;60:1791. author reply 1791-2. [PubMed: 14503117]
281. Schmidt GA, Hoehns JD, Purcell JL, Friedman RL, Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. *J Am Board Fam Med* 2007;20:411–6. [PubMed: 17615423]
282. Golomb BA, Evans MA. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. *Med J Aust* 2007;187:253. [PubMed: 17708735]
283. Varbiro G, Toth A, Tapodi A, Veres B, Sumegi B, Gallyas F Jr. Concentration dependent mitochondrial effect of amiodarone. *Biochem Pharmacol* 2003;65:1115–28. [PubMed: 12663047]
284. Yasuda SU, Sausville EA, Hutchins JB, Kennedy T, Woosley RL. Amiodarone-induced lymphocyte toxicity and mitochondrial function. *J Cardiovasc Pharmacol* 1996;28:94–100. [PubMed: 8797142]
285. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. *J Pharmacol Exp Ther* 1990;255:1377–84. [PubMed: 1979817]
286. Ribeiro SM, Campello AP, Nascimento AJ, Kluppel ML. Effect of amiodarone (AMD) on the antioxidant enzymes, lipid peroxidation and mitochondrial metabolism. *Cell Biochem Funct* 1997;15:145–52. [PubMed: 9377792]
287. Card JW, Racz WJ, Brien JF, Massey TE. Attenuation of amiodarone-induced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction. *J Pharmacol Exp Ther* 2003;304:277–83. [PubMed: 12490602]
288. Bolt MW, Card JW, Racz WJ, Brien JF, Massey TE. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. *J Pharmacol Exp Ther* 2001;298:1280–9. [PubMed: 11504831]
289. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. *AIDS Patient Care STDS* 2000;14:13–8. [PubMed: 12240878]
290. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. *Am J Health Syst Pharm* 2002;59:728–30. [PubMed: 11977859]

291. Nerurkar PV, Pearson L, Frank JE, Yanagihara R, Nerurkar VR. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production. *Cell Mol Biol (Noisy-le-grand)* 2003;49:1205–11. [PubMed: 14983988]
292. Sternfel T, Schmid M, Tischleder A, et al. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells. *Antivir Ther* 2007;12:769–78. [PubMed: 17713160]
293. Lopez S, Miro O, Martinez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. *Antivir Ther* 2004;9:47–55. [PubMed: 15040536]
294. ter Hofstede HJ, Burger DM, Koopmans PP. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. *Neth J Med* 2003;61:393–403. [PubMed: 15025414]
295. Walker UA, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. *Hepatology* 2004;39:311–7. [PubMed: 14767983]
296. Montaner JS, Cote HC, Harris M, et al. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003;34(Suppl 1):S85–90. [PubMed: 14562863]
297. Vittecoq D, Jardel C, Barthelemy C, et al. Mitochondrial damage associated with long-term antiretroviral treatment: associated alteration or causal disorder? *J Acquir Immune Defic Syndr* 2002;31:299–308. [PubMed: 12439205]
298. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? *Curr Opin Infect Dis* 2000;13:5–11. [PubMed: 11964766]
299. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. *Lancet* 1999;354:1112–5. [PubMed: 10509516]
300. Benveniste O, Longuet P, Duval X, Le Moing V, Lepout C, Vilde JL. Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. *Clin Infect Dis* 1999;28:1180–1. [PubMed: 10452668]
301. Garg H, Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. *J Leukoc Biol* 2006;79:351–62. [PubMed: 16330530]
302. Piliero PJ. Interaction between ritonavir and statins. *Am J Med* 2002;112:510–1. [PubMed: 11959074]
303. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [letter]. *Jama* 1997;277:296–7. [PubMed: 9002485]
304. Thompson M, Samuels S. Rhabdomyolysis with simvastatin and nefazodone. *Am J Psychiatry* 2002;159:1607. [PubMed: 12202291]
305. Karnik NS, Maldonado JR. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. *Psychosomatics* 2005;46:565–8. [PubMed: 16288136]
306. Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. *South Med J* 2003;96:1034–5. [PubMed: 14570351]
307. Gutierrez CA. Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? *Am Fam Physician* 2001;63:636–7. [PubMed: 11237079]
308. Mogyorosi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. *J Intern Med* 1999;246:599–602. [PubMed: 10620105]
309. Bhatia V. Massive rhabdomyolysis with simvastatin precipitated by amoxicillin. *J Postgrad Med* 2004;50:234–5. [PubMed: 15377816]
310. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. *Can J Clin Pharmacol* 2003;10:172–4. [PubMed: 14712320]



311. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. *Muscle Nerve* 2004;30:799–802. [PubMed: 15389652]
312. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. *Ann Pharmacother* 2005;39:1368–9. [PubMed: 15956236]
313. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. *Clin Neuropharmacol* 2002;25:266–8. [PubMed: 12410059]
314. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. *Am J Cardiol* 2004;93:1417–8, A9. [PubMed: 15165929]
315. Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. *Clin Lung Cancer* 2008;9:232–4. [PubMed: 18650173]
316. Prueksaritanont T, Vega JM, Zhao J, et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. *J Clin Pharmacol* 2001;41:573–81. [PubMed: 11361054]
317. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. *Toxicol Appl Pharmacol*. 2007
318. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. *Clin Pharmacol Ther* 2006;80:565–81. [PubMed: 17178259]
319. Hippus M, Farker K, Helble S, Hoffmann A. Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, Jena. *Int J Clin Pharmacol Ther* 2002;40:97–101. [PubMed: 11911604]
320. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. *American Journal of Cardiology* 1999;84:811–5. [PubMed: 10513779]
321. Molden E, Westergren T. Interaction risk with statin switch. *Tidsskr Nor Laegeforen* 2007;127:428–31. [PubMed: 17304269]
322. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. *Clin Pharmacol Ther* 1998;64:177–82. [PubMed: 9728898]
323. Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. *Neurology* 2004;62:670. [PubMed: 14981197]
324. Christopher-Stine L. Statin myopathy: an update. *Curr Opin Rheumatol* 2006;18:647–53. [PubMed: 17053514]
325. Davidson MH, Robinson JG. Safety of aggressive lipid management. *J Am Coll Cardiol* 2007;49:1753–62. [PubMed: 17466224]
326. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. *Clin Pharmacol Ther* 1998;64:477–83. [PubMed: 9834039]
327. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. *J Am Pharm Assoc (Wash)* 2000;40:637–44. [PubMed: 11029845]
328. Abbott A. Special section on human genetics: With your genes? Take one of these, three times a day. *Nature* 2003;425:760–762. [PubMed: 14574377]
329. Schmitz G, Langmann T. Pharmacogenomics of cholesterol-lowering therapy. *Vascul Pharmacol* 2006;44:75–89. [PubMed: 16337220]
330. Takane H, Miyata M, Burioka N, et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. *J Hum Genet* 2006;51:822–6. [PubMed: 16917677]
331. Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. *Am J Cardiovasc Drugs* 2004;4:247–55. [PubMed: 15285699]
332. Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. *Expert Opin Drug Saf* 2006;5:651–66. [PubMed: 16907655]
333. Kordas K, Phillips P, Golomb B. Clinical Characteristics of 1053 Patients with Statin-Associated Muscle Complaints. *Arterioscler Thromb Vasc Biol* 2004;24:e51–136.

334. Golomb B, Evans M. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. *Drug Saf* 2006;29:1191. author reply 1191-2. [PubMed: 17147465]
335. Chapplain JM, Beillot J, Begue JM, et al. Mitochondrial Abnormalities in HIV-Infected Lipotrophic Patients Treated With Antiretroviral Agents. *J Acquir Immune Defic Syndr* 2004;37:1477-1488. [PubMed: 15602126]
336. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. *Mitochondrion* 2004;4:763-77. [PubMed: 16120431]
337. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. *Stroke* 2002;33:2337-41. [PubMed: 12215610]
338. Rosenberg AD, Neuwirth MG, Kagen LJ, Singh K, Fischer HD, Bernstein RL. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. *Anesthesia and Analgesia* 1995;81:1089-91. [PubMed: 7486053]
339. Wilhelmi M, Winterhalter M, Fischer S, et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. *Cardiovasc Drugs Ther* 2002;16:471-5. [PubMed: 12652117]
340. Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. *Arch Intern Med* 2003;163:657-9. [PubMed: 12639194]
341. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. *Curr Atheroscler Rep* 2007;9:389-96. [PubMed: 18001622]
342. Sinzinger H, Oguogho A. Variable influence of statins on isoprostanes in hyperlipidemia. *Adv Exp Med Biol* 2003;525:209-12. [PubMed: 12751770]
343. Judy WV, Stogsdill WW, Folkers K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. *Clin Investig* 1993;71:S155-61.
344. Matsushima T, Sueda T, Matsuura Y, Kawasaki T. Protection by coenzyme Q10 of canine myocardial reperfusion injury after preservation. *J Thorac Cardiovasc Surg* 1992;103:945-51. [PubMed: 1569776]
345. Chello M, Mastroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. *Ann Thorac Surg* 1994;58:1427-32. [PubMed: 7979670]
346. Crestanello JA, Doliba NM, Babsky AM, Niborii K, Osbakken MD, Whitman GJ. Effect of coenzyme Q10 supplementation on mitochondrial function after myocardial ischemia reperfusion. *J Surg Res* 2002;102:221-8. [PubMed: 11796022]
347. Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. *J Cardiovasc Pharmacol* 2000;35:256-62. [PubMed: 10672858]
348. Biccard BM, Sear JW, Foex P. Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. *Anaesthesia* 2005;60:1106-14. [PubMed: 16229696]
349. Biccard BM, Sear JW, Foex P. The pharmaco-economics of peri-operative statin therapy. *Anaesthesia* 2005;60:1059-63. [PubMed: 16229688]
350. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation* 2004;110:674-8. [PubMed: 15277322]
351. Finsterer J, Zuntner G. Rhabdomyolysis from Simvastatin triggered by infection and muscle exertion. *South Med J* 2005;98:827-9. [PubMed: 16144183]
352. Wong WM, Wai-Hung Shek T, Chan KH, Chau E, Lai KC. Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy. *J Gastroenterol Hepatol* 2004;19:952-3. [PubMed: 15242511]
353. Hamilton-Craig I. Statin-associated myopathy. *Med J Aust* 2001;175:486-9. [PubMed: 11758079]
354. Mahboobi SK, Shohat EZ, Jellinek SP, Rose M. Systemic infections can decrease the threshold of statin-induced muscle injury. *South Med J* 2006;99:403-4. [PubMed: 16634254]
355. Golomb BA, Evans MA. Re: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. *Neurology* 2008;70:2349. author reply 2349-50. [PubMed: 18541892]

356. Golomb BA, Jaworski B. Statins and dementia. *Arch Neurol* 2001;58:1169–70. [PubMed: 11448316]
357. Almog Y. Statins, inflammation, and sepsis: hypothesis. *Chest* 2003;124:740–3. [PubMed: 12907568]
358. Unnikrishnan D, Satish B. Exertion-induced rhabdomyolysis in a patient on statin therapy. *Nephrol Dial Transplant* 2005;20:244. [PubMed: 15632363]
359. Davidson MH. Controversy surrounding the safety of cerivastatin. *Expert Opin Drug Saf* 2002;1:207–12. [PubMed: 12904136]
360. Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. *Pharmacoepidemiol Drug Saf* 2007;16:352–8. [PubMed: 16892458]
361. Egger SS, Ratz Bravo AE, Hess L, Schlienger RG, Krahenbuhl S. Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. *Drugs Aging* 2007;24:429–40. [PubMed: 17503898]
362. Lenaz G, D'Aurelio M, Merlo Pich M, et al. Mitochondrial bioenergetics in aging. *Biochim Biophys Acta* 2000;1459:397–404. [PubMed: 11004456]
363. Pennisi E. Aging research. Do mitochondrial mutations dim the fire of life? *Science* 1999;286:664.
364. Astra, Zeneca. Crestor®. Rosuvastatin calcium (product insert) 2007;2007
365. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study [see comments]. *Jama* 1998;279:1615–22. [PubMed: 9613910]
366. Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM. Impact of gender on statin efficacy. *Curr Med Res Opin* 2007;23:565–74. [PubMed: 17355737]
367. Nakajima K. Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group. *Clin Ther* 1999;21:2047–57. [PubMed: 10645752]
368. Schieszer J. Adverse vaccine reactions twice as likely to occur in women. *Internal Medicine World Report* June;2003 :25.
369. Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. *Metabolism* 2000;49:1234–8. [PubMed: 11016911]
370. Rangwala SM, Li X, Lindsley L, et al. Estrogen-related receptor alpha is essential for the expression of antioxidant protection genes and mitochondrial function. *Biochem Biophys Res Commun* 2007;357:231–6. [PubMed: 17418099]
371. Biesenbach G, Janko O, Stuby U, Zazgornik J. Terminal myoglobinuric renal failure in lovastatin therapy with pre-existing chronic renal insufficiency. *Wien Klin Wochenschr* 1996;108:334–7. [PubMed: 8767987]
372. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. *Hepatology* 2005;41:690–5. [PubMed: 15789367]
373. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. *Mitochondrion* 2006;6:1–28. [PubMed: 16406828]
374. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. *Diabetes Metab* 2004;30:121–38. [PubMed: 15223984]
375. Berson A, De Beco V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. *Gastroenterology* 1998;114:764–74. [PubMed: 9516397]
376. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. *Gastroenterology* 2002;122:2049–63. [PubMed: 12055609]
377. Sun F, Cui J, Gavras H, Schwartz F. A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases. *Am J Hum Genet* 2003;72:1515–26. [PubMed: 12730827]
378. Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, et al. Safety of statins when response is carefully monitored: a study of 336 heart recipients. *Transplant Proc* 2005;37:4071–3. [PubMed: 16386629]

379. Alberici LC, Oliveira HC, Bighetti EJ, et al. Hypertriglyceridemia increases mitochondrial resting respiration and susceptibility to permeability transition. *J Bioenerg Biomembr* 2003;35:451–7. [PubMed: 14740893]
380. Tokinaga K, Oeda T, Suzuki Y, Matsushima Y. HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. *Endocr J* 2006;53:401–5. [PubMed: 16723812]
381. Rodriguez Framil M, Martinez Rey C, Alende Sixto MR, Torre Carballada JA. Hypothyroidism and lovastatin-induced myositis. *An Med Interna* 2005;22:252–3. [PubMed: 16089017]
382. Bar SL, Holmes DT, Frohlich J. Asymptomatic hypothyroidism and statin-induced myopathy. *Can Fam Physician* 2007;53:428–31. [PubMed: 17872677]
383. Park IR, Mount DB, Himms-Hagen J. Role of T3 in thermogenic and trophic responses of brown adipose tissue to cold. *Am J Physiol* 1989;257:E81–7. [PubMed: 2750898]
384. Martinez B, del Hoyo P, Martin MA, Arenas J, Perez-Castillo A, Santos A. Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats. *J Neurochem* 2001;78:1054–63. [PubMed: 11553679]
385. Schonfeld P, Wieckowski MR, Wojtczak L. Thyroid hormone-induced expression of the ADP/ATP carrier and its effect on fatty acid-induced uncoupling of oxidative phosphorylation. *FEBS Lett* 1997;416:19–22. [PubMed: 9369224]
386. Li R, Luciakova K, Zaid A, Betina S, Fridell E, Nelson BD. Thyroid hormone activates transcription from the promoter regions of some human nuclear-encoded genes of the oxidative phosphorylation system. *Mol Cell Endocrinol* 1997;128:69–75. [PubMed: 9140077]
387. Iossa S, Barletta A, Liverini G. The effect of thyroid state and cold exposure on rat liver oxidative phosphorylation. *Mol Cell Endocrinol* 1991;75:15–8. [PubMed: 2050263]
388. Verhoeven AJ, Kamer P, Groen AK, Tager JM. Effects of thyroid hormone on mitochondrial oxidative phosphorylation. *Biochem J* 1985;226:183–92. [PubMed: 3977864]
389. Holness M, Crespo-Armas A, Mowbray J. The influence of thyroid hormone on the degree of control of oxidative phosphorylation exerted by the adenine nucleotide translocator. *FEBS Lett* 1984;177:231–5. [PubMed: 6094246]
390. Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. *Int J Cardiol* 2007;119:374–6. [PubMed: 17098308]
391. Kisch E, Segall HS. Interaction between simvastatin and L-thyroxine. *Ann Intern Med* 2005;143:547. [PubMed: 16204175]
392. Cohen BH, Gold DR. Mitochondrial cytopathy in adults: what we know so far. *Cleve Clin J Med* 2001;68:625–6, 629–42. [PubMed: 11453081]
393. Lorenzoni PJ, Silvado CE, Scola RH, Luvizotto M, Werneck LC. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. *Arq Neuropsiquiatr* 2007;65:834–7. [PubMed: 17952291]
394. Freedman DB, Housley D. Gitelman's syndrome presenting as intolerance to statin therapy. *Ann Clin Biochem* 2005;42:232–3. [PubMed: 15949161]
395. Rosenmund A, Brand B, Straub PW. Hyperlactataemia, hyperkalemia and heart block in acute iron overload: the fatal role of the hepatic iron-incorporation rate in rats on ferric citrate infusions. *Eur J Clin Invest* 1988;18:69–74. [PubMed: 3130262]
396. Edelman S, Witztum JL. Hyperkalemia during treatment with HMG-CoA reductase inhibitor. *N Engl J Med* 1989;320:1219–20. [PubMed: 2710198]
397. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. *Lipids Health Dis* 2007;6:7. [PubMed: 17376224]
398. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6\*4 polymorphism is associated with statin-induced muscle effects. *Pharmacogenet Genomics* 2007;17:695–707. [PubMed: 17700359]
399. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. *Clin Pharmacol Ther* 2001;70:546–51. [PubMed: 11753271]

400. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteremic response to simvastatin and fluvastatin. *Pharmacol Res* 2007;55:310–7. [PubMed: 17289397]
401. McKeown-Eyssen G, Baines C, Cole DE, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. *Int J Epidemiol* 2004;33:971–8. [PubMed: 15256524]
402. Sams C, Mason HJ, Rawbone R. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. *Toxicol Lett* 2000;116:217–21. [PubMed: 10996483]
403. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. *Neurology* 2001;57:515–8. [PubMed: 11502923]
404. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. *Clin Pharmacol Ther* 2005;78:551–8. [PubMed: 16321621]
405. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. *Muscle Nerve* 2007;36:329–35. [PubMed: 17600820]
406. Gambelli S, Dotti MT, Malandrini A, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. *J Submicrosc Cytol Pathol* 2004;36:85–9. [PubMed: 15311678]
407. Meyer RA, Slade JM, Towse TF, DeLano MC. Elevated muscle phosphodiesterase in 31P-NMR spectra of patients on statins. *Proc Intl Soc Mag Reson Med* 2005;13:2036.
408. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High-Dose Simvastatin. *Clin Pharmacol Ther*. 2007
409. Guis S, Figarella-Branger D, Mattei JP, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. *Arthritis Rheum* 2006;55:551–7. [PubMed: 16874775]
410. Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. *Clin Pharmacol Ther* 2005;78:60–8. [PubMed: 16003294]
411. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. *Eur Neurol* 2007;57:232–5. [PubMed: 17389800]
412. Neale R, Reynolds TM, Saweirs W. Statin precipitated lactic acidosis? *J Clin Pathol* 2004;57:989–90. [PubMed: 15333664]
413. Goli AK, Goli SA, Byrd RP Jr, Roy TM. Simvastatin-induced lactic acidosis: a rare adverse reaction? *Clin Pharmacol Ther* 2002;72:461–4. [PubMed: 12386648]
414. Diaczok BJ, Shali R. Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. *South Med J* 2003;96:318–20. [PubMed: 12659371]
415. Lenaz G, Bovina C, D'Aurelio M, et al. Role of mitochondria in oxidative stress and aging. *Ann N Y Acad Sci* 2002;959:199–213. [PubMed: 11976197]
416. Papucci L, Schiavone N, Witort E, et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. *J Biol Chem* 2003;278:28220–8. [PubMed: 12736273]
417. Menke T, Gille G, Reber F, et al. Coenzyme Q10 reduces the toxicity of rotenone in neuronal cultures by preserving the mitochondrial membrane potential. *Biofactors* 2003;18:65–72. [PubMed: 14695921]
418. Yamamura T, Otani H, Nakao Y, et al. Dual involvement of coenzyme Q10 in redox signaling and inhibition of death signaling in the rat heart mitochondria. *Antioxid Redox Signal* 2001;3:103–12. [PubMed: 11291590]
419. Manoukian AA, Bhagavan NV, Hayashi T, Nestor TA, Rios C, Scottolini AG. Rhabdomyolysis secondary to lovastatin therapy. *Clin Chem* 1990;36:2145–7. [PubMed: 2253372]
420. Wolters M, Hahn A. Plasma ubiquinone status and response to six-month supplementation combined with multivitamins in healthy elderly women--results of a randomized, double-blind, placebo-controlled study. *Int J Vitam Nutr Res* 2003;73:207–14. [PubMed: 12847998]



421. Singh, RB.; Niaz, MA.; Sindberg, CD.; Moesgaard, S.; Littarru, GP. Effect of oral coenzyme Q10 dosages on serum Q10 and MDA levels among healthy men; International Coenzyme Q10 Association Meeting Abstracts; Los Angeles. 2005;
422. Niklowitz P, Menke T, Wiesel T, et al. Coenzyme Q10 in plasma and erythrocytes: comparison of antioxidant levels in healthy probands after oral supplementation and in patients suffering from sickle cell anemia. *Clin Chim Acta* 2002;326:155–61. [PubMed: 12417107]
423. Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by <sup>31</sup>P-MR spectroscopy in patients with mitochondrial cytopathies. *Biofactors* 1999;9:253–60. [PubMed: 10416038]
424. Satoh K, Nakai T, Ichihara K. Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia. *Eur J Pharmacol* 1994;270:365–9. [PubMed: 7805787]
425. Satoh K, Yamato A, Nakai T, Hoshi K, Ichihara K. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. *Br J Pharmacol* 1995;116:1894–8. [PubMed: 8528576]
426. Sugiyama S. HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. *Biochem Mol Biol Int* 1998;46:923–31. [PubMed: 9861446]
427. Diebold BA, Bhagavan NV, Guillory RJ. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. *Biochim Biophys Acta* 1994;1200:100–8. [PubMed: 8031828]
428. Velho JA, Okanobo H, Degasperi GR, et al. Statins induce calcium-dependent mitochondrial permeability transition. *Toxicology* 2006;219:124–32. [PubMed: 16343726]
429. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. *Neurology* 1997;48:1238–43. [PubMed: 9153450]
430. De Vivo DC, DiMauro S. Mitochondrial defects of brain and muscle. *Biol Neonate* 1990;58(Suppl 1):54–69. [PubMed: 2265220]
431. Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy. *South Med J* 1998;91:202–5. [PubMed: 9496876]
432. Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. *Drug Saf* 2007;30:669–75. [PubMed: 17696579]
433. Sastre J, Pallardo FV, Vina J. The role of mitochondrial oxidative stress in aging. *Free Radic Biol Med* 2003;35:1–8. [PubMed: 12826250]
434. Linnane AW, Zhang C, Yarovaya N, et al. Human aging and global function of coenzyme Q10. *Ann N Y Acad Sci* 2002;959:396–411. discussion 463-5. [PubMed: 11976213]
435. Kopsidas G, Kovalenko SA, Heffernan DR, et al. Tissue mitochondrial DNA changes. A stochastic system. *Ann N Y Acad Sci* 2000;908:226–43. [PubMed: 10911962]
436. Ozawa T. Mitochondrial DNA mutations associated with aging and degenerative diseases. *Exp Gerontol* 1995;30:269–90. [PubMed: 7556507]
437. De Flora S, Izzotti A, Randerath K, et al. DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine. *Mutat Res* 1996;366:197–238. [PubMed: 9033668]
438. Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity: implications for neuroimaging. *Trends Neurosci* 2004;27:489–95. [PubMed: 15271497]
439. Fehm HL, Kern W, Peters A. The selfish brain: competition for energy resources. *Prog Brain Res* 2006;153:129–40. [PubMed: 16876572]
440. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. *Proc Natl Acad Sci U S A* 1989;86:2379–82. [PubMed: 2928337]
441. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. *Journal of the Neurological Sciences* 1998;156:41–6. [PubMed: 9559985]
442. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. *Neurology* 2002;58:1333–7. [PubMed: 12011277]

443. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs. *Qjm* 2004;97:229–35. [PubMed: 15028853]
444. Buajordet I, Madsen S, Olsen H. Statins--the pattern of adverse effects with emphasis on mental reactions. Data from a national and an international database. *Tidsskrift for den Norske Laegeforening* 1997;117:3210–3. [PubMed: 9411859]
445. Duits N, Bos FM. Psychiatric disorders with use of simvastatin. *Nederlands Tijdschrift voor Geneeskunde* 1993;137:1312–5. [PubMed: 8345888]
446. Lechleitner M, Hoppichler F, Konwalinka G, Patsch JR, Braunsteiner H. Depressive symptoms in hypercholesterolaemic patients treated with pravastatin [letter] [see comments]. *Lancet* 1992;340:910. [PubMed: 1357315]
447. Golomb BA, Kwon EK, Criqui MH, Dimsdale JE. Simvastatin but not pravastatin affects sleep: Findings from the UCSD Statin Study. *Circulation* 2007;116:II-847.
448. Coskun E, Ulusal G, Bulut N, Bektas H, Oztekin MF, Yildirim IS. Mitochondrial neurogastrointestinal encephalomyopathy. *Turk J Gastroenterol* 2005;16:163–166. [PubMed: 16245230]
449. Suzuki Y, Taniyama M, Hata T, Miyaoka H, Atsumi Y, Matsuoka K. Sleep-wake dysrhythm in mitochondrial diabetes mellitus. *Diabetes Res Clin Pract* 1997;35:61–2. [PubMed: 9113477]
450. Tatsumi C, Takahashi M, Yorifuji S, et al. Mitochondrial encephalomyopathy with sleep apnea. *Eur Neurol* 1988;28:64–9. [PubMed: 3371383]
451. Sherratt EJ, Thomas AW, Alcolado JC. Mitochondrial DNA defects: a widening clinical spectrum of disorders. *Clin Sci (Lond)* 1997;92:225–35. [PubMed: 9093002]
452. Kagawa Y. Molecular genetics of mitochondria and diabetes. *Nippon Rinsho* 1994;52:2599–605. [PubMed: 7983785]
453. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 2003;300:1140–2. [PubMed: 12750520]
454. Lamson DW, Plaza SM. Mitochondrial factors in the pathogenesis of diabetes: a hypothesis for treatment. *Altern Med Rev* 2002;7:94–111. [PubMed: 11991790]
455. Campos Y, Garcia A, Eiris J, et al. Mitochondrial myopathy, cardiomyopathy and psychiatric illness in a Spanish family harbouring the mtDNA 3303C > T mutation. *J Inherit Metab Dis* 2001;24:685–7. [PubMed: 11768589]
456. Odawara M. Mitochondrial gene abnormalities as a cause of psychiatric diseases. *Nucleic Acids Res Suppl* 2002;253–4. [PubMed: 12924423]
457. Hara K, Yamamoto M, Anegawa T, Sakuta R, Nakamura M. Mitochondrial encephalomyopathy associated with parkinsonism and a point mutation in the mitochondrial tRNA(Leu)(UUR) gene. *Rinsho Shinkeigaku* 1994;34:361–5. [PubMed: 8026131]
458. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. *Am J Med* 2000;108:538–46. [PubMed: 10806282]
459. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med* 2004;117:823–9. [PubMed: 15589485]
460. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;360:1623–30. [PubMed: 12457784]
461. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7–22. [PubMed: 12114036]
462. Golomb BA, Dimsdale JE, White HL, Criqui MH. Do Low Dose Statins Affect Cognition? Results of the UCSD Statin Study *Circulation supplement* 2006;114:II-289.
463. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. *Acta Neurol Scand Suppl* 2006;185:78–86. [PubMed: 16866915]
464. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. *Ann Neurol* 2002;52:346–50. [PubMed: 12205648]

465. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. *Ann Pharmacother* 2006;40:1880–3. [PubMed: 16940411]
466. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. *Pharmacotherapy* 2006;26:1190–2. [PubMed: 16863497]
467. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe : implications for the use of lipid-lowering agents. *Drug Saf* 2007;30:195–201. [PubMed: 17343428]
468. King DS, Jones EW, Wofford MR, et al. Cognitive impairment associated with atorvastatin. *Pharmacotherapy* 2001;21:371. Abstract 36.
469. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy* 2003;23:1663–7. [PubMed: 14695047]
470. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. *Pharmacotherapy* 2001;21:767–9. [PubMed: 11401190]
471. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. *Pharmacotherapy* 2003;23:871–80. [PubMed: 12885101]
472. Mathew JP, Grocott HP, McCurdy JR, et al. Preoperative statin therapy does not reduce cognitive dysfunction after cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 2005;19:294–9. [PubMed: 16130053]
473. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. *Cmaj* 2007;176:649–54. [PubMed: 17325332]
474. Caldwell SH, Hespeneheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. *Digestive Diseases and Sciences* 2001;46:376–8. [PubMed: 11281188]
475. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. *Eur J Gastroenterol Hepatol* 2005;17:589–90. [PubMed: 15827453]
476. Ballaré M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. *Recenti Progressi in Medicina* 1991;82:233–5. [PubMed: 1857844]
477. Bruguera M, Joya P, Rodes J. Hepatitis associated with treatment with lovastatin. Presentation of 2 cases. *Gastroenterol Hepatol* 1998;21:127–8. [PubMed: 9607293]
478. Raveh D, Arnon R, Israeli A, Eisenberg S. Lovastatin-induced hepatitis. *Isr J Med Sci* 1992;28:101–2. [PubMed: 1559791]
479. Feydy P, Bogomoletz WV. A case of hepatitis caused by simvastatin. *Gastroenterol Clin Biol* 1991;15:94–5. [PubMed: 2010080]
480. Gavilán Carrasco JC, Bermúdez Recio F, Salgado Ordóñez F, González Santos P. Hepatitis due to lovastatin (letter). *Medicina Clinica* 1996;107:557–8.
481. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. *American Journal of Gastroenterology* 1999;94:1388–90. [PubMed: 10235223]
482. Solomon DH, Avorn J. Coxibs, science, and the public trust. *Arch Intern Med* 2005;165:158–60. [PubMed: 15668360]
483. Stillely CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. *Ann Behav Med* 2004;27:117–24. [PubMed: 15026295]
484. Bruckert E, Simonetta C, Giral P. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team. *J Clin Epidemiol* 1999;52:589–94. [PubMed: 10408999]
485. Golomb B. Cholesterol and violence: is there a connection?[Reply]. *Ann Intern Med* 1998;129:669–70.
486. Golomb BA, Tenkanen L, Alikoski T, et al. Insulin sensitivity markers: predictors of accidents and suicides in Helsinki Heart Study screenees. *J Clin Epidemiol* 2002;55:767–73. [PubMed: 12384190]
487. Klaassen T, Riedel WJ, Deutz NE, Van Praag HM. Mood congruent memory bias induced by tryptophan depletion. *Psychol Med* 2002;32:167–72. [PubMed: 11885569]

488. Partonen T. Vitamin D and serotonin in winter. *Med Hypotheses* 1998;51:267–8. [PubMed: 9792205]
489. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. *Arch Neurol* 2005;62:1849–53. [PubMed: 16216930]
490. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. *Jama* 2006;295:74–80. [PubMed: 16391219]
491. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. *Int J Cancer* 2007;120:833–43. [PubMed: 17131313]
492. Huchzermeyer H, Munzenmaier R. Lovastatin-induced acute cholestatic hepatitis. *Dtsch Med Wochenschr* 1995;120:252–6. [PubMed: 7867482]
493. Jimenez-Alonso J, Osorio JM, Gutierrez-Cabello F, Lopez de la Osa A, Leon L, Mediavilla Garcia JD. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. *Arch Intern Med* 1999;159:1811–2. [PubMed: 10448788]
494. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. *Lancet* 1999;353:1763–4. [PubMed: 10347994]
495. Roblin X, Becot F, Piquemal A, Baziz A. Simvastatin-induced hepatitis. *Gastroenterol Clin Biol* 1992;16:101. [PubMed: 1537472]
496. Heuer T, Gerards H, Pauw M, Gabbert HE, Reis HE. Toxic liver damage caused by HMG-CoA reductase inhibitor. *Med Klin* 2000;95:642–4.
497. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. *Dig Dis Sci* 1994;39:2032–3. [PubMed: 8082513]
498. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. *Lupus* 2003;12:409–12. [PubMed: 12765306]
499. Ballare M, Campanini M, Airoidi G, et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. *Minerva Gastroenterol Dietol* 1992;38:41–4. [PubMed: 1520752]
500. Punthakee Z, Scully LJ, Guindi MM, Ooi TC. Liver fibrosis attributed to lipid lowering medications: two cases. *J Intern Med* 2001;250:249–54. [PubMed: 11555130]
501. Cokca F, Ozkan S, Nergisoglu G, Memikoglu O, Azap A. Statin toxicity: a situation that mimics viral hepatitis. *Int J Clin Pharmacol Ther* 2005;43:543–5. [PubMed: 16300170]
502. Pelli N, Setti M. Atorvastatin as a trigger of autoimmune hepatitis. *J Hepatol* 2004;40:716. [PubMed: 15030994]
503. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. *Eur J Gastroenterol Hepatol* 2003;15:921–4. [PubMed: 12867804]
504. Ridruejo E, Mando OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. *J Hepatol* 2002;37:165–6. [PubMed: 12076881]
505. Torres M, Sobrino J, Asensio C, Lopez D. Acute cholestatic hepatitis induced by cerivastatin. *Med Clin (Barc)* 2002;118:717. [PubMed: 12042141]
506. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. *Ann Clin Biochem* 2005;42:402–4. [PubMed: 16168199]
507. Yoshikawa T, Furukawa Y, Wakamatsu Y, et al. The protection of coenzyme Q10 against carbon tetrachloride hepatotoxicity. *Gastroenterol Jpn* 1981;16:281–5. [PubMed: 7262508]
508. Gavilan Carrasco JC, Bermudez Recio F, Salgado Ordonez F, Gonzalez Santos P. Hepatitis due to lovastatin. *Med Clin (Barc)* 1996;107:557–8. [PubMed: 8999220]
509. Dujovne CA. Side effects of statins: hepatitis versus “transaminitis”-myositis versus “CPKitis”. *Am J Cardiol* 2002;89:1411–3. [PubMed: 12062737]
510. Ashar U, Desai D, Bhaduri A. Flutamide-induced hepatotoxicity with possible potentiation by simvastatin. *J Assoc Physicians India* 2003;51:75–7. [PubMed: 12693464]
511. Koornstra JJ, Ottervanger JP, Fehmers MC, Stricker BH. Clinically manifest liver lesions during use of simvastatin. *Ned Tijdschr Geneesk* 1996;140:846–8. [PubMed: 8668280]
512. Ballare M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. *Recenti Prog Med* 1991;82:233–5. [PubMed: 1857844]

513. Kinman N, Hultcrantz R. Lipid lowering medication and hepatotoxicity. *J Intern Med* 2001;250:183–5. [PubMed: 11555121]
514. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355:549–59. [PubMed: 16899775]
515. Vreecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. *Int J Clin Pharmacol Ther* 2003;41:567–77. [PubMed: 14692706]
516. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. *Circulation* 2001;103:387–92. [PubMed: 11157690]
517. Warshafsky S, Packard D, Marks SJ, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. *J Gen Intern Med* 1999;14:763–74. [PubMed: 10632823]
518. Neaton J, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. *Arch Intern Med* 1992;152:1490–1500. [PubMed: 1627030]
519. Okumura K, Iseki K, Wakugami K, et al. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. *Jpn Circ J* 1999;63:53–8. [PubMed: 10084389]
520. Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. *Stroke* 1996;27:1993–8. [PubMed: 8898804]
521. Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. *Stroke* 2004;35:1360–4. [PubMed: 15087556]
522. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 1987;317:1237–45. [PubMed: 3313041]
523. Okopien B, Krysiak R, Herman ZS. Effect of monthly atorvastatin treatment on hemostasis. *Int J Clin Pharmacol Ther* 2004;42:589–93. [PubMed: 15598024]
524. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. *Am J Cardiol* 2003;91:4B–8B.
525. Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin—an effect unrelated to lipid lowering. *J Cardiovasc Pharmacol Ther* 2002;7:247–53. [PubMed: 12490971]
526. Puccetti L, Pasqui AL, Pastorelli M, et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. *Eur J Clin Invest* 2002;32:901–8. [PubMed: 12534449]
527. Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. *Endocr J* 2005;52:369–72. [PubMed: 16006732]
528. Prasad GV, Kim SJ, Huang M, et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). *Am J Transplant* 2004;4:1897–903. [PubMed: 15476492]
529. Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar BA. Sleep disturbance and appetite loss after lovastatin. *Lancet* 1994;343:973. [PubMed: 7909021]
530. Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbance and HMG CoA reductase inhibitors [letter]. *Jama* 1990;264:1105. [PubMed: 2384934]
531. Boriani G, Biffi M, Strocchi E, Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. *Ann Pharmacother* 2001;35:1292. [PubMed: 11675864]
532. Gregoor PJ. Atorvastatin may cause nightmares. *Bmj* 2006;332:950. [PubMed: 16627511]
533. Malini PL, Ambrosioni E, De Divitiis O, Di Somma S, Rosiello G, Trimarco B. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia. *Clin Ther* 1991;13:500–10. [PubMed: 1934003]
534. Chung N, Cho SY, Choi DH, et al. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. *Simvastatin Treats Asians to Target. Clin Ther* 2001;23:858–70. [PubMed: 11440286]



535. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. *Arch Intern Med* 1993;153:1079–87. [PubMed: 8481075]
536. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. *Clin Pharmacol Ther* 1991;50:730–7. [PubMed: 1752118]
537. Pascual-Cruz M, Chimenos-Kustner E, Garcia-Vicente JA, Mezquiriz-Ferrero X, Borrell-Thio E, Lopez-Lopez J. Adverse side effects of statins in the oral cavity. *Med Oral Patol Oral Cir Bucal* 2008;13:E98–E101. [PubMed: 18223537]
538. Abellan-Miralles I, Sanchez-Perez RM, Perez-Carmona N, Diaz-Marin C, Mallada-Frechin J. Multiple mononeuropathy associated to treatment with pravastatin. *Rev Neurol* 2006;43:659–61. [PubMed: 1713326]
539. Palmucci L, Doriguzzi C, Orsi L, Troni W, De Angelis S, Belliardo F. Neuropathy secondary to vitamin E deficiency in acquired intestinal malabsorption. *Ital J Neurol Sci* 1988;9:599–602. [PubMed: 2852179]
540. McCarron MO, Russell AJ, Metcalfe RA, Deysilva R. Chronic vitamin E deficiency causing spinocerebellar degeneration, peripheral neuropathy, and centro-cecal scotomata. *Nutrition* 1999;15:217–9. [PubMed: 10198917]
541. Traber MG, Sokol RJ, Ringel SP, Neville HE, Thellman CA, Kayden HJ. Lack of tocopherol in peripheral nerves of vitamin E-deficient patients with peripheral neuropathy. *N Engl J Med* 1987;317:262–5. [PubMed: 3037372]
542. Sokol RJ, Butler-Simon N, Heubi JE, et al. Vitamin E deficiency neuropathy in children with fat malabsorption. Studies in cystic fibrosis and chronic cholestasis. *Ann N Y Acad Sci* 1989;570:156–69. [PubMed: 2629595]
543. Pezeshkpour G, Krarup C, Buchthal F, DiMauro S, Bresolin N, McBurney J. Peripheral neuropathy in mitochondrial disease. *J Neurol Sci* 1987;77:285–304. [PubMed: 3029336]
544. Chu CC, Huang CC, Fang W, Chu NS, Pang CY, Wei YH. Peripheral neuropathy in mitochondrial encephalomyopathies. *Eur Neurol* 1997;37:110–5. [PubMed: 9058067]
545. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence [letter]. *Annals of Pharmacotherapy* 1996;30:190.
546. Boyd IW. Comment: HMG-CoA reductase inhibitor-induced impotence. *Ann Pharmacother* 1996;30:1199. [PubMed: 8893134]
547. Jackson G. Simvastatin and impotence. *BMJ* 1997;315:31.
548. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. *J Clin Pharm Ther* 1996;21:89–94. [PubMed: 8809645]
549. Adverse Drug Reactions Advisory Committee. Simvastatin and adverse endocrine effects in men. *Aust Adv Drug React Bull* 1995;14:10.
550. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. *Fam Pract* 2002;19:95–8. [PubMed: 11818357]
551. Pia Iglesias G, Fernandez Fernandez FJ, Ameneiros Lago E, Sesma Sanchez P. HMG-CoA reductase inhibitors and sexual dysfunction. *An Med Interna* 2001;18:171. [PubMed: 11594194]
552. Carvajal A, Macias D, Sainz M, et al. HMG CoA Reductase Inhibitors and Impotence: Two Case Series from the Spanish and French Drug Monitoring Systems. *Drug Saf* 2006;29:143–9. [PubMed: 16454541]
553. Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. *Int J Clin Pract* 2006;60:141–5. [PubMed: 16451283]
554. Blanker MH, Verhagen AP. Lipid-lowering drugs and erectile dysfunction. *Fam Pract* 2002;19:567. [PubMed: 12356716]
555. de Graaf L, Brouwers AH, Diemont WL. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors? *Br J Clin Pharmacol* 2004;58:326–8. [PubMed: 15327593]
556. Hildebrand RD, Hepperlen TW. Lovastatin and hypospermia [letter]. *Annals of Internal Medicine* 1990;112:549–50. [PubMed: 2316945]
557. Niederberger C. Atorvastatin and male infertility: is there a link? *J Androl* 2005;26:12. [PubMed: 15611560]

558. Azzarito C, Boiardi L, Vergoni W, Zini M, Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. *Hormone and Metabolic Research* 1996;28:193–8. [PubMed: 8740196]
559. Andreis PG, Cavallini L, Mazzocchi G, Nussdorfer GG. Effects of prolonged administration of lovastatin, an inhibitor of cholesterol synthesis, on the morphology and function of rat Leydig cells. *Experimental and Clinical Endocrinology* 1990;96:15–24. [PubMed: 2279522]
560. Chen CM, Huang CC. Gonadal dysfunction in mitochondrial encephalomyopathies. *Eur Neurol* 1995;35:281–6. [PubMed: 8542917]
561. Adverse Drug Reactions Advisory Committee (ADRAC). Statins and peripheral neuropathy. *Australian Adverse Drug Reactions Bulletin* 2005;24:6.
562. Ahmad S. Lovastatin and peripheral neuropathy [letter]. *American Heart Journal* 1995;130:1321. [PubMed: 7484806]
563. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. *Ann Pharmacother* 2003;37:274–8. [PubMed: 12549960]
564. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. *Pharmacotherapy* 2004;24:1194–203. [PubMed: 15460180]
565. Corrao G, Zambon A, Bertu L, Botteri E, Leoni O, Contiero P. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. *J Epidemiol Community Health* 2004;58:1047–51. [PubMed: 15547071]
566. Donaghy M. Assessing the risk of drug-induced neurologic disorders: statins and neuropathy. *Neurology* 2002;58:1321–2. [PubMed: 12011272]
567. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? *Eur J Clin Pharmacol* 2001;56:931–3. [PubMed: 11317483]
568. Jeppesen U, Gaist D, Smith T, Sinderup SH. Statins and peripheral neuropathy. *Eur J Clin Pharmacol* 1999;54:835–38. [PubMed: 10027656]
569. Jacobs MB. HMG-CoA reductase inhibitor therapy and peripheral neuropathy (letter). *Ann Intern Med* 1994;120:970. [PubMed: 8172444]
570. Lo YL, Leoh TH, Loh LM, Tan CE. Statin therapy and small fibre neuropathy: a serial electrophysiological study. *J Neurol Sci* 2003;208:105–8. [PubMed: 12639733]
571. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. *Journal of Neurology, Neurosurgery and Psychiatry* 1995;58:625–8.
572. Silverberg C. Atorvastatin-induced polyneuropathy. *Ann Intern Med* 2003;139:792–3. [PubMed: 14597471]
573. Vaughan TB, Bell DS. Statin neuropathy masquerading as diabetic autoimmune polyneuropathy. *Diabetes Care* 2005;28:2082. [PubMed: 16043768]
574. Weimer LH. Medication-induced peripheral neuropathy. *Curr Neurol Neurosci Rep* 2003;3:86–92. [PubMed: 12507417]
575. Ziajka PE, Wehmeier T. Peripheral neuropathy and lipid-lowering therapy. *Southern Medical Journal* 1998;91:667–668. [PubMed: 9671841]
576. Scola RH, Trentin AP, Germiniani FM, Piovesan EJ, Werneck LC. Simvastatin-induced mononeuropathy multiplex: case report. *Arq Neuropsiquiatr* 2004;62:540–2. [PubMed: 15273860]
577. Iannaccone ST, Sokol RJ. Vitamin E deficiency in neuropathy of abetalipoproteinemia. *Neurology* 1986;36:1009. [PubMed: 3012411]
578. Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy. *Can Med Assoc J* 1985;132:41–4. [PubMed: 2981135]
579. Wichman A, Buchthal F, Pezeshkpour GH, Gregg RE. Peripheral neuropathy in abetalipoproteinemia. *Neurology* 1985;35:1279–89. [PubMed: 2991816]
580. Miller RG, Davis CJ, Illingworth DR, Bradley W. The neuropathy of abetalipoproteinemia. *Neurology* 1980;30:1286–91. [PubMed: 6153056]
581. Tackmann W, Herdemerten S. Neurological symptoms in a-beta-lipoproteinemia (author's transl). *Fortschr Neurol Psychiatr Grenzgeb* 1979;47:24–35. [PubMed: 252473]

582. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence [letter] [see comments]. *Annals of Pharmacotherapy* 1996;30:192. [PubMed: 8835058]
583. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence. *Ann Pharmacother* 1996;30:192. [PubMed: 8835058]
584. Smals AG, Weusten JJ, Benraad TJ, Kloppenborg PW. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxidoreductase enzyme activity. *J Steroid Biochem Mol Biol* 1991;38:465–8. [PubMed: 2031860]
585. Azadzo KM, Schulman RN, Aviram M, Siroky MB. Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants. *J Urol* 2005;174:386–93. [PubMed: 15947695]
586. von Keutz E, Schluter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. *American Journal of Cardiology* 1998;82:11J–17J.
587. Dogru MT, Basar MM, Simsek A, et al. Effects of statin treatment on serum sex steroids levels and autonomic and erectile function. *Urology* 2008;71:703–7. [PubMed: 18387399]
588. Herrmann HC, Levine LA, Macaluso J Jr. et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. *J Sex Med* 2006;3:303–8. [PubMed: 16490024]
589. Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. *Eur J Pharmacol* 2004;498:189–94. [PubMed: 15363994]
590. Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. *J Urol* 2004;172:255–8. [PubMed: 15201788]
591. Morita H, Saito Y, Ohashi N, et al. Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin. *Circ J* 2005;69:475–80. [PubMed: 15791046]
592. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. *Circulation* 2004;110:856–61. [PubMed: 15289372]
593. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. *Free Radic Biol Med* 2004;37:2064–71. [PubMed: 15544924]
594. Aerts J, Karmochkine M, Raguin G. Gynecomastia due to pravastatin. *Presse Med* 1999;28:787. [PubMed: 10325934]
595. Hammons KB, Edwards RF, Rice WY. Golf-inhibiting gynecomastia associated with atorvastatin therapy. *Pharmacotherapy* 2006;26:1165–8. [PubMed: 16863492]
596. Oteri A, Catania MA, Travaglini R, et al. Gynecomastia possibly induced by rosuvastatin. *Pharmacotherapy* 2008;28:549–51. [PubMed: 18363539]
597. Fischereder M, Grab C, Anthuber M, et al. Gynaecomastia following solid organ transplantation. *Transplant Proc* 2002;34:2227–8. [PubMed: 12270376]
598. Linnebur SA, Hiatt WH. Probable statin-induced testicular pain. *Ann Pharmacother* 2007;41:138–42. [PubMed: 17200428]
599. van Zyl-Smit R, Firth JC, Duffield M, Marais AD. Renal tubular toxicity of HMG-CoA reductase inhibitors. *Nephrol Dial Transplant* 2004;19:3176–9. [PubMed: 15575008]
600. Deslypere JP, Delanghe J, Vermeulen A. Proteinuria as complication of simvastatin treatment. *Lancet* 1990;336:1453. [PubMed: 1978916]
601. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. *Am J Med* 2002;112:505. [PubMed: 11959068]
602. Bakri R, Wang J, Wierzbicki AS, Goldsmith D. Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. *Int J Cardiol* 2003;91:107–9. [PubMed: 12957739]
603. Oldemeyer JB, Lund RJ, Koch M, Meares AJ, Dunlay R. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations. *Cardiology* 2000;94:127–8. [PubMed: 11173785]

604. de Alava E, Sola JJ, Lozano MD, Pardo-Mindan FJ. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemians. *Nephron* 1994;66:242–3. [PubMed: 8139752]
605. Kusus M, Stapleton DD, Lertora JJ, Simon EE, Dreisbach AW. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. *Am J Med Sci* 2000;320:394–7. [PubMed: 11149552]
606. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. *Am J Med* 2005;118:843–9. [PubMed: 16084176]
607. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. *J Am Soc Nephrol* 2006;17:2006–16. [PubMed: 16762986]
608. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. *Ann Intern Med* 2006;145:117–24. [PubMed: 16847294]
609. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. *Cardiology* 2004;102:52–60. [PubMed: 15073451]
610. Olson MB, Kelsey SF, Matthews KA, et al. Lipid-Lowering Medication Use and Aggression Scores in Women: A Report from the NHLBI-Sponsored WISE Study. *J Womens Health (Larchmt)* 2008;17:187–94. [PubMed: 18321170]
611. Golomb BA. Cholesterol and violence: Is there a connection? *Annals of Internal Medicine* 1998;128:478–487. [PubMed: 9499332]
612. Kaplan J, Shively C, Fontenot D, et al. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. *Psychosom Med* 1994;56:479–84. [PubMed: 7532867]
613. Kaplan JR, Manuck SB. The effects of fat and cholesterol on aggressive behavior in monkeys. *Psychosomatic Med* 1990;52:226–7.
614. Golomb BA, Stattin H, Mednick S. Low cholesterol and violent crime. *J Psychiatr Res* 2000;34:301–9. [PubMed: 11104842]
615. Virkkunen M. Serum cholesterol in antisocial personality. *Neuropsychobiology* 1979;5:27–30. [PubMed: 431794]
616. Virkkunen M. Serum cholesterol levels in homicidal offenders. A low cholesterol level is connected with a habitually violent tendency under the influence of alcohol. *Neuropsychobiology* 1983;10:65–9. [PubMed: 6674827]
617. Virkkunen M, Penttinen H. Serum cholesterol in aggressive conduct disorder: A preliminary study. *Biol Psychiat* 1984;19:435–439. [PubMed: 6722234]
618. Hillbrand M, Foster H. Serum cholesterol levels and severity of aggression. *Psychological Reports* 1993;72:270. [PubMed: 8451361]
619. Hillbrand M, Spitz R, Foster H. Serum cholesterol and aggression in hospitalized male forensic patients. *J Behav Med* 1995;18:33–43. [PubMed: 7595950]
620. Spitz R, Hillbrand M, Foster HJ. Serum cholesterol levels and frequency of aggression. *Psychol Rep* 1994;74:622. [PubMed: 8197299]
621. Mufti R, Balon R, Arfken C. Low cholesterol and violence. *Psychiatric Services* 1998;49:221–224. [PubMed: 9575009]
622. Repo-Tiihonen E, Halonen P, Tiihonen J, Virkkunen M. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder. *Eur Arch Psychiatry Clin Neurosci* 2002;252:8–11. [PubMed: 12056583]
623. Chakrabarti N, Sinha VK. A study of serum lipid profile and serum apolipoproteins A1 and B in Indian male violent criminal offenders. *Crim Behav Ment Health* 2006;16:177–82. [PubMed: 16838385]
624. Muldoon M, Manuck S, Matthews K. Lowering cholesterol concentrations and mortality: a review of primary prevention trials. *Br Med J* 1990;301:309–14. [PubMed: 2144195]
625. Muldoon M, Rossouw J, Manuck S, Gluech C, Kaplan J, Kaufmann P. Low or lowered cholesterol and risk of death from suicide and trauma. *Metabolism* 1993;42:45–56. [PubMed: 8412786]

626. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. *Bmj (Clinical Research Ed.)* 2001;322:11–5.
627. Adonaylo VN, Oteiza PI. Lead intoxication: antioxidant defenses and oxidative damage in rat brain. *Toxicology* 1999;135:77–85. [PubMed: 10463764]
628. Ahamed M, Fareed M, Kumar A, Siddiqui WA, Siddiqui MK. Oxidative stress and neurological disorders in relation to blood lead levels in children. *Redox Rep* 2008;13:117–22. [PubMed: 18544229]
629. Ahamed M, Siddiqui MK. Low level lead exposure and oxidative stress: current opinions. *Clin Chim Acta* 2007;383:57–64. [PubMed: 17573057]
630. Marlowe M, Errera J. Low lead levels and behavior problems in children. *Behavioral Disorders* 1982;7:163–172.
631. Pihl R, Ervin F. Lead and cadmium levels in violent criminals. *Psychological Reports* 1990;66:839–844. [PubMed: 2377701]
632. Stohs SJ, Bagchi D, Hassoun E, Bagchi M. Oxidative mechanisms in the toxicity of chromium and cadmium ions. *J Environ Pathol Toxicol Oncol* 2000;19:201–13. [PubMed: 10983887]
633. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. *Curr Med Chem* 2005;12:1161–208. [PubMed: 15892631]
634. Wolf MB, Baynes JW. Cadmium and mercury cause an oxidative stress-induced endothelial dysfunction. *Biometals*. 2006
635. Devinsky O, Kernan J, Bear DM. Aggressive behavior following exposure to cholinesterase inhibitors. *J Neuropsychiatry Clin Neurosci* 1992;4:189–94. [PubMed: 1627982]
636. Stallones L, Beseler C. Pesticide illness, farm practices, and neurological symptoms among farm residents in Colorado. *Environ Res* 2002;90:89–97. [PubMed: 12483798]
637. Ramanathan L, Gulyani S, Nienhuis R, Siegel JM. Sleep deprivation decreases superoxide dismutase activity in rat hippocampus and brainstem. *Neuroreport* 2002;13:1387–90. [PubMed: 12167758]
638. Schulze G. Sleep protects excitatory cortical circuits against oxidative damage. *Med Hypotheses* 2004;63:203–7. [PubMed: 15236776]
639. Brylewski J, Wiggs L. Sleep problems and daytime challenging behaviour in a community-based sample of adults with intellectual disability. *J Intellect Disabil Res* 1999;43(Pt 6):504–12. [PubMed: 10622367]
640. Flemons WW, Tsai W. Quality of life consequences of sleep-disordered breathing. *J Allergy Clin Immunol* 1997;99:S750–6. [PubMed: 9042067]
641. Haugli L, Skogstad A, Hellesoy OH. Health, sleep, and mood perceptions reported by airline crews flying short and long hauls. *Aviat Space Environ Med* 1994;65:27–34. [PubMed: 8117222]
642. Golomb BA, Dimsdale JE, Evans MA, Denenberg JO, White HL, Criqui MH. Effects of Statins on Aggression Differ by Gender: Results of a Double Blind Placebo Controlled Trial. *Circulation supplement* 2008;117:e268–269.
643. Volatron AC, Belleguic C, Polard E, Le Garff G, Delaval P. Simvastatin-induced chylothorax. *Rev Mal Respir* 2003;20:291–3. [PubMed: 12844029]
644. Yoshioka S, Mukae H, Ishii H, et al. A case of drug-induced pneumonia possibly associated with simvastatin. *Nihon Kokyuki Gakkai Zasshi* 2005;43:600–4. [PubMed: 16285592]
645. De Groot REB, Willems LNA, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastatin. *J Internal Med* 1996;239:361–3. [PubMed: 8774391]
646. Veyrac G, Cellierin L, Jolliet P. A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins. *Therapie* 2006;61:57–67. [PubMed: 16792155]
647. Walker T, McCaffery J, Steinfert C. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. *Med J Aust* 2007;186:91–4. [PubMed: 17223772]
648. Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G. Statin-induced fibrotic nonspecific interstitial pneumonia. *Eur Respir J* 2002;19:577–80. [PubMed: 11936540]
649. Kalomenidis I, Papiris S, Loukides S. Bilateral pleural effusions associated with pravastatin sodium treatment. *Eur Respir J* 2007;30:1022. [PubMed: 17978161]



650. Roncato-Saberan M, Hustache-Mathieu L, Hoen B. Eosinophilic pleural effusion caused by simvastatin after 13 years of exposure. *Eur J Intern Med* 2006;17:450. [PubMed: 16962959]
651. Liscoet-Loheac N, Andre N, Couturaud F, Chenu E, Quiot JJ, Leroyer C. Hypersensitivity pneumonitis in a patient taking pravastatin. *Rev Mal Respir* 2001;18:426–8. [PubMed: 11547251]
652. Liebhaber MI, Wright RS, Gelberg HJ, Dyer Z, Kupperman JL. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. *Chest* 1999;115:886–9. [PubMed: 10084510]
653. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. *Am J Cardiol* 2004;94:1306–10. [PubMed: 15541254]
654. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. *Clin Investig* 1993;71:S134–6.
655. Langsjoen PH, Folkers K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. *Clin Investig* 1993;71:S140–4.
656. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. *J Am Coll Cardiol* 2006;47:332–7. [PubMed: 16412856]
657. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. *Z Kardiol* 2004;93:103–8. [PubMed: 14963675]
658. Akahane T, Mizushige K, Nishio H, Fukui H, Kuriyama S. Atrial fibrillation induced by simvastatin treatment in a 61-year-old man. *Heart Vessels* 2003;18:157–9. [PubMed: 12955433]
659. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report)--antiarrhythmic action of coenzyme Q10 in diabetics. *Tohoku J Exp Med* 1983;141(Suppl):453–63. [PubMed: 6680522]
660. Baggio E, Gandini R, Plancher AC, Passeri M, Carosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. *CoQ10 Drug Surveillance Investigators. Mol Aspects Med* 1994;15(Suppl):s287–94. [PubMed: 7752841]
661. Lin PH, Lee SH, Su CP, Wei YH. Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation. *Free Radic Biol Med* 2003;35:1310–8. [PubMed: 14607530]
662. Ohmae M, Rabkin SW. Hyperkalemia-induced bundle branch block and complete heart block. *Clin Cardiol* 1981;4:43–6. [PubMed: 7226590]
663. Guzman SV, Deleon AC Jr, West JW, Bellet S. Cardiac effects of isoproterenol, norepinephrine and epinephrine in complete A-V heart block during experimental acidosis and hyperkalemia. *Circ Res* 1959;7:666–72. [PubMed: 13663221]
664. Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K. Cholesterol paradox in patients with paroxysmal atrial fibrillation. *Cardiology* 1999;92:21–7. [PubMed: 10640793]
665. Korantzopoulos P, Galaris D, Papaioannides D, Kokkoris S. C-reactive protein and oxidative stress in atrial fibrillation. *Int J Cardiol* 2003;88:103–4. [PubMed: 12659994]
666. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. *Med Sci Monit* 2003;9:RA225–9. [PubMed: 12960937]
667. Korantzopoulos P, Kolettis TM, Goudevenos JA. The anti-inflammatory and antioxidant effects of long-chain n-3 fatty acids or oil-rich fish may favorably affect atrial remodeling in atrial fibrillation. *Med Hypotheses* 2005;64:1245–6. [PubMed: 15823733]
668. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. *Int J Cardiol* 2005;102:321–6. [PubMed: 15982504]
669. Korantzopoulos P, Kountouris E, Kolettis T, Siogas K. Anti-inflammatory and antioxidant actions of statins may favorably affect atrial remodeling in atrial fibrillation. *Am J Cardiol* 2004;93:1200. [PubMed: 15110227]
670. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. *Circulation* 2006;114:1455–61. [PubMed: 17000910]

671. Judy, WV.; Stogsdill, WW.; Judy, JS. CoQ10 in the management of low energy and delayed development in children with Praeder-Willi syndrome; Third Conference of the International Coenzyme Q10 Association; 2002; Nov 22-4:34-5;
672. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. *J Hum Hypertens* 1999;13:203–308. [PubMed: 10204818]
673. Muller T, Kuhn W, Pohlau D, Przuntek H. Parkinsonism unmasked by lovastatin. *Ann Neurol* 1995;37:685–6. [PubMed: 7755369]
674. Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. *Free Radic Res* 2002;36:455–60. [PubMed: 12069110]
675. Beal MF. Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. *Methods Enzymol* 2004;382:473–87. [PubMed: 15047118]
676. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. *Ann Neurol* 1994;36:882–8. [PubMed: 7998775]
677. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* 2002;59:1541–50. [PubMed: 12374491]
678. Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. *Mov Disord*. 2006
679. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. *Neurology*. 2008
680. Oranje WA, Sels JP, Rondas-Colbers GJ, Lemmens PJ, Wolffenbuttel BH. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. *Clin Chim Acta* 2001;311:91–4. [PubMed: 11566168]
681. Finsterer J. Parkinson syndrome as a manifestation of mitochondriopathy. *Acta Neurol Scand* 2002;105:384–9. [PubMed: 11982490]
682. Sohmiya M, Tanaka M, Tak NW, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. *J Neurol Sci* 2004;223:161–6. [PubMed: 15337618]
683. Sudha K, Rao AV, Rao S, Rao A. Free radical toxicity and antioxidants in Parkinson's disease. *Neurol India* 2003;51:60–2. [PubMed: 12865518]
684. Ciccone CD. Free-radical toxicity and antioxidant medications in Parkinson's disease. *Phys Ther* 1998;78:313–9. [PubMed: 9520976]
685. Hill CF, Schwartz LM, Thompson PD, Clarkson PM. Effects Of Statin Treatment And Supplemental Co Q10 On C2C12 Myotubes: 2436. *Medicine & Science in Sports & Exercise* 2005;37:S466–S467.
686. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet* 2000;356:1627–31. [PubMed: 11089820]
687. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol* 2000;57:1439–43. [PubMed: 11030795]
688. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. *BMC Med* 2007;5:20. [PubMed: 17640385]
689. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. *Jama* 2001;285:1489–99. [PubMed: 11255426]
690. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama* 2003;289:2651–62. [PubMed: 12771112]
691. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama* 2003;289:2663–72. [PubMed: 12771113]
692. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

(Adult Treatment Panel III) Executive Summary. 2001.  
[http://www.nhlbi.gov/guidelines/cholesterol/atp\\_iii.htm](http://www.nhlbi.gov/guidelines/cholesterol/atp_iii.htm)

693. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. *Neurology* 2007;69:878–85. [PubMed: 17724290]
694. Ahmad S. Lovastatin-induced lupus erythematosus [see comments]. *Archives of Internal Medicine* 1991;151:1667–8. [PubMed: 1872674]
695. Ahmad A, Fletcher MT, Roy TM. Simvastatin-induced lupus-like syndrome. *Tennessee Medicine* 2000;93:21–2. [PubMed: 10628262]
696. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. *J Clin Gastroenterol* 2006;40:757–61. [PubMed: 16940892]
697. Bannwarth B, Miremont G, Papapietro PM. Lupuslike syndrome associated with simvastatin. *Arch Intern Med* 1992;152:1093. [PubMed: 1510761]
698. Castiella A, Fernandez J, Zapata E. Autoimmune hepatitis after treatment with fluvastatin. *Liver Int* 2007;27:592. [PubMed: 17403199]
699. Hanson J, Bossingham D. Lupus-like syndrome associated with simvastatin. *Lancet* 1998;352.
700. Jimenez-Alonso J, Jaimez L, Sabio JM, Hidalgo C, Leon L. Atorvastatin-induced reversible positive antinuclear antibodies. *Am J Med* 2002;112:329–30. [PubMed: 11893380]
701. Khosla R, Butman AN, Hammer DF. Simvastatin-induced lupus erythematosus. *Southern Med J* 1998;91:873–4.
702. Konig C, Eickert A, Scharfetter-Kochanek K, Krieg T, Hunzelmann N. Linear IgA bullous dermatosis induced by atorvastatin. *J Am Acad Dermatol* 2001;44:689–92. [PubMed: 11260550]
703. Noel B. Autoimmune diseases and statins. *Ann Dermatol Venereol* 2006;133:276–8. [PubMed: 16800184]
704. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. *J Eur Acad Dermatol Venereol* 2007;21:17–24. [PubMed: 17207162]
705. Noel B. Autoimmune disease and other potential side-effects of statins. *Lancet* 2004;363:2000. [PubMed: 15194268]
706. Noel B, Panizzon RG. Lupus-like syndrome associated with statin therapy. *Dermatology* 2004;208:276–7. [PubMed: 15118389]
707. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. *Medicine (Baltimore)* 1998;77:378–83. [PubMed: 9854600]
708. Schmutz JL, Barbaud A, Trechot P. Statines and lupus erythematosus. *Ann Dermatol Venereol* 2006;133:98. [PubMed: 16495868]
709. Sridhar MK, Abdulla A. Fatal lupus-like syndrome and ARDS induced by fluvastatin. *Lancet* 1998:352.
710. Suchak R, Benson K, Swale V. Statin-induced Ro/SSA-positive subacute cutaneous lupus erythematosus. *Clin Exp Dermatol* 2007;32:589–91. [PubMed: 17692061]
711. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev* 2006;5:114–7. [PubMed: 16431339]
712. Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. *Prog Biophys Mol Biol* 2006;92:60–4. [PubMed: 16563470]
713. Mark BL, Carson JA. Vitamin D and autoimmune disease--implications for practice from the multiple sclerosis literature. *J Am Diet Assoc* 2006;106:418–24. [PubMed: 16503232]
714. Ponsonby AL, Lucas RM, van der Mei IA. UVR, vitamin D and three autoimmune diseases--multiple sclerosis, type 1 diabetes, rheumatoid arthritis. *Photochem Photobiol* 2005;81:1267–75. [PubMed: 15971932]
715. VanAmerongen BM, Dijkstra CD, Lips P, Polman CH. Multiple sclerosis and vitamin D: an update. *Eur J Clin Nutr* 2004;58:1095–109. [PubMed: 15054436]
716. Luong K, Nguyen LT, Nguyen DN. The role of vitamin D in protecting type 1 diabetes mellitus. *Diabetes Metab Res Rev* 2005;21:338–46. [PubMed: 15852446]
717. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. *Trends Endocrinol Metab* 2005;16:261–6. [PubMed: 15996876]

718. Brown SJ. The role of vitamin D in multiple sclerosis. *Ann Pharmacother* 2006;40:1158–61. [PubMed: 16684809]
719. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. *South Med J* 2005;98:1024–7. [PubMed: 16295817]
720. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr* 2004;80:1678S–88S. [PubMed: 15585788]
721. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. *Annu Rev Nutr* 2003;23:117–45. [PubMed: 12651965]
722. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. *J Cell Biochem* 2003;88:216–22. [PubMed: 12520517]
723. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. *Int Immunopharmacol* 2002;2:1017–28. [PubMed: 12188026]
724. Neuhaus O, Stuve O, Zamvil SS, Hartung HP. Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles. *CNS Drugs* 2005;19:833–41. [PubMed: 16185093]
725. Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. *J Clin Gastroenterol* 2002;35:406–8. [PubMed: 12394230]
726. Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? *Jop* 2004;5:502–4. [PubMed: 15536291]
727. Singh S. Drug induced pancreatitis might be a class effect of statin drugs. *Jop* 2005;6:380. author reply 380-1. [PubMed: 16006693]
728. Ramdani M, Schmitt AM, Liautard J, et al. Simvastatin-induced acute pancreatitis: two cases]. *Gastroenterol Clin Biol* 1991;15:986. [PubMed: 1783260]
729. Pezzilli R, Ceciliato R, Corinaldesi R, Barakat B. Acute pancreatitis due to simvastatin therapy: increased severity after rechallenge. *Dig Liver Dis* 2004;36:639–40. [PubMed: 15460851]
730. Miltiados G, Anthopoulou A, Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. *Jop* 2003;4:20–1. [PubMed: 12555012]
731. McDonald KB, Garber BG, Perreault MM. Pancreatitis associated with simvastatin plus fenofibrate. *Ann Pharmacother* 2002;36:275–9. [PubMed: 11847949]
732. Lons T, Chousterman M. Simvastatin: a new drug responsible for acute pancreatitis? *Gastroenterol Clin Biol* 1991;15:93–4. [PubMed: 2010079]
733. Kanbay M, Sekuk H, Yilmaz U, Gur G, Boyacioglu S. Acute pancreatitis associated with combined lisinopril and atorvastatin therapy. *Dig Dis* 2005;23:92–4. [PubMed: 15920330]
734. Johnson JL, Loomis IB. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. *Pharmacotherapy* 2006;26:414–22. [PubMed: 16503723]
735. Grahit Vidosa V, Aviles Ciguela S, Ribas Batllori A, Juncadella Garcia E. Acute pancreatitis due to lipid-lowering drugs. *Aten Primaria* 2005;35:437–8. [PubMed: 15882504]
736. Couderc M, Blanc P, Rouillon JM, Bauret P, Larrey D, Michel H. A new case of simvastatin-induced acute pancreatitis. *Gastroenterol Clin Biol* 1991;15:986–7. [PubMed: 1783261]
737. Becker C, Hvalic C, Delmore G, Krahenbuhl S, Schlienger R. Recurrent acute pancreatitis during pravastatin-therapy. *Schweiz Rundsch Med Prax* 2006;95:111–6.
738. Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Acute pancreatitis due to pravastatin therapy. *Jop* 2003;4:129–32. [PubMed: 12743419]
739. Belaiche G, Ley G, Slama JL. Acute pancreatitis associated with atorvastatin therapy. *Gastroenterol Clin Biol* 2000;24:471–2. [PubMed: 10844297]
740. Singh S, Loke YK. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. *Drug Saf* 2006;29:1123–32. [PubMed: 17147459]
741. Tsigrelis C, Pitchumoni CS. Pravastatin: a potential cause for acute pancreatitis. *World J Gastroenterol* 2006;12:7055–7. [PubMed: 17109506]
742. Thisted H, Jacobsen J, Munk EM, et al. Statins and the risk of acute pancreatitis: a population-based case-control study. *Aliment Pharmacol Ther* 2006;23:185–90. [PubMed: 16393296]

743. Verny C, Amati-Bonneau P, Letournel F, et al. Mitochondrial DNA A3243G mutation involved in familial diabetes, chronic intestinal pseudo-obstruction and recurrent pancreatitis. *Diabetes Metab* 2008
744. Singh L, Bakshi DK, Majumdar S, Arora SK, Vasishta RK, Wig JD. Mitochondrial dysfunction and apoptosis of acinar cells in chronic pancreatitis. *J Gastroenterol* 2008;43:473–83. [PubMed: 18600392]
745. Odinkova IV, Sung KF, Mareninova OA, Hermann K, Gukovsky I, Gukovskaya AS. Mitochondrial mechanisms of death responses in pancreatitis. *J Gastroenterol Hepatol* 2008;23(Suppl 1):S25–30. [PubMed: 18336659]
746. Mukherjee R, Criddle DN, Gukovskaya A, Pandol S, Petersen OH, Sutton R. Mitochondrial injury in pancreatitis. *Cell Calcium* 2008;44:14–23. [PubMed: 18207570]
747. Finsterer J. Recurrent pancreatitis as a manifestation of multisystem mitochondrial disorder. *Minerva Gastroenterol Dietol* 2007;53:285–9. [PubMed: 17912191]
748. Finsterer J. Pancreatitis as a manifestation of mitochondrial disorder. *Am J Med Genet A* 2007;143:632–3. [PubMed: 17318846]
749. Debray FG, Drouin E, Herzog D, et al. Recurrent pancreatitis in mitochondrial cytopathy. *Am J Med Genet A* 2006;140:2330–5. [PubMed: 17022070]
750. Toyono M, Nakano K, Kiuchi M, et al. A case of MERRF associated with chronic pancreatitis. *Neuromuscul Disord* 2001;11:300–4. [PubMed: 11297946]
751. Spreckelsen U, Kirchoff R, Haacke H. Cholestatic jaundice during lovastatin medication. *Dtsch Med Wochenschr* 1991;116:739–40. [PubMed: 2026107]
752. Yoshida EM, Levin A. Lovastatin and cholestasis. *Cmaj* 1993;148:374. [PubMed: 8439902]
753. Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. *Pharmacotherapy* 2008;28:1188–93. [PubMed: 18752389]
754. Holme SA, Pearse AD, Anstey AV. Chronic actinic dermatitis secondary to simvastatin. *Photodermatol Photoimmunol Photomed* 2002;18:313–4. [PubMed: 12535029]
755. Granados MT, de la Torre C, Cruces MJ, Pineiro G. Chronic actinic dermatitis due to simvastatin. *Contact Dermatitis* 1998;38:294–5. [PubMed: 9667459]
756. Oskay T, Kutluay L. Acute generalized exanthematous pustulosis induced by simvastatin. *Clin Exp Dermatol* 2003;28:558–9. [PubMed: 12950356]
757. Segal AS. Alopecia associated with atorvastatin. *Am J Med* 2002;113:171. [PubMed: 12133763]
758. Lee TH. By the way, doctor... My hair has been thinning out for the past decade or so, but since my doctor started me on Lipitor (atorvastatin) a few months ago for high cholesterol, I swear it's been falling out much faster. My doctor discounts the possibility, but I looked in the Physicians' desk reference (PDR) and alopecia is listed under "adverse reactions." What do you think? *Harv Health Lett* 2000;25:8.
759. Robb-Nicholson C. Recently, I heard on a TV show that anticholesterol drugs can cause hair loss. I've been taking Zocor for about 18 months now, and in the past 6 months I've noticed hair loss from the top and sides of my head. Is this common? Will my hair regrow once I stop taking the drug? *Harv Womens Health Watch* 1998;5:8.
760. Hampson JP, Smith D, Cowell R, Baker A. Hypotension and eosinophilia with atorvastatin. *Pharm World Sci* 2005;27:279–80. [PubMed: 16228623]
761. Mehregan DR, Mehregan DA, Pakideh S. Cheilitis due to treatment with simvastatin. *Cutis* 1998;62:197–8. [PubMed: 9798110]
762. Peramiquel L, Serra E, Dalmau J, Vila AT, Mascaro JM, Alomar A. Occupational contact dermatitis from simvastatin. *Contact Dermatitis* 2005;52:286–7. [PubMed: 15899006]
763. Field S, Bourke B, Hazelwood E, Bourke JF. Simvastatin - occupational contact dermatitis. *Contact Dermatitis* 2007;57:282–3. [PubMed: 17868229]
764. Adcock BB, Hornsby LB, Jenkins K. Dermographism: an adverse effect of atorvastatin. *J Am Board Fam Pract* 2001;14:148–51. [PubMed: 11314923]
765. de Boer EM, Bruynzeel DP. Allergy to pravastatin. *Contact Dermatitis* 1994;30:238. [PubMed: 8033551]



766. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. *Dermatology* 1993;186:248–52. [PubMed: 8513188]
767. Proksch E. Antilipemic drug-induced skin manifestations. *Hautarzt* 1995;46:76–80. [PubMed: 7706076]
768. DeGiovanni C, Chard M, Woollons A. Eosinophilic fasciitis secondary to treatment with atorvastatin. *Clin Exp Dermatol* 2006;31:131–2. [PubMed: 16309506]
769. Williams ML, Feingold KR, Grubauer G, Elias PM. Ichthyosis induced by cholesterol-lowering drugs. Implications for epidermal cholesterol homeostasis. *Arch Dermatol* 1987;123:1535–8. [PubMed: 3674913]
770. Sparsa A, Boulinguez S, Le Brun V, Roux C, Bonnetblanc JM, Bedane C. Acquired ichthyosis with pravastatin. *J Eur Acad Dermatol Venereol* 2007;21:549–50. [PubMed: 17373993]
771. Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L. Simvastatin-induced lichen planus pemphigoides. *Ann Dermatol Venereol* 2003;130:187–90. [PubMed: 12671581]
772. Roger D, Rolle F, Labrousse F, Brosset A, Bonnetblanc JM. Simvastatin-induced lichenoid drug eruption. *Clin Exp Dermatol* 1994;19:88–9. [PubMed: 8313650]
773. Keough GC, Richardson TT, Grabski WJ. Pravastatin-induced lichenoid drug eruption. *Cutis* 1998;61:98–100. [PubMed: 9515217]
774. Sebok B, Toth M, Anga B, Harangi F, Schneider I. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin). *Acta Derm Venereol* 2004;84:229–30. [PubMed: 15202842]
775. Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoid drug eruption. *Australas J Dermatol* 2006;47:57–9. [PubMed: 16405486]
776. Marguery MC, Chouini-Lalanne N, Drugeon C, et al. UV-B phototoxic effects induced by atorvastatin. *Arch Dermatol* 2006;142:1082–4. [PubMed: 16924075]
777. Morimoto K, Kawada A, Hiruma M, Ishibashi A, Banba H. Photosensitivity to simvastatin with an unusual response to photopatch and photo tests. *Contact Dermatitis* 1995;33:274. [PubMed: 8654087]
778. Abadir R, Liebmann J. Radiation reaction recall following simvastatin therapy: a new observation. *Clinical Oncology (Royal College of Radiologists)* 1995;7:325–6.
779. Feldmann R, Mainetti C, Saurat JH. Skin lesions due to treatment with simvastatin (Zocor). *Dermatology* 1993;186:272. [PubMed: 8513195]
780. Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. *Jama* 1998;279:1613–4. [PubMed: 9613909]
781. Anliker MD, Wuthrich B. Chronic urticaria to atorvastatin. *Allergy* 2002;57:366. [PubMed: 11906371]
782. Proksch E, Feingold KR, Elias PM. Epidermal HMG CoA reductase activity in essential fatty acid deficiency: barrier requirements rather than eicosanoid generation regulate cholesterol synthesis. *J Invest Dermatol* 1992;99:216–20. [PubMed: 1629633]
783. Feingold KR, Man MQ, Menon GK, Cho SS, Brown BE, Elias PM. Cholesterol synthesis is required for cutaneous barrier function in mice. *J Clin Invest* 1990;86:1738–45. [PubMed: 2243142]
784. Mao-Qiang M, Feingold KR, Elias PM. Inhibition of cholesterol and sphingolipid synthesis causes paradoxical effects on permeability barrier homeostasis. *J Invest Dermatol* 1993;101:185–90. [PubMed: 8345219]
785. Haratake A, Ikenaga K, Katoh N, Uchiwa H, Hirano S, Yasuno H. Topical mevalonic acid stimulates de novo cholesterol synthesis and epidermal permeability barrier homeostasis in aged mice. *J Invest Dermatol* 2000;114:247–52. [PubMed: 10651982]
786. Ramsing D, Agner E, Malinowski J, Meibom J, Agner T. Effect of systemic treatment with cholesterol-lowering drugs on the skin barrier function in humans. *Acta Derm Venereol* 1995;75:198–201. [PubMed: 7653179]
787. Namazi MR. Statins: novel additions to the dermatologic arsenal? *Exp Dermatol* 2004;13:337–9. [PubMed: 15186318]
788. Noel M, Gagne C, Bergeron J, Jobin J, Poirier P. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. *Lipids Health Dis* 2004;3:7. [PubMed: 15134579]

789. Bousquet E, Amar J, Salvador M, Chamontin B. Cataract and simvastatin: case report (letter). *Therapie* 1998;53:505–7. [PubMed: 9921047]
790. Laties AM, Keates EU, Taylor HR, et al. The human lens after 48 weeks of treatment with lovastatin [letter]. *New England Journal of Medicine* 1990;323:683–4. [PubMed: 2385275]
791. Langer J. Drug against high cholesterol can affect vision. *Sygeplejersken* 1991;91:13. [PubMed: 2063276]
792. Negevesky GJ, Kolsky MP, Laureno R, Yau TH. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. *Arch Ophthalmol* 2000;118:427–8. [PubMed: 10721974]
793. Fraunfelder FW, Richards AB. Diplopia, Blepharoptosis, and Ophthalmoplegia and 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Use. *Ophthalmology*. 2008
794. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. *Arch Intern Med* 2001;161:2021–6. [PubMed: 11525705]
795. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. *Qjm* 2003;96:337–43. [PubMed: 12702782]
796. Behrens-Baumann W, Morawietz A, Thiery J, Creutzfeldt C, Seidel D. Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up. *Lens Eye Toxic Res* 1989;6:331–7. [PubMed: 2488025]
797. Hutnik CM, Nichols BD. Cataracts in systemic diseases and syndromes. *Curr Opin Ophthalmol* 1999;10:22–8. [PubMed: 10387315]
798. Taylor A, Jacques PF, Epstein EM. Relations among aging, antioxidant status, and cataract. *Am J Clin Nutr* 1995;62:1439S–1447S. [PubMed: 7495245]
799. Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. *Jama* 2006;295:2752–8. [PubMed: 16788130]
800. Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. *Ophthalmologica* 2005;219:154–66. [PubMed: 15947501]
801. Dunlop IS, Dunlop P. Reversible ophthalmoplegia in CPEO. *Aust N Z J Ophthalmol* 1995;23:231–4. [PubMed: 8534451]
802. Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy. *Proc Natl Acad Sci U S A* 1989;86:7952–6. [PubMed: 2554297]
803. Wallace DC. Mitochondrial DNA mutations in diseases of energy metabolism. *J Bioenerg Biomembr* 1994;26:241–50. [PubMed: 8077179]
804. Nonaka I. Mitochondrial diseases. *Curr Opin Neurol Neurosurg* 1992;5:622–32. [PubMed: 1392136]
805. Nakagawa M, Kaminishi Y, Isashiki Y, et al. Familial mitochondrial encephalomyopathy with deaf-mutism, ophthalmoplegia and leukodystrophy. *Acta Neurol Scand* 1995;92:102–8. [PubMed: 7572054]
806. Barboni P, Savini G, Plazzi G, et al. Ocular findings in mitochondrial neurogastrointestinal encephalomyopathy: a case report. *Graefes Arch Clin Exp Ophthalmol* 2004;42:878–80. [PubMed: 15042378]
807. Tomasi LG. Reversibility of human myopathy caused by vitamin E deficiency. *Neurology* 1979;29:1182–6. [PubMed: 572510]
808. Weber R, Raschka C, Bonzel T. Toxic drug-induced hyposmia with lovastatin. *Laryngorhinootologie* 1992;71:483–4. [PubMed: 1388478]
809. Rock CL, Thornquist MD, Kristal AR, et al. Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. *J Nutr* 1999;129:855–64. [PubMed: 10203561]
810. Duncan RB, Briggs M. Treatment of uncomplicated anosmia by vitamin A. *Arch Otolaryngol* 1962;75:116–24. [PubMed: 13888447]

811. Toth J, Temmel AF. Drug therapy for disturbances of smelling. *Laryngorhinootologie* 2004;83:124–34. [PubMed: 14999590]
812. Henkin RI, Smith FR. Hyposmia in acute viral hepatitis. *Lancet* 1971;1:823–6. [PubMed: 4102525]
813. Fraunfelder FW. Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors. *J Ocul Pharmacol Ther* 2004;20:179–82. [PubMed: 15117574]
814. Nikolsky E, Sadeghi HM, Effron MB, et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2005;96:474–81. [PubMed: 16098296]
815. Horiuchi Y, Maruoka H. Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis [letter]. *Journal of Dermatology* 1997;24:549–51. [PubMed: 9301152]
816. McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF. Thrombotic thrombocytopenic purpura and simvastatin[letter; comment] [see comments]. *Lancet* 1998;352:1284–5. [PubMed: 9788466]
817. Possamai G, Bovo P, Santonastaso M. Thrombocytopenic purpura during therapy with simvastatin. *Haematologica* 1992;77:357–8. [PubMed: 1427446]
818. Sundram F, Roberts P, Kennedy B, Pavord S. Thrombotic thrombocytopenic purpura associated with statin treatment. *Postgrad Med J* 2004;80:551–2. [PubMed: 15356359]
819. Paradiso-Hardy FL, Papastergiou J, Lancot KL, Cohen EA. Thrombotic thrombocytopenic purpura associated with clopidogrel: further evaluation. *Can J Cardiol* 2002;18:771–3. [PubMed: 12167967]
820. Koduri PR. Simvastatin and thrombotic thrombocytopenic purpura. *Lancet* 1998;352:2020. [PubMed: 9872276]
821. McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF. Thrombotic thrombocytopenic purpura and simvastatin. *Lancet* 1998;352:1284–5. [PubMed: 9788466]
822. Horiuchi Y, Maruoka H. Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis. *J Dermatol* 1997;24:549–51. [PubMed: 9301152]
823. Robbins MJ, Iqbal A, Hershman R. Lovastatin-induced hemolytic anemia: not a class-specific reaction. *Am J Med* 1995;99:328–9. [PubMed: 7653497]
824. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. *Am Heart J* 2006;151:976 e1–6. [PubMed: 16644315]
825. Douketis JD, Melo M, Bell CM, Mamdani MM. Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin? *Am J Med* 2007;120:369 e9–369 e14. [PubMed: 17398234]
826. De Denus S, Spinler SA. Early statin therapy for acute coronary syndromes. *Ann Pharmacother* 2002;36:1749–58. [PubMed: 12398573]
827. Szapary L, Horvath B, Marton Z, et al. Short-term effect of low-dose atorvastatin on haemorrhological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia. *CNS Drugs* 2004;18:165–72. [PubMed: 14871160]
828. Novela C, Hennekens CH. Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. *J Cardiovasc Pharmacol Ther* 2004;9:61–3. [PubMed: 15094970]
829. Corsini A. Fluvastatin: effects beyond cholesterol lowering. *J Cardiovasc Pharmacol Ther* 2000;5:161–75. [PubMed: 11150405]
830. Walsh KM, Albassam MA, Clarke DE. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. *Toxicologic Pathology* 1996;24:468–76. [PubMed: 8864188]
831. Gattermann N, Wulfert M, Junge B, Germing U, Haas R, Hofhaus G. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. *Blood* 2004;103:1499–502. [PubMed: 14576046]
832. Golomb BA, Ritchie JB, Criqui MH, Dimsdale JE. Statins lower blood pressure: Results of the UCSD Statin Study. *Circulation* 2004;110:III–1904.
833. Rea WE, Durrant DC, Boldy DA. Ulcerative colitis after statin treatment. *Postgrad Med J* 2002;78:286–7. [PubMed: 12151572]

834. Mukhopadhy A, Gilmour H, Plevris J. Pravastatin-induced colitis. *Eur J Gastroenterol Hepatol* 2008;20:810–2. [PubMed: 18617789]
835. El H II, Mourad FH, Shabb NS, Barada KA. Atorvastatin-induced severe gastric ulceration: a case report. *World J Gastroenterol* 2005;11:3159–60. [PubMed: 15918210]
836. Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy [letter]. *American Journal of Gastroenterology* 1992;87:257. [PubMed: 1734709]
837. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. *Am J Cardiol* 2003;92:670–6. [PubMed: 12972104]
838. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. *Am J Clin Nutr* 2006;83:1505S–1519S. [PubMed: 16841861]
839. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. *Nat Clin Pract Gastroenterol Hepatol* 2005;2:308–15. [PubMed: 16265284]
840. Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. *Gut* 2004;53:1129–36. [PubMed: 15247180]
841. Dimauro S, Mancuso M, Naini A. Mitochondrial encephalomyopathies: therapeutic approach. *Ann N Y Acad Sci* 2004;1011:232–45. [PubMed: 15126300]
842. Aksoy F, Demirel G, Bilgic T, Gungor IG, Ozcelik A. A previously diagnosed mitochondrial neurogastrointestinal encephalomyopathy patient presenting with perforated ileal diverticulitis. *Turk J Gastroenterol* 2005;16:228–31. [PubMed: 16547854]
843. Millar WS, Lignelli A, Hirano M. MRI of five patients with mitochondrial neurogastrointestinal encephalomyopathy. *AJR Am J Roentgenol* 2004;182:1537–41. [PubMed: 15150004]
844. Marti R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M. Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. *Clin Chem* 2004;50:120–4. [PubMed: 14633909]
845. Reidenberg MM. Statins, lack of energy and ubiquinone. *Br J Clin Pharmacol* 2005;59:606–7. [PubMed: 15842563]
846. Peters JT, Garwood CL, Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin. *Am J Geriatr Pharmacother* 2008;6:28–32. [PubMed: 18396246]
847. Megarbane A, Khalil G, Waked N, Rotig A, Caillaud C, Loiselet J. Two sibs with myoclonic epilepsy, congenital deafness, macular dystrophy, and psychiatric disorders. *Am J Med Genet* 1999;87:289–93. [PubMed: 10588831]
848. Shinkai T, Nakashima M, Ohmori O, et al. Coenzyme Q10 improves psychiatric symptoms in adult-onset mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a case report. *Aust N Z J Psychiatry* 2000;34:1034–5. [PubMed: 11127618]
849. Yamazaki M, Igarashi H, Hamamoto M, Miyazaki T, Nonaka I. A case of mitochondrial encephalomyopathy with schizophrenic psychosis, dementia and neuroleptic malignant syndrome. *Rinsho Shinkeigaku* 1991;31:1219–23. [PubMed: 1813191]
850. Kato C, Umekage T, Tochigi M, et al. Mitochondrial DNA polymorphisms and extraversions. *Am J Med Genet B Neuropsychiatr Genet* 2004;128:76–9. [PubMed: 15211636]
851. Fattal O, Link J, Quinn K, Cohen BH, Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. *CNS Spectr* 2007;12:429–38. [PubMed: 17545953]
852. Inagaki T, Ishino H, Seno H, Ohguni S, Tanaka J, Kato Y. Psychiatric symptoms in a patient with diabetes mellitus associated with point mutation in mitochondrial DNA. *Biol Psychiatry* 1997;42:1067–9. [PubMed: 9386859]
853. Kazuno AA, Munakata K, Mori K, et al. Mitochondrial DNA sequence analysis of patients with 'atypical psychosis'. *Psychiatry Clin Neurosci* 2005;59:497–503. [PubMed: 16048457]
854. Shao L, Martin MV, Watson SJ, et al. Mitochondrial involvement in psychiatric disorders. *Ann Med* 2008;40:281–95. [PubMed: 18428021]
855. Suzuki T, Koizumi J, Shiraishi H, et al. Psychiatric disturbance in mitochondrial encephalomyopathy. *J Neurol Neurosurg Psychiatry* 1989;52:920–2. [PubMed: 2769294]

856. Vasconcellos LF, Leite AC, Cavalcanti JL, Moreira DM, Feijo D, Souza CF. Psychotic syndrome developing into dementia as a clinical manifestation of mitochondrial DNA deletion. *Arq Neuropsiquiatr* 2007;65:114–7. [PubMed: 17420839]
857. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. *Psychosomatics* 2006;47:1–7. [PubMed: 16384802]
858. Rapoport D. Unrecognized adverse drug reactions. *Cmaj* 1993;149:1233. [PubMed: 8221476]
859. Shuster J. Lipid-lowering drugs and headache. *Nursing* 1998;28:32. [PubMed: 9856031]
860. Ramsey CS, Snyder QC. Altitude-induced migraine headache secondary to pravastatin: case report. *Aviation Space and Environmental Medicine* 1998;69:603–6.
861. Jacome DE. Primary yawning headache. *Cephalalgia* 2001;21:697–9. [PubMed: 11531903]
862. Caan B, Shanske S, Otaegui D, et al. Study of mitochondrial DNA mutations in patients with migraine with prolonged aura. *Headache* 2004;44:674–7. [PubMed: 15209689]
863. Bresolin N, Martinelli P, Barbiroli B, et al. Muscle mitochondrial DNA deletion and 31P-NMR spectroscopy alterations in a migraine patient. *J Neurol Sci* 1991;104:182–9. [PubMed: 1658240]
864. Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. *Neurology* 1992;42:1209–14. [PubMed: 1603349]
865. Sacquegna T, Lodi R, De Carolis P, et al. Brain energy metabolism studied by 31P-MR spectroscopy in a case of migraine with prolonged aura. *Acta Neurol Scand* 1992;86:376–80. [PubMed: 1455984]
866. Uncini A, Lodi R, Di Muzio A, et al. Abnormal brain and muscle energy metabolism shown by 31P-MRS in familial hemiplegic migraine. *J Neurol Sci* 1995;129:214–22. [PubMed: 7608738]
867. Crimmins D, Morris JG, Walker GL, et al. Mitochondrial encephalomyopathy: variable clinical expression within a single kindred. *J Neurol Neurosurg Psychiatry* 1993;56:900–5. [PubMed: 8350109]
868. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. *Neurology* 2005;64:713–5. [PubMed: 15728298]
869. Singhal AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. *Neurology* 2005;64:1008–13. [PubMed: 15781818]
870. Bucca C, Marsico A, Panaro E, Bigo P, Brussino L. Statins and nasal polyps. *Ann Intern Med* 2005;142:310–1. [PubMed: 15710970]
871. von Pohle WR. Recurrent hyperthermia due to lovastatin. *West J Med* 1994;161:427–8. [PubMed: 7817565]
872. Krivosic-Horber R, Depret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. *Eur J Anaesthesiol* 2004;21:572–4. [PubMed: 15318472]
873. Vladutiu G. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al. *Arthritis Rheum* 2007;57:186–7. author reply 187–8. [PubMed: 17266123]
874. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. *Birth Defects Res A Clin Mol Teratol* 2005;73:888–96. [PubMed: 16163683]
875. Gibb H, Scialli AR. Statin drugs and congenital anomalies. *Am J Med Genet A* 2005;135:230–1. author reply 232–4. [PubMed: 15810007]
876. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. *Am J Med Genet* 2004;131A:287–98. [PubMed: 15546153]
877. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. *N Engl J Med* 2004;350:1579–82. [PubMed: 15071140]
878. Edison RJ, Muenke M. Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly. *N Engl J Med* 2005;352:2759. [PubMed: 15987932]
879. Ghidini A, Sicherer S, Willner J. Congenital abnormalities (VATER) in baby born to mother using lovastatin. *Lancet* 1992;339:1416–7. [PubMed: 1350826]
880. Statins: beware during pregnancy. *Prescrire Int* 2006;15:18–9. [PubMed: 16548110]



881. Devroey D, Betz W, Coigniez P, Lauwers R, Velkeniers B. A "bad responder" to statins. *Cardiology* 2002;97:230–2. [PubMed: 12145480]
882. Doherty E, Lumb PJ, Chik G, Wierzbicki AS. Ezetimibe-induced hyperlipidaemia. *Int J Clin Pract Suppl* 2005;3–5. [PubMed: 15875607]
883. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. *Biofactors* 2005;25:147–52. [PubMed: 16873939]
884. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. *Am J Cardiol* 2007;99:1409–12. [PubMed: 17493470]
885. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol. *Biofactors* 2003;18:125–7. [PubMed: 14695927]
886. Young JM, Florkowski CM, Molyneux SL, et al. Abstract 343: Coenzyme Q10 does not Improve Simvastatin Tolerability in Dyslipidemic Patients with Prior Statin-Induced Myalgia. *Circulation* 2006;114:II\_41–d-42.
887. Chopra, RK.; Bhagavan, HX.; Sinatra, S.; Goldman, R. Relative bioavailability of coenzyme Q10 in human subjects; First Conference of the International Coenzyme Q10 Association; Boston. May 21-May 24, 1998;
888. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. *Arch Intern Med* 2005;165:2671–6. [PubMed: 16344427]
889. Phillips PS, Haas RH. Observations from a statin myopathy clinic. *Arch Intern Med* 2006;166:1232–3. [PubMed: 16772252]
890. Trontell A. Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind. *N Engl J Med* 2004;351:1385–7. [PubMed: 15459298]
891. Kennedy DL, Goldman SA. Monitoring for adverse drug events. *Am Fam Physician* 1997;56:1718, 1721. [PubMed: 9371003]
892. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction--modulation by statins. *Endothelium* 2003;10:23–33. [PubMed: 12699074]

Table I

Muscle Effects Reported on Statins

Muscle Problem	Description and Citations	Comment
Muscle AEs Generally <sup>a</sup>	<p>- Reported incidence is low in clinical trials but higher in studies of real world use.</p> <p>- In a French longitudinal study, statin users showed a 10.5% incidence of muscle AEs over 6 months, with a median time to onset of 1 month.<sup>34</sup></p> <p>- In a French study, among 815 adults on lipid therapy in a cardiovascular prevention unit, 165 (23%) reportedly had experienced or currently experienced muscle symptoms they attributed to lipid therapy.<sup>79</sup> AEs commonly appeared soon after drug initiation and/or abated with drug discontinuation. Approximately 40% required pain medications. Cramps, stiffness, and tendinitis were common. Many reported pain during rest. In many, other family members had also experienced muscle AEs on lipid treatment.<sup>79</sup></p> <p>- A European study prospectively identified patients with muscle complaints limiting daily activity during statin use. Of 18 patients with muscle AEs deemed probably attributable to statins in whom CK was evaluated, 28% showed no CK elevation and 33% showed a minor increase only. Symptoms resolved with statin discontinuation and CK normalized in 11 of 13 showing elevated CK. Authors concluded "Statins may cause clinically important muscle symptoms without inducing a marked creatine kinase elevation."<sup>80</sup></p> <p>- A double-blind crossover biopsy study affirmed presence of a partially reversible mitochondrial myopathy in four subjects with non-CK-elevating or minimally CK-elevating statin muscle AEs.<sup>31</sup></p> <p>- In a patient-targeted adverse event surveillance effort, in patients citing statin muscle AEs who had improved on statin discontinuation, most who were rechallenged with equivalent or higher expected potency agents experienced recurrence; while recurrence occurred significantly less frequently in those rechallenged with lower potency agents.<sup>37</sup></p>	
Rhabdomyolysis <sup>a</sup>	<p>- Severe muscle breakdown leading to markedly elevated CK is termed rhabdomyolysis; some definitions also require kidney involvement. The kidneys can be overwhelmed, leading to myoglobinuria, with renal failure and death a well recognized, serious complication that can occur with statins alone and in combination with fibrates or other interacting agents.<sup>81-89</sup></p> <p>- In one (atypical) case, rhabdomyolysis was reported to occur after a single statin dose.<sup>90</sup> In other cases, it has occurred 2-4 days after statin initiation<sup>91, 92</sup> or addition of</p>	<p>Statin rhabdomyolysis reports include a range of instances in which there is multiple organ failure.<sup>96, 97</sup> including renal failure,<sup>96-104</sup> respiratory failure,<sup>98</sup> pancreatitis,<sup>96, 105</sup> hepatitis or hepatotoxicity,<sup>97, 100, 106-108</sup> heart failure or cardiac rhabdomyolysis,<sup>91, 96, 109-111</sup> MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes),<sup>112</sup> and cognitive failure.<sup>96</sup></p>

Muscle Problem	Description and Citations	Comment
	<p>other drugs to lipid-lowering treatment.<sup>93</sup></p> <ul style="list-style-type: none"> <li>- While muscle pain and weakness may be characteristic, physicians should be aware that rhabdomyolysis may present atypically, as fatigue, low back pain, flu-like illness, or shortness of breath.<sup>94, 95</sup> Symptoms can build over several weeks; the mean time to occurrence after statin initiation in one analysis was a year.<sup>94</sup></li> </ul>	
New Difficulty Walking <sup>d</sup>	<p>Statins were a significant (partially) reversible cause of new difficulty walking in patients presenting to a rehabilitation clinic.<sup>113</sup></p>	
Exercise Limitations or Exercise-induced Muscle Symptoms <sup>d</sup>	<ul style="list-style-type: none"> <li>- Statin associated exercise-induced muscle pain.<sup>114</sup></li> <li>- Professional athletes with familial hyperlipidemia seldom tolerate statins due to muscle adverse effects.<sup>58</sup></li> <li>- Combined statins and beta blockers adversely affect perceived effort and cardiorespiratory function.<sup>59</sup></li> <li>- Statin-induced myopathy in a competitive cyclist.<sup>115</sup></li> <li>- Increases in CK after exercise have been reported with statins.<sup>116</sup></li> <li>- Variations of statin-associated exercise-induced muscle pain without CK elevation have been reported.<sup>114</sup></li> <li>- See also 'Exercise limitation and fatigue/lack of energy,' Table VIII.</li> </ul>	<ul style="list-style-type: none"> <li>- In animals, exercise exacerbated statin-induced muscle injury.<sup>60</sup></li> <li>- In humans, statins exacerbated exercise-induced muscle injury.<sup>61</sup></li> <li>- In a placebo-controlled study, high-dose atorvastatin 80mg had little effect on muscle gene expression at rest in healthy volunteers, but it affected expression of 56 genes when combined with exercise (18% involved in the ubiquitin proteasome pathway and 20% involved in protein folding/catabolism &amp; apoptosis). The authors speculated this mechanism may be involved in exercise-related symptoms arising on statins.<sup>62</sup></li> <li>- Effect modification: Statins have increased walking distance on average in persons with and without peripheral artery disease.<sup>29</sup></li> <li>- Mitochondrial pathology can be associated with exercise intolerance, and mitochondrial abnormalities can cause exercise limitation in otherwise normal adults.<sup>117-123</sup></li> </ul>
Inflammatory Myopathies <sup>d</sup>	<p>Dermatomyositis, polymyositis and inflammatory myopathies have been reported in association with statins (see also 'Immune, autoimmune' entry, Table VIII),<sup>63-75</sup></p>	<ul style="list-style-type: none"> <li>- Statins' prooxidant effects may predominate in some patients,<sup>51</sup> and may contribute to proinflammatory effects.<sup>76, 77</sup></li> <li>- Effect modification: Statins have anti-inflammatory effects (in part via antioxidant effects that predominate in many).<sup>51</sup> and in clinical trial samples, have on average reduced markers of inflammation (e.g. C-reactive protein). For this reason, statins have undergone testing for a range of inflammatory conditions.</li> <li>- Statins reduce LDL-C transport and/or production of key anti-inflammatory nutrients or their precursors, including coenzyme Q10, retinol (vitamin A), cholecalciferol (vitamin D). They affect the omega-3 to omega-6 ratio, which may foster inflammation.<sup>17</sup></li> </ul>

Muscle Problem	Description and Citations	Comment
Myasthenia Gravis (MG) <sup>a</sup>	Occurrence, exacerbation, or mimic of MG have been reported in the literature. <sup>78, 124, 125</sup>	<ul style="list-style-type: none"> <li>- Muscle weakness from statins may exacerbate existing conditions or mimic other conditions involving muscle weakness.</li> <li>- In the case of MG, drug interactions with dual mitochondrial toxicity may play a role. AChE inhibitors used to treat MG are potent oxidative stressors<sup>126, 127</sup> and patients with this condition have mitochondrial pathology<sup>128</sup> whether by disease or drug treatment.</li> </ul>
Rippling Muscle Disease <sup>a</sup>	Rippling muscle disease comprising "stiffness, myalgias, and classic rippling" arose on statins, was relieved with discontinuation, and recurred with rechallenge. <sup>129</sup>	
Guillain Barre (GB) or GB-like Syndrome <sup>a</sup>	GB (or GB-like syndromes, i.e. acute polyradiculoneuropathy) in apparent association with statins has been reported. <sup>130</sup>	Although GB is by definition a radiculoneuropathy, it is clinically manifested by muscle weakness and for this reason is included in this Table.
Tendinopathy <sup>a</sup>	<ul style="list-style-type: none"> <li>- Tendinopathy and tendon disorders, often reproducible with rechallenge, have been reported in a case series.<sup>79, 131-134</sup></li> <li>- A report from New Zealand noted, "A search of the WHO database revealed 205 reports of tendonitis, tendon disorder or tendon rupture associated with statins."<sup>135</sup></li> <li>- In a French series where 165 of 815 hypolipidemic patients on lipid-lowering therapy reported muscle symptoms, nearly half included tendonitis-associated pain among their symptoms.<sup>79</sup></li> <li>- Of 96 patients with tendon complaints in a French pharmacovigilance database, 63 exhibited tendonitis and 33 tendon rupture. Statin reinitiation occurred in 7 cases with recurrence of tendinopathy in all.<sup>136</sup></li> </ul>	<ul style="list-style-type: none"> <li>- As one instance, in a case of spontaneous biceps tendon rupture in a physician, rechallenge led to tendinopathy in the contralateral biceps tendon that improved with statin discontinuation.<sup>133</sup></li> <li>- A mitochondrial mechanism may underlie statin-related tendinopathy as reported for other classes of drugs with tendon toxicity (such as fluoroquinolones,<sup>137-139</sup>) which have also been linked to myopathy, arthralgia and rhabdomyolysis.<sup>140-142</sup></li> </ul>
Shoulder Stiffness <sup>a</sup>	Citation reported that "nearly one-tenth of women (6/66)" taking statins reported drug-related shoulder stiffness. <sup>143</sup>	
Amyotrophic Lateral Sclerosis (ALS) or ALS-Like Syndromes <sup>a</sup>	Based on pharmacovigilance data, an apparent disproportionate reporting (possible "signal") of ALS and ALS-like problems on statins has been reported. <sup>144, 145</sup> (Although ALS is a motor neuron condition, it leads clinically to muscle weakness and atrophy, prompting its inclusion in this table.) See Table VIII for further discussion.	<ul style="list-style-type: none"> <li>- An apparent signal of increased ALS in patients on statins was also reported by one of the authors (Golomb, November 2005 and November 2006 Robert Wood Johnson Generalist Physician Faculty Scholars program). Although association is not causation, it was noted that other factors are present that suggest possible causality. For instance, biological plausibility is present since statins lower concentrations of coenzyme Q10, while supplementation with coenzyme Q10 protects against animal models of neurodegeneration including ALS and Parkinson's disease.</li> <li>- Bidirectional influences by statins on ALS cannot be excluded, since statins have both pro-oxidant and antioxidant effects, and in different</li> </ul>

Muscle Problem	Description and Citations	Comment
Other Progressive Wasting Conditions <sup>a</sup>	Citation reported a case of progressive bilateral muscle weakness attributed to statin therapy, with dysphagia, dysarthria, and dyspnea. Progression continued after statin discontinuation, culminating in death. <sup>146</sup> (A low vitamin D level was noted, which can produce a severe myopathy. <sup>147</sup> Of note cholesterol is the biochemical precursor for vitamin D.)	individuals either effect may dominate. <sup>145</sup> (This is analogous to findings we have shown for statin effects on muscle, kidney, etc.)
Compartment Syndrome	Has been reported with statin myositis, and produced myonecrosis. <sup>153, 154</sup>	- See discussion for amyotrophic lateral sclerosis – a condition that has been found to involve mitochondrial defects in muscle, not just motor neurons. <sup>148-152</sup>

ACHe = acetylcholinesterase; CK = creatine kinase; LDL-C = low density lipoprotein cholesterol.

<sup>a</sup>Our study group has also received reports of these and a variety of additional conditions from patients and/or physicians.



Table II

Evidence For, and Suggestive Of, Dose/Potency Dependence of Statin Adverse Effects (AEs)

AE	Comment
All AEs	<ul style="list-style-type: none"> <li>- OR 1.4; 95% CI 1.09-1.80, p=0.008 statin therapy vs placebo<sup>175</sup> (meta-analysis of placebo-controlled RCTs).</li> <li>- OR 1.44; 95% CI 1.33-1.55, p&lt;0.001 intensive- vs moderate-dose statin therapy<sup>176</sup> (meta-analysis of RCTs).</li> </ul>
AEs Leading to Discontinuation of Therapy	<ul style="list-style-type: none"> <li>- OR 1.28; 95% CI 1.18-1.39, p&lt;0.001 intensive- vs moderate-dose statin therapy<sup>176</sup> (meta-analysis of RCTs).</li> </ul> <p>Note: Though intensive-dose statins lead to more discontinuation due to AEs than moderate-dose statins, moderate-dose statins do not necessarily lead to more discontinuation due to AEs than placebo<sup>177</sup> (meta-analysis of RCTs).</p>
CK Elevation	<p>Although some meta-analyses fail to show significant CK elevations with statins (usually moderate dose) vs placebo,<sup>177</sup> meta-analysis of head-to-head RCTs of high- vs low- potency statins showed a significant increase in CK elevation with high-dose statins:</p> <ul style="list-style-type: none"> <li>• CK elevation OR 6.12 with higher- vs lower- dose statin therapy (95% CI 1.36-27.5).<sup>178</sup> The odds appeared to be greater for lipophilic statins, which can more readily enter muscle tissue.</li> <li>• CK elevation OR 9.97 with intensive vs less intensive statins (95% CI 1.3-77.9, p=0.028).<sup>176</sup></li> </ul>
LFT Elevation	<ul style="list-style-type: none"> <li>- Meta-analyses of RCTs show significant increases in LFTs with statin vs placebo (risk difference per 1000 patients 4.2, 95% CI 1.5-6.9).<sup>177</sup></li> <li>- Meta-analysis of head-to-head RCTs of higher- vs lower- potency statins showed significant increase in LFT elevation with higher-dose statins: <ul style="list-style-type: none"> <li>• LFT (transaminase) elevation OR 2.7 (1.5-5.0) with higher vs lower dose statins.<sup>178</sup> The effect appeared to be greater for hydrophilic statins (pravastatin, the most hydrophilic, is actively taken up into the liver).</li> <li>• LFT elevation (alanine or aspartate aminotransferase <math>\geq 3</math> times the ULN) OR 4.5 (95% CI 3.3-6.2) with intensive- vs nonintensive- statin therapy.<sup>176</sup></li> </ul> </li> <li>- In a different study design, looking not at dose, but LDL-C reduction, the magnitude of LDL-C drop was not related to AE risk. In contrast, the higher the statin dose needed to achieve a given LDL-C reduction, the higher the rates of elevated LFTs.<sup>181</sup> For many reasons, this type of study is less interpretable from a dose-response standpoint.<sup>a</sup></li> </ul>
Rhabdomyolysis	<ul style="list-style-type: none"> <li>- Excess rhabdomyolysis cases on cerivastatin primarily involved high-potency use and/or combination with gemfibrozil, which increases the effective dose.<sup>170, 171, 179</sup></li> <li>- Drugs that inhibit the CYP3A4 system and thereby increase statin concentrations (e.g. for atorvastatin, simvastatin, lovastatin, and cerivastatin) increase risk for statin AEs (including rhabdomyolysis) 6-fold.<sup>167</sup> supporting a dose relationship of statins to AEs.</li> <li>- In a VA database, when statins were combined with agents that inhibit their clearance (CYP3A4 inhibitors) the rate of rhabdomyolysis was increased 3- to 5-fold.<sup>185</sup></li> <li>- US FDA Advisory advised caution with high-dose (40mg) rosuvastatin due to elevated risk of rhabdomyolysis.<sup>180</sup></li> <li>- In a meta-analysis of RCTs, the percent LDL-C reduction was not associated with rhabdomyolysis risk. (However, LDL-C reduction is a problematic metric – see footnote a; and footnote b in Table IV – and more so across trials since sample differences can swamp dose effects.<sup>181(c)</sup></li> <li>- In the SEARCH trial in which 12,064 subjects were randomized to 20 or 80mg simvastatin, there were 49</li> </ul>

AE	Comment
	cases of “definite myopathy” in the simvastatin 80mg group and 2 in the simvastatin 20mg group. <sup>186b</sup> There were 49 of “incipient myopathy” in the simvastatin 80mg group and 6 in the simvastatin 20mg group. <sup>b</sup> - See also Table IV, “Risk Factors for Statin Adverse Effects (AEs).”
Non-CK Elevating Muscle Symptoms	Recurrence of statin AEs was significantly higher when subjects were rechallenged with an equivalent expected potency statin, relative to a lower potency statin (~95% vs 55%, p<0.01). <sup>37</sup>
Cancer	According to a meta-analysis of statin RCTs, achieved LDL-C levels were significantly inversely related to cancer risk (p=0.009), though LDL-C reduction was not. <sup>181</sup> On average statins do not increase cancer in those under age 70 years in clinical trials (see Table VII). One could postulate a relation to LDL-C transport of antioxidants or cholesterol status as a precursor to vitamin D.
Proteinuria	FDA Advisory: “Mild, transient proteinuria (or protein in the urine, usually from the tubules), with and without microscopic hematuria (minute amounts of blood in the urine), occurred with Crestor [rosuvastatin], as it has with other statins, in Crestor’s pre-approval trials. The frequency of occurrence of proteinuria appeared dose-related.” <sup>180</sup>
Glycemia	<ul style="list-style-type: none"> <li>- Atorvastatin 80mg increased glycemia significantly on average in the PROVE-IT –TIMI trial.<sup>184</sup></li> <li>- Rosuvastatin 20mg vs placebo significantly increased HbA1c (p=0.001), and increased newly diagnosed diabetes mellitus (relative risk 1.25; p=0.01) in the JUPITER trial.<sup>187</sup></li> <li>- Lower statin potencies have led to reproducible elevations in glucose in individual subjects,<sup>182</sup> but elevations in glucose or HbA1c have usually not been reported on average in RCTs of low- or moderate-dose statins (although in one RCT the statin group exhibited a modest but statistically significant increase in HbA1c<sup>183</sup>).</li> </ul>

ALT = alanine aminotransferase; CK = creatine kinase; CYP = cytochrome P450; HbA1c = glycosylated hemoglobin; JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C = low-density lipoprotein cholesterol; LFTs = liver function tests; OR = odds ratio; PROVE-IT-TIMI = Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction trial; RCT = randomized controlled trial; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; ULN = upper limit of normal; VA = US Department of Veterans Affairs.

<sup>a</sup>Statin use is associated with transcriptional upregulation of HMG-CoA reductase.<sup>188</sup> We suggest that persons on statins with more unfavorable antioxidant/oxidant state may (on average) upregulate HMG-CoA reductase especially strongly in response to statins. Lesser LDL-C reduction for the same dose may signal a less favorable oxidant/antioxidant milieu on average,<sup>189</sup> which in turn may be associated with higher risk of statin AEs.<sup>51-53</sup> Consistent with this, LDL-C tachyphylaxis occurred with high-dose atorvastatin, but not if coenzyme Q10 was concurrently administered (2005 International Coenzyme Q10 Association Meeting presentation<sup>190</sup>). LDL-C reduction for a *given* dose may not be a good way to examine dose effects. For some persons, the same statin dose may confer a *lesser* LDL-C reduction due to factors that promote oxidation and thus may also increase AE risk. In contrast, for some persons, the same statin dose may confer *greater* LDL-C reduction due to factors that increase statin assimilation or reduce clearance, which may also, by causing functionally greater statin “dose,” increase AE risk. (See also Table IV, footnote b.)

<sup>b</sup>“Definite myopathy” was defined as muscle symptoms with CK elevations exceeding 10x ULN (meeting definitions of rhabdomyolysis that do not require renal involvement); “incipient myopathy” was defined as CK exceeding 3x ULN and more than 5x baseline CK, coupled with an ALT elevation exceeding 1.7x baseline ALT without an isolated ALT elevation at any other visit, irrespective of muscle symptoms.<sup>186</sup> (Note that ALT elevation reflects liver compromise and is not a characteristic of myopathy. However, concurrent muscle and liver dysfunction may signal widespread cellular consequences of statins.)

Table III

## Drug Interactions Reported in Statin Rhabdomyolysis

Drug Class/ Drug	Examples	Comments
Fibric Acid Derivatives (Especially Gemfibrozil) <sup>226</sup>	Gemfibrozil. <sup>105, 196-199, 202, 210, 227, 234</sup> Bezafibrate. <sup>228</sup> Fenofibrate. <sup>229</sup>	- This likely reflects two major factors:  1 Fibrates affect the metabolic pathways of statins, leading to a functionally increased dose. Indeed, a high plurality of excess rhabdomyolysis cases on cerivastatin (now withdrawn) occurred in combination expressly with gemfibrozil. <sup>169</sup> Gemfibrozil significantly inhibits both major metabolic pathways for cerivastatin (oxidation and glucuronidation); it affects metabolic pathways less for other statins. <sup>170, 171, 179</sup> Overall gemfibrozil-statin combinations have been more problematic than fenofibrate-statin combinations. <sup>195</sup>  2 Fibrates are generally used in the setting of high triglycerides, a marker of impaired fatty acid oxidation that may signal mitochondrial vulnerability. <sup>155</sup> (see 'High triglycerides' as a risk factor, <b>Table IV</b> ).  - Gemfibrozil inhibits glucuronidation and also CYP2C8 (non-CYP3) oxidation of statin hydroxy acids. The CYP2C8 pathway has specific relevance to cerivastatin. Thus gemfibrozil increases statin concentrations to a greater degree than do other fibrates, an effect that is far stronger for cerivastatin due to the added effect on oxidation. This is likely responsible for the disproportionately higher rates of rhabdomyolysis with gemfibrozil, specifically, with gemfibrozil in combination with cerivastatin. <sup>170, 171, 179</sup>
Other Lipid- lowering Drugs	Cholestyramine. <sup>223</sup> Niacin. <sup>224</sup> Ezetimibe. <sup>225, 230, 231</sup>	Although combinations of statins with all lipid drugs may pose risk, there are comparatively few reports of rhabdomyolysis with statins in combination with niacin.
Macrolide Antibiotics <sup>226, 232</sup> , 233, 235	Erythromycin. <sup>236</sup> Clarithromycin. <sup>237-241</sup> Azithromycin. <sup>237</sup> Roxithromycin. <sup>242</sup>	CYP3A4 inhibitors.
Azole Antifungals <sup>226, 232</sup>	Ketoconazole. <sup>106, 243-245</sup> Itraconazole. <sup>203, 246-248</sup> Fluconazole. <sup>89, 249, 250</sup>	CYP3A4 inhibitors.
Cyclosporin <sup>232</sup>	For reports see. <sup>203, 226, 247, 251-255</sup>	CYP3A4 inhibitors.
Calcium Channel Blockers	Diltiazem. <sup>172, 226, 256</sup> Verapamil. <sup>257</sup> Mibefradil. <sup>226, 258, 259</sup>	CYP3A4 inhibitors. - In subjects assigned to simvastatin 80mg (SEARCH trial), the use of calcium channel blockers at baseline was linked to increased "definite or incipient myopathy" with a relative risk of 1.7 (95% CI 1.2-2.6) overall (n=98); and 2.7 (95% CI 1.6-4.5) in the first year (n=56). <sup>186 a</sup> (After the first year, the relative risk was 0.9, 95% CI 0.4 - 1.8; n=42; however, subjects on and off calcium channel blocker at baseline may have changed calcium channel blocker status by later years.)
Antipsychotics	Risperidone. <sup>260-262</sup>	- Some antipsychotics have CYP3A4 inhibiting properties (quetiapine, <sup>263,264</sup> risperidone <sup>264</sup> ), may have mitochondrial toxicity, <sup>265</sup> and can cause rhabdomyolysis. <sup>260,266</sup> .

Drug Class/ Drug	Examples	Comments
Amiodarone	For reports see. <sup>107, 279-281</sup>	<p>277</p> <ul style="list-style-type: none"> <li>- Antipsychotics are a marker for schizophrenia which has been associated with mitochondrial pathology – either intrinsically or as a result of these drugs.<sup>278</sup></li> <li>- This drug has mitochondrial toxicity.<sup>282-288</sup> and is also a weak CYP3A4 inhibitor.</li> <li>- In subjects assigned to simvastatin 80mg (SEARCH trial), the use of amiodarone at baseline was associated with increased “definite or incipient myopathy,” with a relative risk in the first year of 8.8 (95% CI 4.2-18.4).<sup>186 a</sup> After detection of the association early in the trial, those on amiodarone in the 80mg group were switched to 20mg (it was not specified precisely when). It was observed that this may explain the lesser relative risk after the first year of 3.5 (95% CI 1.1-11.6); with an overall relative risk of 6.4 (95% CI 3.4 -12.1).</li> </ul>
Antiretrovirals <sup>214, 281, 289</sup>	Ritonavir. <sup>290</sup> Nelfinavir. <sup>86</sup> Atazanavir. <sup>281</sup>	<ul style="list-style-type: none"> <li>- These classes of drugs are mitochondrial toxins,<sup>291-299</sup> and have been associated with rhabdomyolysis.<sup>300</sup></li> <li>- They are also CYP3A4 inhibitors, and can serve as a marker for a condition, AIDS, that has been associated with mitochondrial dysfunction.<sup>301</sup></li> <li>- According to one report looking at pharmacokinetic interactions between these drugs and statins, in patients receiving ritonavir and saquinavir, the “area under the curve increased about fivefold for atorvastatin and about 32-fold for simvastatin, but decreased 0.5-fold for pravastatin.”<sup>302</sup> (This refers to the area under the plasma concentration-time curve.)</li> </ul>
Nefazodone	For reports see. <sup>303-306</sup>	
Reports of Other Drug Interactions	Sildenafil. <sup>307</sup> Warfarin. <sup>226, 308</sup> Chlorzoxazone. <sup>108</sup> Digoxin. <sup>226</sup> Amoxicillin. <sup>309</sup> Danazol. <sup>310</sup> Colchicine. <sup>311-313</sup> Thiazolidinediones with atorvastatin. <sup>314</sup> Erlotinib. <sup>315</sup> Multiple interacting medications. <sup>281</sup>	<p>Atorvastatin AE reports were 3.1 times as likely to list thiazolidinediones (pioglitazone, rosiglitazone) as concomitant medication than simvastatin AE reports. Possibly:</p> <ul style="list-style-type: none"> <li>- Thiazolidinediones are reportedly mild <i>inhibitors</i> (i.e. opposite of inhibitors) of CYP3 and thus slightly <i>reduce</i> simvastatin concentrations.<sup>316</sup> Note that thiazolidinediones also induce mitochondrial toxicity.<sup>317</sup></li> <li>- Patients with diabetes mellitus may be more often placed on the more potent agent, atorvastatin, because they are considered by many to be CAD equivalent in terms of cardiac risk and to require lower LDL-C targets.<sup>314</sup></li> </ul>

AE = adverse effect; ALT = alanine aminotransferase; CAD = coronary artery disease; CK = creatine kinase; CYP = cytochrome P450; LDL-C = low-density lipoprotein cholesterol; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; ULN = upper limit of normal.

<sup>a</sup>The SEARCH trial randomly allocated 12,064 subjects with prior myocardial infarction to 20 or 80mg of simvastatin. Relative risks for developing “definite/incipient myopathy” based on baseline characteristics were calculated from the 6031 subjects assigned to 80mg of simvastatin. “Definite myopathy” was defined as muscle symptoms with CK elevations exceeding 10 × ULN (meeting definitions of rhabdomyolysis that do not require renal involvement). “Incipient myopathy” was defined as CK exceeding 3 × ULN and more than 5 × baseline, coupled with an ALT elevation exceeding 1.7 × baseline without an isolated ALT elevation at any other visit, irrespective of muscle symptoms. 50% of cases were “definite.” (Note that ALT elevation reflects liver function and is not a characteristic of myopathy. However, conjoint muscle and liver dysfunction may signal widespread cellular consequences of statins.)

Table IV

Risk Factors for Statin Adverse Effects (AEs)

Risk Factor	Considerations
Dose (or Potency; see Table II) <sup>36, 37, 163, 176, 178, 180, 185, 334</sup>	<ul style="list-style-type: none"> <li>- As discussed in the text (section 'Dose Response'), many statin AEs are dose dependent.</li> <li>- Although some literature advises "the lower the better" with regard to LDL-C and aggressive statin use,<sup>191, 192</sup> the US FDA states "all statins...should be prescribed at the lowest dose that achieves the goals of therapy (e.g., target LDL-C level)."<sup>180</sup></li> </ul>
Other Interacting Drugs (see Table III) <sup>36, 163, 180</sup> and Polypharmacy <sup>341</sup>	<ul style="list-style-type: none"> <li>- As discussed in the text (section 'Drug Interactions'), many drug interactions functionally increase dose. In some cases, interacting drugs may, in addition, cause/compound mitochondrial toxicity (e.g. amiodarone;<sup>283, 288</sup> HIV protease inhibitors<sup>335, 336</sup>), and may themselves conduce to rhabdomyolysis.<sup>300</sup></li> <li>- Use of CYP3A4 inhibitors were associated with a 6.0-fold increase in hospitalizations for myopathy including rhabdomyolysis in patients on lipid therapy (95% CI 2.1-17.4), and a 2.3-fold increase in hospitalizations for renal AEs (95% CI 1.6-3.2) based on administrative claims data, matching controls to cases on age, sex, geographic region, length of follow-up, and time of index drug fill.<sup>167</sup></li> </ul>
'Frailty' or Small Body Frame <sup>94, 325, 337</sup>	<p>Small size and frailty may signal higher mg/kg dose (and also lower clinical or cellular reserve).</p>
Surgery <sup>94, 338-340</sup>	<ul style="list-style-type: none"> <li>- Intraoperative or perioperative rhabdomyolysis.</li> <li>- Surgery may increase energy demands, which may be a problem in settings of marginal supply if mitochondrial effects that are otherwise subclinical are present. Surgery may also be associated with use of interacting drugs. Surgery may worsen oxidative stress, aggravating risk in those subjects for whom statins increase lipid peroxidation markers.<sup>51-53, 342</sup></li> <li>- Coenzyme Q10 has reportedly improved surgical outcomes and reduced reperfusion injury in some human and animal studies.<sup>343-346</sup> (statins reduce coenzyme Q10 concentrations).</li> <li>- However, while animal studies have suggested worsening of myocardial stunning with statin pretreatment,<sup>347</sup> in a range of human studies, statins have apparently improved surgical outcomes for vascular and heart surgery,<sup>348-350</sup> possibly via statin antioxidant effects that predominate in many people.<sup>51</sup></li> </ul>
Infection <sup>351-354</sup>	<ul style="list-style-type: none"> <li>- One possible mechanism is that infection may increase energy demands, which may be a problem in settings of marginal supply if statin mitochondrial effects occur that might otherwise be subclinical. Infection may also be associated with use of drugs that interact with statins, such as macrolide antibiotics.</li> <li>- Some evidence suggests statin users may have lower incidence of sepsis. However, confounding (by indication [i.e. if high LDL-C rather than statins drives the protection] or by socioeconomic status,<sup>355-357</sup> for instance) cannot be excluded as a basis of such findings.</li> </ul>
Exertion <sup>94, 351, 358</sup>	<ul style="list-style-type: none"> <li>- Exertion may increase energy demands, which may be a problem in settings of marginal supply if mitochondrial effects that are otherwise subclinical are present.</li> <li>- Treadmill exercise increased incidence and severity of statin damage in Type 2 fiber-predominant muscles.<sup>60</sup></li> </ul>



Risk Factor	Considerations
<p>'Elderly' or Older Age: &gt;65, &gt;70, &gt;75, &gt;80 Years in Different Sources<sup>34, 94, 163, 180, 325, 340, 359</sup></p>	<ul style="list-style-type: none"> <li>- Statins alter gene expression selectively with exercise.<sup>62</sup></li> <li>- A nested case control study of a cohort of 252,460 new users of lipid-lowering medications found the odds of rhabdomyolysis for those over age 65 relative to those under were 4.36 (95% CI 1.5-14.1).<sup>360</sup></li> <li>- In subjects assigned to simvastatin 80mg (SEARCH trial), age ≥65 at baseline was linked to increased "definite or incipient myopathy" with a relative risk of 2.2 (95% CI 1.4-3.4) overall (n=98); and 2.3 (95% CI 1.3-4.1) in the first year (n=56).<sup>186a</sup> (The relative risk was 2.0 in later years, 95% CI 1.1-3.9, n=42.)</li> <li>- Older age signals both higher effective dose (through impaired clearance, increased polypharmacy with more potential drug interactions,<sup>361</sup> and sometimes smaller body frame), and pre-existing mitochondrial vulnerability (since DNA mutations rise with age<sup>362, 363</sup>).</li> </ul>
<p>Asian Ethnicity (Japanese or Chinese)<sup>36, 180</sup></p>	<p>Asian ethnicity has been associated with elevated blood levels (higher functional dose, reduced clearance) for rosuvastatin.<sup>364</sup></p>
<p>Female Gender<sup>337, 340, 359</sup></p>	<ul style="list-style-type: none"> <li>- A nested case control study of a cohort of 252,460 new users of lipid-lowering medication found a trend to increased odds of rhabdomyolysis in females (OR 2.53; 95% CI 0.91-7.3).<sup>360</sup></li> <li>- The risk-benefit balance of statins, as indexed by the available objective metric (total mortality), appears less favorable in women than in men, for those major clinical trials for which data are available.<sup>8, 9, 365, 366</sup></li> <li>- In subjects assigned to simvastatin 80mg (SEARCH trial), female gender at baseline was linked to increased "definite or incipient myopathy" with a relative risk of 1.8 (95% CI 1.1-2.8) overall (n=98); and 2.0 (95% CI 1.0-3.9) after the first year (n=42).<sup>186a</sup> (The relative risk was 1.6 in the first year, 95% CI 0.9-3.0, n=56.)</li> <li>- Possible considerations include:             <ul style="list-style-type: none"> <li>- Smaller body size for the same dose may imply a higher effective dose for the same milligram dose. Whether for this and/or other reasons, greater statin-induced reductions in lipids have been reported in women.<sup>367</sup></li> <li>- Women have increased AEs to many medications and vaccinations.<sup>368</sup></li> <li>- If statins modestly lower estrogens (a product of cholesterol) as they have been found to lower testosterone,<sup>15, 369</sup> they may diminish levels of an essential antioxidant mediator for women that affords key mitochondrial protection.<sup>370</sup></li> </ul> </li> </ul>
<p>Renal Insufficiency<sup>36, 94, 180, 340, 359</sup></p>	<ul style="list-style-type: none"> <li>- In subjects assigned to simvastatin 80mg (SEARCH trial), low glomerular filtration rate (&lt;60 mL/min/1.73m<sup>2</sup>) was linked to increased "definite or incipient myopathy" with a relative risk of 2.5 (95% CI 1.6-3.9) overall (n=98); and 2.6 (95% CI 1.3-5.1) after the first year (n=42).<sup>186a</sup> (The relative risk was 2.4 in the first year, 95% CI 1.3-4.3, n=56.)</li> <li>- In subjects assigned to simvastatin 80mg (SEARCH trial), elevated Creatinine (≥85µmol/L; i.e. 1.0mg/dL) was linked to increased "definite or incipient myopathy" with a relative risk of 2.0 (95% CI 1.3-3.1) overall (n=98); and 2.5 (95% CI 1.4-4.6) in the first year (n=56).<sup>186a</sup> (The relative risk was 1.5 after the first year, 95% CI 0.8-2.8, n=42.)</li> <li>- A number of case reports describe complications of statins arising with renal insufficiency.<sup>371</sup></li> <li>- A nested case control study of a cohort of 252,460 new users of lipid-lowering medication found increased odds of rhabdomyolysis, testing the joint effect of high statin dose</li> </ul>

Risk Factor	Considerations
Hepatic Dysfunction <sup>94, 163, 340</sup>	and renal disease (p=0.022). <sup>360</sup> - May increase drug levels by impaired hepatic clearance; for instance, fatty liver is reportedly associated with reduced CYP3A activity. <sup>372</sup> - May in some instances signal mitochondrial dysfunction, at least in the liver (e.g. with fatty liver i.e. hepatic steatosis, whether or not of alcohol origin) <sup>373-375</sup> .
Alcohol Abuse <sup>36, 94</sup>	Potential mechanisms (same as for drug interactions) include the following factors: - Alcohol may increase drug levels if hepatic function is impaired. - Alcohol is a mitochondrial toxin. <sup>376</sup>
Hypertension <sup>167</sup>	- Hypertension was associated with a 5.1-fold increase in hospitalizations for myopathy including rhabdomyolysis in patients on lipid therapy (95% CI 2.4-10.9), a 7.0-fold increase in hospitalizations for renal AEs (95% CI 3.7-13.4), and a 2.6-fold increase in hospitalizations for hepatic events (95% CI 1.8-3.7) based on administrative claims data, matching controls to cases on age, sex, geographic region, length of follow-up, and time of index drug fill. <sup>167</sup> - Essential hypertension is strongly tied to mitochondrial dysfunction, with an estimated 55% (95% CI 45%-65%) of hypertension cases associated with mitochondrial DNA mutations. <sup>377</sup>
Diabetes Mellitus <sup>167, 340, 341</sup>	- Diabetes mellitus was associated with a 2.8-fold increase in hospitalizations for renal AEs in patients on lipid therapy (95% CI 2.4-3.3), and a 1.8-fold increase in hospitalizations for hepatic events (95% CI 1.5-2.3) based on administrative claims data, matching controls to cases on age, sex, geographic region, length of follow-up, and time of index drug fill. <sup>167</sup> - In subjects assigned to simvastatin 80mg (SEARCH trial), diabetes mellitus at baseline was linked to increased "definite or incipient myopathy" with a relative risk of 1.7 (95% CI 1.0-2.9) overall (n=98); and 2.3 (95% CI 1.1-4.9) after the first year (n=42). <sup>186a</sup> (The relative risk was 1.2 in the first year, 95% CI 0.6-2.7; n=56.) - Type 2 diabetes mellitus is strongly linked to impaired mitochondrial function, with an estimated 22% (95% CI 6%-38%) of type 2 diabetes mellitus associated with mitochondrial DNA defects. <sup>377</sup>
Obesity <sup>378</sup>	In a study of statin AEs in the transplant setting, "the incidence of confirmed statin-related complications was higher among patients with BMI>29kg/m <sup>2</sup> than among those with lower BMI (p=0.055)." <sup>378</sup>
High Triglycerides <sup>94, 333</sup>	- Triglyceride concentrations were commonly high in patients with myopathy (n=972) or rhabdomyolysis (n=81), with a mean triglyceride value in the combined sample of 341mg/dL. <sup>94, 333</sup> - High triglycerides arise in settings of impaired fatty acid beta oxidation and may signal existing metabolic/ mitochondrial derangement. - In mice, high triglycerides increased resting respiration and predispose animals to mitochondrial permeability transition. <sup>379</sup>
History of CK Elevation <sup>34</sup>	- OR 2.04; 95% CI 1.55-2.68, p<0.0001 for development of statin muscle AEs in the setting of history of high CK. <sup>34</sup> - Elevated CK may signal existing metabolic derangement.
Thyroid Disorders, Hypothyroidism, Including Unnoticed or Asymptomatic	- Thyroid hormone is critically involved in regulation of oxidative phosphorylation (mitochondrial function), and thyroid pathology, even if treated, may signal

Risk Factor	Considerations
<p>Hypothyroidism<sup>36, 94, 163, 180, 222, 353, 380-382</sup></p>	<p>metabolic vulnerability because of the importance of triiodothyronine (thyroid replacement focuses on thyroxine).<sup>383-389</sup></p> <ul style="list-style-type: none"> <li>- Thyroid problems alone are a risk factor for rhabdomyolysis.<sup>222</sup></li> <li>- Statins have rarely aggravated hypothyroidism – produced loss of stable control on thyroid medication, with control restored on statin discontinuation.<sup>390, 391</sup> One case involved amiodarone-induced hypothyroidism.<sup>391</sup> Since both statins and amiodarone produce AEs through mitochondrial toxicity,<sup>282</sup> we suggest thyroid dysfunction on statins may occur in cases of hypothyroidism linked to mitochondrial or energetic impairment.<sup>392</sup></li> </ul>
<p>Personal History or Family History of Hereditary Muscle Problems<sup>36, 393</sup></p>	<p>Possible mechanisms include:</p> <ul style="list-style-type: none"> <li>- May signal pre-existing mitochondrial or metabolic vulnerability.</li> <li>- May provide for a lower threshold at which damage to muscle is clinically evident.</li> </ul>
<p>Prior Muscle Problems on Statins or Other Cholesterol Drugs<sup>34, 36, 180</sup></p>	<ul style="list-style-type: none"> <li>- OR was reported to be 10.1, 95% CI 8.2-12.5 for statin muscle AEs (p&lt;0.0001).<sup>34, 35</sup></li> <li>- Not merely an index of vulnerability, but of expressed problems.</li> </ul>
<p>Hyperkalemia<sup>163, 394</sup></p>	<ul style="list-style-type: none"> <li>- Risk may arise in part with hyperkalemia serving as a marker of mitochondrial derangements that produce lactic acidosis, which can cause elevated potassium.<sup>395</sup></li> <li>- Statins might therefore be expected to sometimes cause potassium elevation, and indeed have been reported to do so.<sup>394, 396</sup></li> </ul>
<p>Genetic Mutations Associated with Mitochondrial Dysfunction<sup>155, 397</sup></p>	<ul style="list-style-type: none"> <li>- Just as adequate coenzyme Q10 ‘bypasses’ and renders clinically silent a range of respiratory chain defects, so statin-induced reductions in coenzyme Q10 may ‘unmask’ previously clinically silent mitochondrial pathology, such as that demonstrated in a plurality of cases of statin-induced mitochondrial myopathy.<sup>155</sup></li> <li>- The term ‘unmask’ may be misunderstood to imply that a clinical condition was always present. There is no basis to presume clinical expression would necessarily have occurred in the absence of pharmacological reduction of coenzyme Q10: in the pre-drug state, the subjects may have had adequate physiological compensatory mechanisms in place.</li> <li>- Mutations in the <i>COQ2</i> gene are associated with primary coenzyme Q10 deficiency and severe inherited myopathy. Mild common variants were associated with vulnerability to myopathy on statin monotherapy (113 myopathy subjects, 158 matched statin tolerators).<sup>397</sup></li> </ul>
<p>Other Genetic Variants</p>	<ul style="list-style-type: none"> <li>- The C-allele of the rs4149056 single-nucleotide polymorphism (SNP), located within <i>SLCO1B1</i> on chromosome 12,<sup>b</sup> was associated with increased risk, with OR 4.5 (95% CI 2.6-7.7) per copy of the C-allele, and 16.9 (95% CI 4.7-61.1) for CC homozygotes relative to TT homozygotes.<sup>6f</sup> More than 60% of the ‘myopathy’ cases in that trial (SEARCH trial) could reportedly be attributed to the C variant.<sup>186</sup> The C-allele has a prevalence of approximately 15% in those of European descent.</li> <li>- Genetic polymorphism of CYP2D6 have been linked to susceptibility to atorvastatin AEs;<sup>398</sup> and to simvastatin AEs in some studies<sup>331, 398, 399</sup> but not others.<sup>400</sup></li> <li>- In a case-control discovery study the CYP2D6*4 isoform was linked to atorvastatin muscle AEs (OR 2.5, p=0.001, frequency ~50% in cases vs 28% in controls) and simvastatin muscle AEs (OR 1.7, 49% of cases, p=0.067).<sup>398</sup> Sources disagree about the role for CYP2D6 in simvastatin metabolism<sup>331, 398, 399</sup>. The</li> </ul>

Risk Factor	Considerations
	<p>excess in AEs with one genetic group was not accompanied by greater absolute lipid reduction.<sup>399</sup></p> <ul style="list-style-type: none"> <li>- CYP2D6 variants are involved in toxin (e.g. pesticide) detoxification and both inactivation and bioactivation.<sup>401, 402</sup> We conjecture that some CYP2D6 variants may heighten vulnerability to oxidative stressors. While adequate coenzyme Q10 levels may functionally 'bypass' resulting mitochondrial defects,<sup>23, 25, 403</sup> dose-dependent reductions in coenzyme Q10 by more potent statins,<sup>20, 21</sup> like atorvastatin and simvastatin, may 'unmask' mitochondrial dysfunction and lead to muscle symptoms.</li> <li>- One study reported an association of <i>ABCB1</i> gene polymorphisms and AEs on simvastatin.<sup>404</sup></li> <li>- Genetic variants in serotonin receptor genes have been presumptively linked to statin myalgia, an effect hypothesized to be mediated by influences on pain pathways.<sup>405</sup></li> </ul>

ALT = alanine aminotransferase; BMI = body mass index; CK = creatine kinase; CYP = cytochrome P450; LDL-C = low-density lipoprotein cholesterol; OR = odds ratio; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; ULN = upper limit of normal.

<sup>a</sup>The SEARCH trial randomly allocated 12,064 subjects with prior myocardial infarction to 20 or 80mg of simvastatin. Relative risks for developing "definite/incipient myopathy" based on baseline characteristics were calculated from the 6031 subjects assigned to 80mg of simvastatin. ORs for genetic characteristics in genome-wide association studies were based on 85 cases of "definite or incipient myopathy" that arose on 80mg of simvastatin within that trial, compared to 90 age, sex, glomerular filtration rate, and amiodarone-use 'matched' simvastatin controls who did not develop "definite or incipient myopathy." "Definite myopathy" was defined as muscle symptoms with CK elevations exceeding 10 × ULN (meeting definitions of rhabdomyolysis that do not require renal involvement). "Incipient myopathy" was defined as CK exceeding 3 × ULN and more than 5 × baseline, coupled with an ALT elevation exceeding 1.7 × baseline without an isolated ALT elevation at any other visit, irrespective of muscle symptoms. 50% of cases were 'definite.' (Note that ALT elevation reflects liver function and is not a characteristic of myopathy. However, joint muscle and liver dysfunction may signal widespread cellular consequences of statins.)

<sup>b</sup>Comment: SLCO1B1 encodes OATP1B1, an organic anion-transporting polypeptide that regulates hepatic uptake of statins. The C-allele retards hepatic uptake of statins, and in most reports increases statin serum concentrations, while slightly attenuating the LDL-C reduction by simvastatin.<sup>186</sup> Of note, the study found that the G variant of rs 2306283 showed lower risk of myopathy – and was associated with lower statin concentrations.<sup>186</sup>

**Table V**

Mitochondrial (mt) Effects Reported in Patients Treated with Statins<sup>a</sup>

Study (year)	Finding	Specifics	Comments
<b>Vladutiu et al.</b> 155 (2006)	Mt pathology on biopsy in patients with statin-associated muscle symptoms.	52% of muscle biopsies (among biopsied persons with statin muscle symptoms) showed significant biochemical abnormalities in mt or fatty acid metabolism, with 31% having multiple defects. 155	Fraction of abnormalities that represent cause of statin vulnerability vs consequence of statin cannot be ascertained from these data (i.e. degree to which the mt pathology preceded and predisposed to symptoms on statins, vs resulted from the statins, remains unclear).
<b>Oh et al.</b> 397 (2007)	Genetic impairment in coenzyme Q10 production is linked to risk of statin myopathy.	Mild common mutations in a gene involved in production of coenzyme Q10 were linked to risk of statin myopathy. 397	Persons with rarer and more severe mutations linked to primary coenzyme Q10 deficiency, a severe condition, can have myopathy without statins.
<b>Gambelli et al.</b> 406 (2004)	Mt pathology on biopsy in patients with statin-associated muscle symptoms.	In nine patients with "various myopathic syndromes" taking statins, muscle biopsy showed mt alterations such as COX-negative staining fibers. Findings were felt to "confirm that statins may cause muscle damage and impair oxidative metabolism." 406	Cause vs consequence ambiguity.
<b>Meyer et al.</b> 407 (2005)	Patients on statins showed altered <sup>31</sup> P-MRS spectra.	Elevated muscle phosphodiesterase was seen in <sup>31</sup> P-MRS spectra of patients on statins relative to controls. 407 (However, still more marked alterations were seen in one control subject – who had recently discontinued statins due to muscle symptoms.)	In the person experiencing muscle AEs, there remains cause vs consequence ambiguity.
<b>Schick et al.</b> 408 (2007)	High-dose (lipophilic) statins significantly reduced muscle coenzyme Q10 and muscle mt DNA.	Decreased skeletal muscle mt DNA was seen in muscle biopsies of patients treated with high-dose simvastatin (80mg); this correlated with reductions in muscle ubiquinone (coenzyme Q10). 408	Study involved high-dose simvastatin (80mg) vs atorvastatin (40mg) vs placebo. Effects appeared to be most marked for coenzyme Q10 reduction and mt DNA/nuclear DNA in the simvastatin group (p=0.002).
<b>Guis et al.</b> 409 (2006)	Statin myopathy patients showed abnormal pH recovery on <sup>31</sup> P-MRS.	Patients with CK elevation and muscle symptoms on statins did not show altered phosphocreatine recovery of <sup>31</sup> P-MRS or mt defects on gross histology, but <sup>31</sup> P-MRS did show slowed pH recovery kinetics. 409 (Biopsies were not	



Study (year)	Finding	Specifics	Comments
Phillips et al. <sup>31</sup> (2002)	Statin myopathy was associated with partially reversible mt myopathy in a double-blind, crossover, biopsy study.	<p>assessed by up-to-date mt testing techniques.)</p> <p>In four patients with non-CK-elevating or minimally-CK-elevating muscle symptoms on statins who underwent double-blind, crossover, biopsy study, muscle biopsies showed evidence of mt dysfunction that included “abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy while off statins.”<sup>31</sup></p>	
Phillips et al. <sup>158</sup> (2004)	Statin use increased RER consistent with reduced lipid oxidation. Statin myopathy patients had high RER even off statins.	<p>- Statin myotoxicity is associated with abnormal lipid oxidation.<sup>158</sup></p> <p>- Statins significantly increased fasting RER in 16 normal controls (with decreased lipid oxidation) (<math>p=0.00001</math>).<sup>158</sup></p> <p>- Persons who had had statin myopathy (and were off statins) had abnormally high fasting RER relative to controls (<math>n=11</math>, <math>p=0.00001</math>).</p> <p>- Post-myositis patients had a depressed anaerobic threshold (<math>p=0.009</math>). Patients included those with rhabdomyolysis (defined here as muscle symptoms with <math>CK \geq 10 \times ULN</math>) or myositis (defined here as muscle symptoms with any CK elevation).</p>	In the post-myositis group, it is again unclear the degree to which the high RER preexisted and predisposed to statin myopathy, vs was caused by statins in the setting of statin myopathy.
Paiva et al. <sup>410</sup> (2005)	Patients on high potency simvastatin showed reduced muscle coenzyme Q10, reduced respiratory enzyme and citrate synthase activity on biopsy, and reduced mt volume.	<p>- 48 patients (33 men, 15 women) with hyperlipidemia were randomly assigned, 16 per group, to simvastatin 80mg, atorvastatin 40mg, or placebo for 8 weeks with muscle biopsy at baseline and end 4/10</p> <p>- The ratio of plasma lathosterol: cholesterol decreased 66% in both statin groups. Muscle campesterol increased similarly in the two statin groups (simvastatin <math>21 \pm 7</math> to <math>41 \pm 27</math>nmol/g; atorvastatin <math>23 \pm 9</math> to <math>40 \pm 19</math>nmol/g, <math>p=0.005</math>). Muscle coenzyme Q10 dropped significantly in the simvastatin group only (<math>40 \pm 14</math> to <math>26 \pm</math></p>	Larger sample may clarify if qualitatively similar effects occur in a subset of patients on atorvastatin as well.

Study (year)	Finding	Specifics	Comments
De Pinioux et al. <sup>22</sup> (1996)	Statins (but not fibrates) significantly lowered coenzyme Q10 and increased the lactate : pyruvate ratio, used as a marker of mt function.	8mmol/g, p=0.03). - Respiratory chain enzyme and citrate synthase activities dropped significantly in those with marked reductions in muscle coenzyme Q10 on simvastatin 80mg, compared with "matched" patients on atorvastatin 40mg or placebo (n=6 in each group).	80 hyperlipidemic persons on statins (n=40), on fibrates (n=20), or untreated (n=20), and 20 healthy controls were compared. <sup>22</sup> Statin use was linked to significantly higher lactate: pyruvate ratios than in untreated subjects (p<0.05) or healthy controls (p<0.001). Coenzyme Q10 was lower in statin-treated than in untreated patients (0.75 ± 0.04mg/L vs 0.95 ± 0.09mg/L, p<0.05).

AE = adverse effect; CK = creatine kinase; COX = cytochrome C oxidase; MRS = magnetic resonance spectroscopy; RER = respiratory exchange ratio; ULN = upper limit of normal.

<sup>a</sup> Either in settings of statin use or of statin AEs.

Table VI

Mitochondrial Adverse Effects (AEs) with Statins in Individuals and Families: Evidence from Case Reports<sup>a</sup>

Study (year)	Statin mitochondrial AE	Description
Chariot et al. <sup>112</sup> (1993)	MELAS.	MELAS followed a case of simvastatin-induced rhabdomyolysis. <sup>112</sup>
Thomas et al. <sup>411</sup> (2007)	MELAS.	Statin associated with MELAS syndrome (case report). <sup>411</sup>
Neale et al. <sup>412</sup> (2004)	Lactic acidosis.	Statin induced lactic acidosis: An 82-year-old woman presented with lactic acidosis that resolved with discontinuation of atorvastatin. <sup>412</sup>
Goli et al. <sup>413</sup> (2002)	Lactic acidosis.	Lactic acidosis accompanied rhabdomyolysis and hepatitis as a statin AE. <sup>413</sup>
England et al. <sup>413</sup> (1995)	Mitochondrial myopathy.	Mitochondrial myopathy developed on treatment with statins: simvastatin and pravastatin. <sup>162</sup>
Diazok et al. <sup>414</sup> (2003)	Mitochondrial myopathy.	Statins 'unmasked' a mitochondrial myopathy. <sup>414</sup>
Troseid et al. <sup>32</sup> (2005)	Mitochondrial myopathy.	Statin-associated myopathy with normal CK levels occurred in four members of one Norwegian family with evidence of mitochondrial myopathy on biopsy in some but not all. <sup>32</sup>

CK = creatine kinase; MELAS = Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes.

<sup>a</sup> As this Table indicates, mitochondrial encephalomyopathy, not just myopathy, has been reported in association with statins. Low coenzyme Q10 is classically associated with brain as well as muscle symptoms.

429

Table VII

Statin Adverse Effects (AEs) Supported by Evidence from Randomized Controlled Trials (RCTs)<sup>4c</sup>

Domain	Evidence	Comment
<b>Muscle</b>	<p>- A meta-analysis of randomized, double-blind, head-to-head, statin comparisons showed more CK elevation with higher dose statins.<sup>178</sup></p> <p>- A meta-analysis of RCTs showed an increase in myositis on statins (with myositis defined here as CK <math>\geq 10 \times</math> ULN).<sup>28</sup></p> <p>- Placebo-controlled, double-blind, crossover, biopsy study showed partially reversible mitochondrial myopathy on statins in persons reporting non-CK-elevating or minimally-CK-elevating muscle symptoms on statins.<sup>31</sup> This study has the validity attached to randomization and blinding that support a true causal occurrence of muscle AEs on statins; but does not have implications for the likelihood of occurrence in the average statin vs placebo user.</p>	
<b>Cognition</b>	<p>- Two RCTs of statins vs placebo in relatively younger healthier samples (lovastatin in one, simvastatin in the other) showed significant worsening of cognitive indices relative to placebo.<sup>458, 459</sup></p> <p>- Effect modification by age and CVD risk:</p> <ul style="list-style-type: none"> <li>o Two trials in older, high-CVD-risk sample showed an average neutral effect on cognition.<sup>460, 461</sup> (One trial, the Heart Protection Study, employed limited cognitive assessment and more troublingly employed an active drug compliance run-in.<sup>461</sup> This may bias outcomes because people who experience memory problems from statins may forget to take their pills reliably and thus be excluded from randomization.<sup>483</sup> Additionally, non-compliance on statins has been linked to statin AEs.<sup>484</sup>)</li> <li>o One trial with subjects of younger and older age showed intermediate findings and preliminary evidence for mitochondrially based effect modification.<sup>462</sup></li> </ul> <p>Note: Two trials in Alzheimer samples suggest possible trends to cognitive benefit, although these appeared to dissipate at 1 year.<sup>463, 464</sup></p> <p>- Case reports and case series complement RCT data citing instances of cognitive loss on statins that resolve with discontinuation and recurred with rechallenge.<sup>465-471</sup></p>	<p>- Muscle and brain are classically affected in coenzyme-Q10-deficiency mitochondrial syndromes. The same predominant pattern is seen in patient-targeted statin AE surveillance.</p> <p>- In one study, postoperative statins significantly reduced cognitive recovery following bypass (<i>post hoc</i> analysis, <math>p=0.011</math>), although preoperative statins did not affect it.<sup>472</sup></p> <p>- Potential mechanisms include low central serotonin<sup>485-487</sup> (conceivably including vitamin D influences<sup>488</sup> because cholesterol is the precursor to vitamin D; however, little information is available on the impact of statins on vitamin D), and altered omega-3 to omega-6 ratios.<sup>17, 489</sup> We here add the suggestion of impaired cell energetics and oxidation. This offers the possibility that benefits may predominate in some persons through endothelial function/flow as well as anti-inflammatory benefits.</p>
<b>Cancer</b>	<p>- The sole randomized trial in the elderly (age <math>&gt;70</math>) showed significant increase in incident cancer with statin use relative to placebo (HR 1.25, 95% CI 1.04-1.51, <math>p=0.02</math>).<sup>460</sup></p> <p>- Effect modification: meta-analyses of randomized trials in samples of generally middle age persons clearly and reproducibly show average neutrality of statins on cancer, with risk ratios squarely centered at 1.0.<sup>490, 491</sup> One study affirmed an (age <math>\times</math> pravastatin) interaction on cancer risk.<sup>473</sup></p> <p>- A meta-analysis found that statin effects on cancer were significant</p>	<p>- It may merit note that elderly have greater pre-existing mitochondrial vulnerability.</p> <p>- Lower LDL-C signals lower coenzyme Q10 and antioxidant carrying capacity.</p> <p>- There is a case, from triangulating animal and human literature, that statins could reduce risk of melanoma.</p>

Domain	Evidence	Comment
<b>Liver</b>	<p>and determined by achieved LDL-C.<sup>181</sup></p> <p>A meta-analysis of randomized, double-blind, head-to-head, statin comparisons showed more LFT elevations with higher dose statins.<sup>178</sup></p>	<p>RCT data of LFT elevations are buttressed by many cases of statin hepatopathy arising alone or in concert with statin rhabdomyolysis.<sup>96, 107, 108, 172, 375, 474-481, 492-513</sup></p>
<b>Hemorrhagic Stroke</b>	<ul style="list-style-type: none"> <li>- The RCT arguably best powered to look at effects on stroke (in a sample with prior TIA or stroke given high-dose statin vs placebo) showed a significant increase in hemorrhagic stroke (adjusted HR 1.66, 95% CI 1.08-2.55).<sup>514</sup></li> <li>- Statins lead to average significant reductions in stroke in meta-analyses of RCTs of subjects primarily in middle age.<sup>515-517</sup> They do not in elderly (at high cardiovascular risk); no trend to stroke reduction was seen in the sole clinical trial targeted to that group.<sup>460</sup></li> <li>- Note that in samples where ischemic stroke benefit is seen, including the study with elevated hemorrhagic stroke, ischemic stroke is more prevalent than hemorrhagic stroke, and the ischemic stroke benefits of statins dominate the impact of statins on stroke overall. However, results might differ in individuals with history of or risk factors for hemorrhagic stroke.</li> </ul>	<ul style="list-style-type: none"> <li>- This extends evidence from observational data showing higher hemorrhagic stroke risk with low cholesterol.<sup>518-521</sup> and prestatin randomized trials supporting an association of lipid therapy to increased hemorrhagic stroke.<sup>522</sup></li> <li>- Statins have reported antithrombotic and antiplatelet effects.<sup>523-526</sup></li> </ul>
<b>Blood Glucose</b>	<ul style="list-style-type: none"> <li>- High-dose statins led to statistically significant increase in glycemia in the PROVE-IT-TIMI trial.<sup>184</sup></li> <li>- In the JUPITER trial, those randomized to rosuvastatin 20mg vs placebo showed a significant increase in HbA1c (p=0.001) and in newly diagnosed diabetes mellitus (relative risk 1.25; p=0.01).<sup>187</sup></li> <li>- These supplement data from another RCT, showing a significant but modest average increase in HbA1c with (non-high-dose) statins.<sup>183</sup></li> </ul>	<ul style="list-style-type: none"> <li>- Lower dose statins have not led to average increases in glycemia in most trials, but case reports clarify that large increases can arise in selected individuals reproducibly with statins.<sup>182, 527</sup></li> <li>- One observational study reports that patients on statins may be less likely to develop diabetes mellitus after renal transplant;<sup>528</sup> however (particularly in light of PROVE-IT-TIMI and JUPITER results), this could reflect indication bias.</li> </ul>
<b>Sleep</b>	<p>Significant reductions in average sleep quality were seen with simvastatin but not pravastatin relative to placebo.<sup>447</sup> Significant increases in self-rated "sleep problems" occurred on simvastatin relative to placebo; results for pravastatin were intermediate between those of simvastatin and placebo (as were LDL-C reductions).<sup>447</sup></p>	<ul style="list-style-type: none"> <li>- Also, there are case reports and case series of sleep problems<sup>444, 529, 530</sup> and nightmares,<sup>531, 532</sup> and reports of sleep AEs in clinical trials of statins.<sup>196, 533, 535</sup></li> <li>- A small study reported development of objective sleep problems on lovastatin but not pravastatin<sup>536</sup> (although other small studies reported no objective findings).</li> <li>- In one statin AE evaluation study in Spain, 26 patients were referred for oral evaluation; however, it was noted that 17% of these subjects cited insomnia, with 16/17 improving with</li> </ul>

Domain	Evidence	Comment
		interruption of statin treatment. <sup>537</sup>

CK = creatine kinase; CVD = cardiovascular disease; HbA1c = glycosylated hemoglobin; HR = hazard ratio; JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C = low-density lipoprotein cholesterol; LFTs = liver function tests; PROVE-IT-TIMI = Pravastatin or Atorvastatin Evaluation and Infection Therapy – Thrombolysis in Myocardial Infarction trial; TIA = transient ischemic attack; ULN = upper limit of normal.

<sup>a</sup>For the sample employed in that RCT. Effect modification can lead to effects that differ in different samples.



Table VIII

Statin Adverse Effects (AEs) Supported or Suggested by Case Series, Case Studies and Observational Designs<sup>a,b</sup>

Statin AE	Relevant reports	Triangulating evidence and effect modification
<p><b>Peripheral Neuropathy (PN)<sup>c</sup></b></p>	<p>- High-quality case control study using Danish databases.<sup>442</sup></p> <p>- Also, many case reports/case series.<sup>561-575</sup></p> <p>- Includes reports of multiple mononeuropathy.<sup>538, 576</sup></p> <p>- Reversibility is not complete in all cases, inferable from some case reports; from rate in former relative to current statin users<sup>442</sup> and shown in Australian Adverse Drug Reaction Advisory Committee report.<sup>561</sup></p>	<p>- Hypo-lipoproteinemia is linked to PN.<sup>577-581</sup></p> <p>- Cholesterol transports antioxidants essential to protection against PN.<sup>539-542</sup></p> <p>- We also observe that statins impair mitochondrial function, and impaired mitochondrial function has been linked to PN.<sup>543, 544</sup></p>
<p><b>Sexual Dysfunction<sup>c</sup></b></p>	<p>Numerous case reports, case series, including several from European and Australian AE databases.<sup>444, 545-555, 582, 583</sup></p>	<p>- Cholesterol is the biochemical precursor to testosterone.</p> <p>- Experimental and RCT evidence shows that statins reduce testosterone in men, though the average effect is modest.<sup>15, 369, 558</sup> (Studies in small samples and /or with lower statin doses do not show a significant change in testosterone on average.) Clinical data showing testosterone reductions complement <i>in vitro</i> studies demonstrating statin effects on human testicular testosterone synthesis.<sup>584</sup> and animal studies demonstrating statin effects on morphology and function of Leydig cells.<sup>559</sup></p> <p>- Mitochondrial dysfunction associated with gonadal dysfunction<sup>560</sup> – of potential relevance given statin effects on mitochondrial function.</p> <p>- Oxidative stress associated with gonadal dysfunction<sup>585</sup> – of potential relevance given adverse statin effects on oxidation in some.<sup>51, 52</sup></p> <p>- Testicular morphologic changes occurred in an animal study of high-dose statins, in which it was stated that testicular tissue (in dogs) was “the only organ for which a comparably low margin of safety was observed.”<sup>586</sup></p> <p>- Note that statins have also been reported to improve erectile function<sup>587</sup> and the sexual benefits of sildenafil (Viagra<sup>TM</sup>) in some subjects through endothelial function benefits.<sup>588-590</sup> which may rely on the antioxidant effects of statins<sup>591-593</sup> that predominate over pro-oxidant effects in many.<sup>51</sup></p>
<p><b>Male Endocrine, Other<sup>c</sup></b></p>	<p>- Gynecomastia: several reports of gynecomastia associated with statins.<sup>594-596</sup> Statin use in organ transplant recipients was associated with increased risk of gynecomastia (statin use in 83.3% of those with gynecomastia, 39.6% of those without, p=0.041).<sup>597</sup></p>	<p>See above, “Sexual dysfunction.”</p>

Statin AE	Relevant reports	Triangulating evidence and effect modification
<b>Thyroid Dysfunction</b>	<p>See discussion in Table IV under 'Thyroid disorders.'</p>	
<b>Renal<sup>c</sup></b>	<ul style="list-style-type: none"> <li>- Renal tubule toxicity.<sup>599</sup></li> <li>- Proteinuria: statins, particularly, high-dose statins, have led to proteinuria and hematuria.<sup>180, 600</sup></li> <li>- Statins have led to renal failure and death from renal failure in the context of rhabdomyolysis.<sup>82, 98-100, 102-104, 110, 202, 219, 247, 308, 419, 431, 601-605</sup></li> </ul>	<ul style="list-style-type: none"> <li>- Statins have been reported, in an observational study, to be associated with less contrast nephropathy.<sup>606</sup> This could reflect that statins signal higher lipids (and fat-soluble antioxidant transport) – i.e. indication bias, or could result from antioxidant effects of statins (antioxidants have been reported to reduce contrast nephropathy).</li> <li>- Statins have reduced proteinuria in some groups on average but may not do so in other groups (meta-analysis of RCTs – proteinuria was not reduced, e.g. in diabetes mellitus or hypertension).<sup>607, 608</sup> Moreover, statins have been reported to increase proteinuria in some.<sup>180</sup> In one study, statin use (compared with placebo) was associated with lower creatinine,<sup>609</sup> which was presumed to reflect better kidney function.<sup>609</sup> However, because muscle mass correlates with creatinine, and statins can reduce muscle mass, it is unclear the extent to which the creatinine reduction was driven by benefit to the kidney versus harm to the muscle (subclinical muscle wasting).<sup>60</sup></li> </ul>
<b>Irritability/Aggression / Behavior Change<sup>c</sup></b>	<ul style="list-style-type: none"> <li>- Case series of severe irritability and/or aggression reproducibly arising on statins,<sup>443</sup> also in pharmacovigilance database.<sup>467</sup></li> <li>- Observational study showing women on statins are more aggressive.<sup>610</sup></li> </ul>	<ul style="list-style-type: none"> <li>- Low cholesterol linked to conduct disorder, violent antisocial personality disorder, and violent crime prospectively; to violent death in numerous observational studies; and in animal studies to aggression.<sup>611-623</sup></li> <li>- Several meta-analyses of prestatin cholesterol-lowering RCTs (including those with the most appropriate inclusion/exclusion criteria<sup>624, 625</sup>) showed significant increases in violent death.<sup>611</sup> Statin meta-analysis has not.<sup>626</sup></li> <li>- Elucidated potential mechanisms include low central serotonin<sup>486, 611</sup> and altered omega-3 to omega-6 ratios.<sup>17</sup> Here, we add the suggestion of impaired cell energetics and oxidative stress, which are associated with a number of other aggression- and irritability related exposures.<sup>127, 627-641</sup> This offers the possibility that benefits may predominate in some persons through benefits to endothelial function/ flow and/or anti-inflammation, consistent with bidirectional effects suggested in an RCT.<sup>642</sup></li> </ul>
<b>Pulmonary, Respiratory, Shortness of Breath (see also 'Cardiac</b>	<ul style="list-style-type: none"> <li>- Shortness of breath as a symptom in statin AEs (including reports of dyspnea as the presenting symptom of otherwise asymptomatic rhabdomyolysis,<sup>95</sup> associated with lactic</li> </ul>	<ul style="list-style-type: none"> <li>- Cardiopulmonary function and respiratory exchange ratio are affected by statins.<sup>156, 157</sup></li> <li>- Mitochondrial (cellular) respiration is affected by statins (see section 5).</li> </ul>

<p><b>Statin AE Function and Heart Failure</b><sup>c</sup></p>	<p><b>Relevant reports</b></p> <ul style="list-style-type: none"> <li>- acidosis.<sup>412</sup>,</li> <li>- Respiratory failure has accompanied statin rhabdomyolysis.<sup>98</sup> The following have also been reported in association with statins:             <ul style="list-style-type: none"> <li>- Chylothorax.<sup>643</sup></li> <li>- Dermatomyositis with lung involvement/pulmonary fibrosis.<sup>65, 74</sup></li> <li>- Eosinophilic pneumonia.<sup>644</sup></li> <li>- Interstitial lung disease.<sup>282, 645-647</sup></li> <li>- Pulmonary fibrosis.<sup>74, 648</sup></li> <li>- Pleural effusion (see also 'Cardiac function and heart failure').<sup>645, 649, 650</sup></li> <li>- Hypersensitivity pneumonitis.<sup>651, 652</sup></li> <li>- Autoimmune conditions affecting pulmonary function (see 'Immune, autoimmune').</li> <li>- Cough (see 'Oral cavity').</li> </ul> </li> </ul>	<p><b>Triangulating evidence and effect modification</b></p> <ul style="list-style-type: none"> <li>- Statins accelerate aging effect on (rat) diaphragm mitochondrial cellular respiration.<sup>426</sup> – affecting the major muscle of breathing.</li> <li>- Myopathy arises with statins (see section 1): effective respiration relies on skeletal muscles such as the diaphragm.</li> <li>- Statin pulmonary restrictive disease occurs, and resembles amiodarone pulmonary disease.<sup>647</sup> compatible with common mitochondrial origin.<sup>282</sup></li> <li>- Statins lower cholesterol, which is the precursor to vitamin D, which is associated with protection against autoimmune diseases, including lupus.</li> <li>- See also 'Cardiac function and heart failure.'</li> </ul>
<p><b>Cardiac Function and Heart Failure</b><sup>c</sup></p>	<ul style="list-style-type: none"> <li>- Heart failure, pulmonary edema, and cardiac muscle rhabdomyolysis have been reported in cases of statin rhabdomyolysis.<sup>91, 109, 111</sup></li> <li>- In an observational study, statins adversely affected cardiac diastolic function in a fashion that was partially reversed by coenzyme Q10.<sup>653</sup></li> </ul>	<ul style="list-style-type: none"> <li>- The heart muscle, like other muscles, may be affected in myopathy.</li> <li>- Statins lower coenzyme Q10, while addition of coenzyme Q10 in RCTs has reduced hospitalizations for heart failure and pulmonary edema.<sup>654</sup></li> <li>- Statins reduce coenzyme Q10, and coenzyme Q10 reportedly improves diastolic function,<sup>655</sup> which is strongly ATP dependent. Diastolic function has reportedly been reduced with statins, an effect reversed by coenzyme Q10.<sup>653</sup> (study prospective but not placebo-controlled).</li> <li>- Statins lead to average improvement in heart failure or left ventricular systolic function in some studies, including randomized trials.<sup>656, 657</sup></li> </ul>
<p><b>Heart Rhythm Disturbance:<sup>c</sup> Heart Block, Atrial Fibrillation</b></p>	<ul style="list-style-type: none"> <li>- Atrioventricular block with rhabdomyolysis reported.<sup>239</sup></li> <li>- Bradycardia including heart block in a range of US FDA reports (secured under the Freedom of Information Act dated 8-1-06).</li> <li>- Atrial fibrillation with statin use reported.<sup>658</sup></li> </ul>	<ul style="list-style-type: none"> <li>- Statins lower coenzyme Q10, and coenzyme Q10 has reportedly reduced arrhythmia in a range of settings.<sup>659, 660</sup></li> <li>- Patients with atrial fibrillation show greater oxidative damage to atrial mitochondrial DNA than those without,<sup>661</sup> consistent with a role for statin oxidative/antioxidant effects.</li> <li>- Statins have reportedly produced heart block.<sup>239</sup> They have also produced lactic acidosis.<sup>22, 411, 413</sup> and hyperkalemia,<sup>209, 396</sup> each of which have been linked to heart block.<sup>662, 663</sup></li> </ul>

Statin AE	Relevant reports	Triangulating evidence and effect modification
		<ul style="list-style-type: none"> <li>- Heart block may arise because of the energy dependence of cell signaling (with mitochondrial impairments impeding these) or due to alterations in tissue excitability (due to change in pH etc.). Heart block has been induced in other settings in which mitochondrial dysfunction induced high lactate.<sup>395</sup></li> <li>- Low cholesterol, associated with lower transport of fat-soluble antioxidants, has been linked observationally to higher atrial fibrillation rates.<sup>664</sup></li> <li>- Statins have pro-oxidant and antioxidant, proinflammatory and anti-inflammatory effects, with each dominating in different persons (more commonly, antioxidant and anti-inflammatory at modest doses in clinical-trial-equivalent middle-aged men). Atrial fibrillation has been linked to oxidant and inflammatory mechanisms, and its protection to the reverse.<sup>665-669</sup></li> <li>- Statins have reduced arrhythmia/atrial fibrillation in a clinical trial setting;<sup>670</sup> individual effects may depart from average effects.</li> </ul>
<b>Hyperkalemia</b>	See discussion under 'Heart rhythm disturbance' (immediately above).	
<b>Weight Gain<sup>c</sup></b>	Observational study with high rate of weight gain in high-dose statin group. <sup>27</sup>	<ul style="list-style-type: none"> <li>- Statins lead to dose-dependent reductions in coenzyme Q10.<sup>20, 21</sup></li> <li>- Coenzyme Q10 supplementation has reduced appetite in patients with hyperphagia,<sup>671</sup> and also improved insulin sensitivity.<sup>672</sup></li> </ul>
<b>Neurodegenerative Disease: Parkinson Disease, also ALS or ALS-like Syndrome<sup>c</sup></b>	Case reports <sup>673</sup> and case series. <sup>144, 145</sup>	<ul style="list-style-type: none"> <li>- Statins reduce coenzyme Q10.<sup>20, 21</sup></li> <li>- Coenzyme Q10 protects against neurodegeneration in animal models; and retards progression of early Parkinson disease in humans.<sup>674-677</sup></li> <li>- Low LDL-C has been linked to increased risk of Parkinson disease.<sup>678</sup></li> <li>- Higher cholesterol has been linked to increased survival with ALS.<sup>679</sup></li> <li>- LDL-C transports (and statins reduce) key fat-soluble antioxidants;<sup>680</sup> reduced antioxidant transport unfavorably affects redox state (and mitochondrial function), which has a role in neurodegeneration protection.<sup>681-684</sup></li> <li>- Statins may be selectively toxic to muscle satellite cells, the stem cells for muscle that have (finite) regenerative potential.<sup>685</sup> This may impair recovery of muscle in some statin users who experience normal or increased muscle injury on statins. (However, this is based on <i>in vitro</i> study.)</li> <li>- Observational studies link lower but not higher potency statins with dramatically lower rates of neurodegeneration<sup>686-688</sup> and have implied there is causality, although this is incompatible with findings from RCTs, and is more consistent with confounding, e.g. by education and</li> </ul>

Statin AE	Relevant reports	Triangulating evidence and effect modification
<p><b>Immune, Autoimmune<sup>c</sup></b></p>	<p>- Case series and reports of lupus-like syndrome, autoimmune hepatitis, dermatomyositis and other.<sup>67, 71, 72, 74, 475, 498, 502, 503, 506, 694-710</sup></p> <p>- See above (Table D) for case reports of Guillain Barre-like syndrome and myasthenia gravis on statins.</p>	<p>indication. Confounding by education was a likely factor in the similar apparent association of HRT to lower Alzheimer disease rates, which similarly suggested vastly lower rates of dementia in users;<sup>689</sup> however, in fact, significantly increased rates of dementia arose with HRT when compared to placebo in RCTs, i.e. when treatment and placebo groups were chosen to be otherwise similar.<sup>690, 691</sup> Confounding by indication<sup>356</sup> is also a significant possibility given the protective association of higher LDL-C to lower Parkinson disease rates,<sup>678</sup> and the use of LDL-C as a criterion for statin use.<sup>692</sup> (That is, statin use is a proxy for higher LDL-C prior to and often despite statin treatment – except with the most potent statins.)</p> <p>- Authors of recent studies continued not to control for lipids,<sup>688, 693</sup> despite prior criticisms<sup>355, 356</sup> noting potential for indication bias in similar studies.<sup>687</sup> A later study attributed the lesser benefit of the more potent atorvastatin to selective benefits by simvastatin – the less potent statin in that study (vs alternative explanations such as atorvastatin more effectively overcoming benefit of high LDL-C). However, in the same authors' prior study, simvastatin was the more potent statin, and the one with which statin "benefit" was lost.<sup>687</sup> The author holds a patent on simvastatin for Alzheimer disease.</p> <p>- Findings are potentially consistent with confounding by indication for Parkinson disease (given the association of higher LDL-C with Parkinson disease protection, and the association of statins as a proxy for higher prior, perhaps lifelong, and often current LDL-C), and confounding by education (higher education is linked to lower rates of incident dementia, and also higher use of preventive healthcare).<sup>355, 356</sup></p> <p>- It merits additional note that pro-oxidant conditions may spawn physiologic adaptations that ramp up antioxidant access, which may include elevation of lipid levels to boost antioxidant delivery. Association of higher lipid levels to conditions<sup>679</sup> may reflect protective adaptations rather than causal predisposition.</p> <p>See in-depth discussion of proposed mechanism for statin-associated neurodegeneration.<sup>145</sup></p>
<p><b>Pancreatitis<sup>c</sup></b></p>	<p>Case reports of statin-induced pancreatitis alone or associated with statin rhabdomyolysis or</p>	<p>- Cholesterol is the precursor to vitamin D. High levels of vitamin D are associated with lower autoimmune disease risk, which we propose as a possible mechanism.<sup>711-723</sup></p> <p>- Enthusiasm for trials of statins has been expressed in autoimmune diseases, particularly those with inflammatory components.<sup>724</sup></p>
		<p>See also discussion in this table, in rows entitled 'Gastrointestinal' and 'Immune, autoimmune.'</p>

<p><b>Statin AE</b></p>	<p><b>Relevant reports</b></p> <p>muscle pain; 105, 725-739 including recurrent cases. 726, 737, 740, 741</p>	<p><b>Triangulating evidence and effect modification</b></p> <p>- A population-based case-control study using Danish databases reported the adjusted OR for acute pancreatitis “among ever, current, new and former users of statins” (respectively) were: 1.44 (95% CI 1.12-1.80), 1.26 (95% CI 0.96-1.64), 1.01 (95% CI 0.43-2.37), and 2.02 (95% CI 1.37-2.97).<sup>742</sup> The authors suggest this may imply protection by statins. However, this conclusion does not follow from this study design. Former users may disproportionately include those who experienced statin AEs (statin ‘noncompliance’ is linked to statin AEs.<sup>484</sup>) and attendant mitochondrial injury (arising with and contributing to statin use). Occurrence of pancreatitis accompanying statin rhabdomyolysis suggest causal mediation by shared mitochondrial effects of statins, which may persist after treatment is discontinued; and mitochondrial pathology has repeatedly been linked to acute, chronic, and recurrent pancreatitis.<sup>743-750</sup> However, it is also possible that statins may, analogously to the case for muscle and kidney function, both protect from pancreatitis and conduce to it in different subjects (based on predominance, e.g. of statin antioxidant vs pro-oxidant effects).</p> <p>Includes documentation of hepatic failure necessitating liver transplant.<sup>753</sup></p>
<p><b>Liver Pathology<sup>c</sup></b></p>	<p>Case reports of statin hepatitis or hepatic dysfunction alone or associated with rhabdomyolysis: autoimmune hepatitis, cholestasis, cholestatic hepatitis, steatosis, viral-like hepatitis, microvesicular hepatitis, hepatic fibrosis, progression to cirrhosis.<sup>96, 107, 108, 172, 474, 475, 477-479, 481, 492-504, 506, 508, 512, 513, 751, 752</sup></p>	<p>See section 5 for discussion of mitochondrial effects of statins.</p>
<p><b>MELAS, Lactic Acidosis, other Mitochondrial Syndromes<sup>c</sup></b></p>	<p>- Statin induced lactic acidosis as an AE.<sup>413</sup>                  - ‘Unmasking’ of mitochondrial myopathy as an AE, reduced fatty oxidation.                  - Statin induced MELAS alone or associated with rhabdomyolysis.<sup>112, 411</sup></p>	<p>- Range of potential mechanisms: hypersensitivity, autoimmune, nutritional.                  - Cholesterol is important in skin barrier function.<sup>782-785</sup>                  - Ichthyosis and disorders of cornification have been reported with several lipid-lowering agents.<sup>769</sup>                  - Statins were reported to possibly improve skin response to sodium lauryl sulfate in one experiment.<sup>786</sup>                  - Statins have been theorized as potential treatments for a range of skin disorders.<sup>787</sup>                  - Regression of vitiligo with high-dose simvastatin was reported in one case.<sup>788</sup></p>
<p><b>Dermatologic<sup>c</sup></b></p>	<p>- See also “Immune, autoimmune” (dermatomyositis, lupus and lupus-like reactions).                  - Actinic dermatitis (chronic).<sup>754, 755</sup>                  - Acute generalized exanthematous pustulosis.<sup>756</sup>                  - Alopecia.<sup>757, 759</sup>                  - Angioneurotic edema.<sup>760</sup>                  - IgA bullous dermatosis.<sup>702</sup>                  - Cheilitis.<sup>761</sup>                  - Contact dermatitis.<sup>762, 763</sup>                  - Dermatographism.<sup>764</sup>                  - Drug eruption.<sup>765</sup>                  - Eczema.<sup>766, 767</sup></p>	<p>- Range of potential mechanisms: hypersensitivity, autoimmune, nutritional.                  - Cholesterol is important in skin barrier function.<sup>782-785</sup>                  - Ichthyosis and disorders of cornification have been reported with several lipid-lowering agents.<sup>769</sup>                  - Statins were reported to possibly improve skin response to sodium lauryl sulfate in one experiment.<sup>786</sup>                  - Statins have been theorized as potential treatments for a range of skin disorders.<sup>787</sup>                  - Regression of vitiligo with high-dose simvastatin was reported in one case.<sup>788</sup></p>



Statin AE	Relevant reports	Triangulating evidence and effect modification
<p><b>Oral Cavity</b></p>	<ul style="list-style-type: none"> <li>- Eosinophilic fasciitis.<sup>768</sup></li> <li>- Ichthyosis.<sup>769,770</sup></li> <li>- Lichen planus pemphagoides.<sup>771</sup></li> <li>- Lichenoid drug eruption.<sup>772,775</sup></li> <li>- Photosensitivity/Phototoxicity.<sup>776,777</sup></li> <li>- Radiation recall.<sup>778</sup></li> <li>- Skin lesions.<sup>779</sup></li> <li>- Toxic epidermal necrolysis.<sup>780</sup></li> <li>- Urticaria (chronic).<sup>781</sup></li> </ul>	<p>Oral symptoms were appraised in a study in which 26 patients (50-70 years of age) with hyperlipidemia on statins in a general practice were referred over a month for oral evaluation.<sup>537</sup> Of these, 23 reported dry mouth, 15 oral itch or paresthesia, 14 bitterness, and 12 cough. A trial of 2 weeks off statins led to marked abatement or resolution in each of these symptoms in 74%, 87%, 93%, and 92%, respectively.<sup>537</sup></p>
<p><b>Vision<sup>c</sup></b></p>	<ul style="list-style-type: none"> <li>- Cataracts.<sup>789-791</sup></li> <li>- External ophthalmoplegia.<sup>792</sup></li> <li>- A case series of 256 pharmacovigilance reports of ptosis, diplopia, and ophthalmoplegia on statins included 62 positive dechallenge and 14 positive rechallenge reports.<sup>793</sup> Reports include 23 instances of total ophthalmoplegia; 8 of ptosis alone and 18 of ptosis in concert with diplopia.</li> </ul>	<ul style="list-style-type: none"> <li>- Lens opacity seen in animal studies (high-dose).<sup>586</sup> These led to concerns about cataracts with statins, but cataracts have not been increased <i>on average</i> in small studies of humans.<sup>794,796</sup> Cataracts are thought to be induced by oxidative stress.<sup>794,797,798</sup> so statins' bi-directional effects on oxidation with effect modification may be operative. Cataracts have been described in mitochondrial cytopathy.<sup>797</sup></li> <li>- In a British study, the unadjusted OR linking any recorded statin exposure to cataract was 1.41 (95% CI 1.21-1.65). It was 1.04 (95% CI 0.89-1.23, p=0.6) after "adjustment for consultation rate."<sup>795</sup> This is difficult to interpret: those seen more due to lipid therapy could have better access to cataract diagnosis leading to incorrect inferences in absence of adjustment; however, such adjustment could also extinguish a true association, through collinearity.</li> <li>- In a US study, incidence of nuclear cataract was lower in statin users relative to nonusers controlling for age (OR 0.55; 95% CI 0.36-0.84).<sup>799</sup> Five-year incidence of cortical cataract showed the opposite trend (OR 1.28; 95% CI 0.79-2.08) but was not significant.<sup>799</sup> Confounding is a major concern in such correlational studies, and associations observed may be different in magnitude and direction from true relationships.</li> <li>- Statins lower coenzyme Q10 and alter omega-3 to omega-6 balance;<sup>17</sup> combination of coenzyme Q10 with omega-3 (and one other substance) reportedly reversed early age-related macular degeneration in an RCT.<sup>800</sup></li> <li>- External ophthalmoplegia has been widely described in</li> </ul>

Statin AE	Relevant reports	Triangulating evidence and effect modification
<b>Olfaction</b>	Hyposmia. 808	Lipids transport carotenoids, 809 the precursor to retinol (vitamin A), which is important in smell and has been used in treatment of anosmia. 810-812
<b>Hematologic and Bone Marrow, Including Hemorrhagic<sup>c</sup></b>	<ul style="list-style-type: none"> <li>- See 'Hemorrhagic Stroke' Table VII.</li> <li>- Ocular hemorrhage reported as a statin AE. 813</li> <li>- Hematuria (microscopic). 110, 180</li> <li>- Bone marrow toxicity among multiple-organ toxicity arising on statins. 96, 173</li> <li>- Thrombocytopenia. 814</li> <li>- Petechia, and thrombotic thrombocytopenic purpura. 815-822</li> <li>- Hemolytic anemia. 823</li> <li>- Nonhemolytic anemia. 96</li> </ul>	<ul style="list-style-type: none"> <li>- Statin use has been observationally linked to lower bleeding, possibly as a proxy for higher cholesterol (and vitamin K?) in studies not adjusted for lipids. 824, 825 (In one, only long-term [not current] statin use was linked to this, and those patients started on statins in an earlier era had higher average lipids. 825)</li> <li>- After percutaneous coronary intervention, acquired thrombocytopenia developed more frequently, assessed by multivariate analysis, in patients who had previous statin administration (OR 3.28; p=0.0002). 814</li> <li>- Statins reportedly have antithrombotic effects, inhibit platelet aggregation, decrease platelet activity, have anticoagulant activity, affect blood viscosity, RBC deformability, and 'improve' von Willebrand factor activity. 826-829</li> <li>- Erosions and hemorrhage in the gastrointestinal tract and the brain in animal studies (high-dose). 586</li> <li>- Hemorrhage in gall bladder and brain, erosions in large intestines in animal study. 830</li> <li>- Mitochondrial mechanisms have been linked to ineffective erythropoiesis. 831</li> <li>- Statins inhibit bone-marrow-derived dendritic cell maturation – <i>in vitro</i>. 174</li> </ul>
<b>Hypotension<sup>c</sup></b>	Hypotension and angioedema have been described in a case of an atorvastatin hypersensitivity reaction entailing shock and collapse – with recurrence of angioedema on rechallenge. 760	Statins (simvastatin and pravastatin), compared to placebo, led on average to modest but significant reductions in systolic and diastolic blood pressure in an RCT. The effect extended to persons with blood pressure below the sample median. 832
<b>Gastrointestinal<sup>c</sup></b>	<ul style="list-style-type: none"> <li>- Ulcerative colitis. 833, 834</li> <li>- Severe gastric ulceration (with abdominal pain). 835</li> <li>- Ileus in association with statin rhabdomyolysis. 431</li> <li>- Protein-losing enteropathy. 836</li> <li>- Gastrointestinal AEs were the most common AE class in an analysis of AEs from clinical trials, 837 and were the second most common in a small study. 26</li> </ul>	<ul style="list-style-type: none"> <li>- Statins affect omega-3 to omega-6 ratio; 17 omega-3s provisionally associated with reduced gastrointestinal inflammation. 838</li> <li>- Additionally, cholesterol is the precursor to vitamin D, which has been linked to protection against inflammatory bowel disease. 712, 839, 840</li> <li>- Mitochondrial dysfunction can produce gastrointestinal symptomatology. 448, 841-844</li> </ul>

Statin AE	Relevant reports	Triangulating evidence and effect modification
<b>Exercise Limitation<sup>c</sup> and Fatigue/Lack of Energy</b>	<ul style="list-style-type: none"> <li>- Patients who are noncompliant on statins are more likely to have AEs – e.g. gastrointestinal and neurologic.<sup>484</sup></li> <li>- See 'Exercise limitations or exercise-induced muscle symptoms,' Table I.</li> <li>- Fatigue without muscle pain on statins was reported and evaluated in three patients.<sup>845</sup> All were found to have low serum coenzyme Q10. Coenzyme Q10 supplements conferred subjective benefit to energy and reduced fatigue with exertion.<sup>845</sup></li> </ul>	<p>Combined statins and beta blockers affect perceived effort and cardiorespiratory function.<sup>59</sup></p>
<b>Psychiatric<sup>c</sup></b>	<ul style="list-style-type: none"> <li>- See also 'Irritability/aggression/behavior change' in this table and 'Sleep' in Table VII.</li> <li>- Reports of psychosis, depression, paranoia, anxiety, and personality change, to surveillance databases (including Scandinavian and New Zealand pharmacovigilance databases as well as our UCSD Statin Effects Study patient targeted statin AE surveillance database).<sup>444, 445, 467, 846</sup></li> <li>- One report described four cases of depression arising with initiation of pravastatin and reversing on discontinuation, including one case with "the likelihood of suicide."<sup>446</sup></li> </ul>	<p>Mitochondrial dysfunction can produce psychiatric symptoms.<sup>455, 456, 847-857</sup></p>
<b>Headache<sup>c</sup></b>	<ul style="list-style-type: none"> <li>- Headache.<sup>858, 859</sup></li> <li>- Migraine (altitude associated).<sup>860</sup></li> <li>- A case of yawning headache was described in a patient with statin-induced myopathy and neuropathy, but was not ascribed to statins.<sup>861</sup></li> </ul>	<ul style="list-style-type: none"> <li>- Mitochondrial dysfunction is linked to migraines.<sup>862-867</sup></li> <li>- Migraine occurrence in migraineurs has been shown to be reduced with coenzyme Q10 in an RCT.<sup>868</sup></li> </ul>
<b>Other</b>	<ul style="list-style-type: none"> <li>- Acid maltase deficiency.<sup>161</sup></li> <li>- Vasospasm after subarachnoid hemorrhage reported to be greater in statin users.<sup>869</sup> (possibly from statin withdrawal or indication bias, however).</li> <li>- Nasal obstruction and nasal polyps resolving with statin discontinuation; three cases reported.<sup>870</sup></li> <li>- Temperature dysregulation<sup>c</sup>, including hyperthermia.<sup>871-873</sup></li> </ul>	

ALS = amyotrophic lateral sclerosis; CI = confidence interval; HRT = hormone-replacement therapy; LDL-C = low-density lipoprotein cholesterol; MELAS = Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; OR = odds ratio; RBC = red blood cells; RCT = randomized controlled trial; UCSD = University of California, San Diego.

<sup>a</sup>List is not complete.

<sup>b</sup>Comment: statins are contraindicated during pregnancy due to concerns about teratogenicity.<sup>874-880</sup>

<sup>c</sup>Also reported to our UCSD Statin Effects Study group.